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Abstract 
Human African trypanosomiasis (HAT) is caused by the protozoan parasite 
Trypanosoma brucei. The use of existing drug regimens is controversial as they are 
toxic, have limited efficacy with resistance on the rise. Therefore, there is an urgent 
need for new therapies. One group of compounds that are being exploited or 
evaluated in treating infectious diseases and cancer are the quinones, with these 
agents mediating their cytotoxic activities by acting as prodrugs or inhibiting key 
metabolic pathways. Here, we report the screening of a quinone-based compound 
library against bloodstream form T. brucei and against the related parasites 
Trypanosoma cruzi and Leishmania major, the causative agents of Chagas disease 
and cutaneous leishmaniasis, respectively. This analysis demonstrated that the most 
potent compounds were those that possessed an aziridinyl 1,4-benzoquinone (ABQs) 
core with the most effective displaying a 50% growth inhibitory concentrations of < 
1 µM against all three pathogens. Using RH1, the archetypal ABQ, as a selective 
agent, a combination of a T. brucei whole genome loss of function assay and drug 
selection studies demonstrated that these compounds function as prodrugs with the 
activation mechanism catalysed by a type I nitroreductase (NTR). Functional studies 
using T. brucei that express altered levels of NTR further demonstrated the 
importance of this enzyme in activating the majority of quinone-based moieties 
tested. Using genetic approaches, we next demonstrated that following NTR-
mediated activation the resultant products go on to promote formation of interstrand 
crosslinks (ICLs) within the parasites’ genomes: T. brucei lacking the DNA repair 
enzyme SNM1, a nuclease that specifically fixes ICL damage, were more susceptible 
to ABQs than controls. In conclusion, ABQs are potent antiparasitic prodrugs 
although mammalian toxicity studies indicate these compounds may not be suitable 
potential therapies for systemic infections although they are of interest as genetic 
tools for probing gene function. 
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Chapter 1: Introduction 
1.1 Introduction to Trypanosomatid parasites 
Trypanosomatids represent a monophyletic order of protozoa belonging to the Class 
Kinetoplastida (Stevens et al. 2001). The trypanosomatids are obligate parasites 
primarily of insects although several genera are heteroxenous, having complex life 
cycles involving a secondary plant, invertebrate or vertebrate host (Lopes 2010). 
During their life cycles, trypanosomatids are characterised by having at least one 
form with a long slender morphology and single flagellum that together give the cell 
a corkscrew-like motion (trypano = borer, soma = body). As eukaryotes, 
trypanosomatid cells possess membrane bound organelles such as the nucleus, 
endoplasmic reticulum and Golgi bodies, peroxisomes and mitochondrion although 
the specific arrangement and function of some of these structures can be unusual 
(Lopes 2010) (Figure 1.1). For example, the peroxisomes of trypanosomatids are 
known as glycosomes as several enzymes of the glycolytic pathway are 
compartmentalised in this organelle (Barrett et al. 2003; Parsons 2004; Stuart et al. 
2008; Lopes 2010), while they only contain one mitochondrion whose genome, 
known as the kinetoplast, is composed of a highly complex interconnected network 
of mini and maxi circle DNAs known as ktDNAs (Stevens et al. 2001; Barrett et al. 
2003; Stuart et al. 2008; Lopes 2010).   
      
 
 
(17) 
 
 
 
Figure 1.1: Structure of trypanosomatid cell. Trypanosomatid cells contain a 
range of organelles including a large single mitochondrion and its associated 
kinetoplast (the mitochondrial genome), the flagellum and flagellum pocket, nucleus, 
ribosomes, endoplasmic reticulum, Golgi apparatus and glycosomes (modified 
peroxisomes that contain glycolytic enzymes) (Image taken from  Lopes (2010)) 
 
Trypanosomatids cause several major infections in humans and animals. It is 
estimated that 22 million people worldwide are infected by these microbes (Barrett et 
al. 2003; Stuart et al. 2008; Lopes 2010) with the parasites responsible for three 
human diseases namely human African trypanosomiasis (HAT), Chagas disease 
(also known as American trypanosomiasis) and Leishmaniasis, which are caused by 
Trypanosoma brucei, Trypanosoma cruzi and Leishmania species, respectively. All 
three of these infections are transmitted by the blood feeding habits of an insect 
vector with the pathogens causing predominantly chronic infections that can be lead 
to longer term disability, disfigurement, neurological abnormalities and death. These 
three diseases are classified by the World Health Organisation (WHO) as 'Neglected 
Tropical Diseases' (NTDs). In total, there are seventeen such conditions caused by 
various agents including helminths, protozoa, viruses and bacteria.  This diverse 
group of illnesses principally affects  low-income populations in developing regions 
of the World and causing substantial illness in more than 1.4 billion people globally 
(CDC 2011). Besides being responsible for the deaths of over 500,000 people 
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worldwide every year these infections often impair the physical and cognitive 
development of children, making it difficult to farm or earn a living, and limit 
productivity in the workplace. As such NTDs often trap the most vulnerable 
individuals within a community in a cycle of poverty and disease. As the cost of new 
drug innovations is now estimated to be greater than US$2.5 billion (Tufts Center for 
the Study of Drug Development 2014), pharmaceutical companies are unwilling to 
invest in therapeutic development specifically targeting diseases that affect the 
world's poorest communities as the returns do not justify such a financial outlay. Of 
the 1393 new drugs that came onto the market between 1975 and 1999 only 16 were 
developed for treating NTDs (Pécoul 2004).Therefore, there is an urgent need for 
new safer drugs against these debilitating conditions. 
 
1.2 Human African trypanosomiasis 
Human African trypanosomiasis, also known as African sleeping sickness, is a 
public health problem across sub-Saharan Africa. First recorded by the physician 
Thomas Winterbottom in 1734 (Steverding, 2008), this infection along with Nagana, 
the equivalent disease found in ungulate animals, has affected the development of 
this region of the World essentially making vast tracts of land ranging from south of 
the Sahara to north of the Kalahari desert economically unviable in terms of farming. 
Currently over 60 million people are at risk of infection, especially poor rural 
communities in areas such as Sudan, Angola and the Democratic Republic of Congo, 
where agriculture, fishing and hunting are the main sources of income (World Health 
Organisation 2011). 
 
      
 
 
(19) 
 
The improving political situation and the ability of non-governmental organisations 
(NGOs) such as WHO, Médecins Sans Frontières and Drugs for Neglected Diseases 
Initiative to access the above regions and thus safely implement diagnosis and 
treatment programmes has resulted in the number of reported new cases falling to 
below 10,000 (Simarro et al. 2011; Franco et al. 2014). The success of these 
schemes has prompted Dr Jean Jannin, Coordinator of the Innovative and Intensified 
Disease Management unit of the WHO Department of Control of Neglected Tropical 
Diseases in Geneva, to state that “The target is to eliminate the gambiense (West 
African) form of the disease (HAT) as a public-health problem by 2020” and “It 
means bringing down the incidence of the disease to less than 1 case per 10 000 of 
the population in at least 90% of the areas where cases exist.” (World Health 
Organisation 2013) with the ultimate goal of a sustainable disease elimination by 
2030 (Franco et al. 2014). However, history has demonstrated that such aspirations 
will only prevail if effective diagnosis and treatment programmes are maintained. 
Over the last 120 years there have been several HAT epidemics. The first of these 
occurred at the turn of the 20th century (1896-1906) and affected mainly the northern 
shore of Lake Victoria where up to two thirds of the population in the affected region 
died: this equates to an estimated 250,000 people  (Lundkvist et al. 2004). This 
alarming situation promoted an increase in research targeting HAT resulting in the 
development of the arsenic-based trypanocidal therapy tryparsamide and eventually 
suramin, a drug that is still in use today.  A second major epidemic which started in 
1920 and came to an end in the late 1940’s, resulted to the then governing colonial 
powers to instigate systematic screening, treatment and surveillance strategies using 
experiences learnt from the 1896-1906 outbreak. As a result from the 1940s through 
to the 1970s the estimated number of new cases fell to levels on par with the 
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situation we are seeing today. However, as many African countries gained 
independence during the late 1960’s and the early 1970’s, the resultant social 
upheaval and political instability caused the public health services and control 
programmes previously used by the colonial powers to control HAT to collapse. As 
a consequence there was a dramatic increase in the number of new cases and deaths 
directly attributable to this disease, peaking during the mid-1990s where in one year 
(1996) alone, estimates indicated that there were approximately 450,000 new cases 
of the disease and causing approximately 50,000 deaths. It was in light of these 
worrying statistics coupled with a decline in civil unrest, several NGOs were 
promoted to initiate many of the screening, treatment and surveillance strategies used 
today. 
 
1.3 The causative agent 
The pathogen responsible for causing HAT is the protozoan parasite T. brucei, that 
dependent on geographical location, is transmitted via anthropomorphic and zoonotic 
cycles by the haematophagous behaviour of the tsetse fly (Glossina genus). Unlike 
the other human infective trypanosomatid parasites Trypanosoma cruzi and 
Leishmania, this protozoan does not invade cells instead lives extracellularly in 
various body fluids such as the bloodstream, lymphatic system and cerebral spinal 
fluid (CSF). Analysis of T. brucei from different sites in Africa has shown that this 
species can be split into two distinct sub-species with each grouping showing 
differences in disease progression, epidemiology, mechanisms of transmission etc 
(Table 1.1).  
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 West African HAT East African HAT 
Causative agent T.b. gambiense T.b. rhodesiense 
Vector Riverine (Glossina palpalis) Savannah (Glossina morsitans) 
Ecology Rainforest, rivers and lakes Woodland and dry bush 
Location West and Central Africa East and Southern Africa 
Transmission Anthropomorphic Zoonotic 
Epidemiology Endemic, some epidemics Sporadic outbreaks 
Prognosis 
Slow progression to chronic 
disease 
 
Rapid progression to death 
Parasitaemia Low High 
Asymptomatic 
carriers Common Rare 
Non-human hosts Rare 
Wild and domestic animals 
(ungulates) 
 
Table 1.1: Differences between the different forms of human African 
trypanosomiasis.Adapted from Wiser, M. Protozoan and Human diseases (2011).  
 
In West and Central Africa, a form of HAT known as West African trypanosomiasis 
predominates (Figure 1.2). This chronic infection, caused by T.b. gambiense and 
transmitted mainly via an anthropomorphic cycle, accounts for the vast majority 
(98%) of HAT cases (World Health Organisation 2014). However, recent data 
indicates that the disease prevalence figures may be higher than those quoted by 
WHO as infected individuals having an active immune system are usually able to 
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suppress the parasitemia to levels that fails to promote disease symptoms for periods 
longer than originally thought (Wastling et al. 2011; Jamonneau et al. 2012): in one 
case, a patient was infected by T.b. gambiense for nearly 30 years before developing 
the cerebral symptoms associated with HAT (Sudarshi et al. 2014). As such it is now 
apparent that there are significantly more asymptomatic carriers than previously 
thought with many individuals leading a full and productive life, unaware that they 
are infected but still acting as a reservoir for this form of the disease. 
 
Figure 1.2:Distribution and incidence of the different human African 
trypanosomiasis forms. The white countries represent areas where the tsetse vectors 
are not found and no cases of HAT have been reported.Image taken fromBrun et al. 
(2010). Available from: http://www.thelancet.com/journals/lancet/article/PIIS0140-
6736(09)60829-1/fulltext.Copyright © 2016 Elsevier Limited. 
 
Endemic in East and Southern Africa the second HAT variant known as East African 
trypanosomiasis is prevalent (Figure 1.2). Caused by T.b. rhodesiense, this 
predominantly zoonotic infection only accounts for 2% of HAT cases. In contrast to 
T.b. gambiense, the parasite loads in a T.b. rhodesiense-infected individual can reach 
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high levels and can result in the rapid death of the host. As such East African 
trypanosomiasis is said to be an acute infection. Although the two T. brucei sub-
species are found at different geographical sites, there now appears to be an 
emerging overlap of the endemic areas in Uganda, potentially through the movement 
of T.  b. rhodesiense animal reservoirs to non-zoonotic T.b. gambiense endemic sites 
(Picozzi et al. 2005). This is of particular concern as T. brucei does undergo genetic 
exchange that in theory could result in the hybridization of the different T. brucei 
sub-species to generate new trypanosome variants (Picozzi et al. 2005; Franco et al. 
2014). 
1.4 Trypanosoma brucei life cycle 
To deal with the various environments T. brucei is exposed to during its life cycle, 
the parasite exhibits several distinct forms (Figure 1.3). 
 
Figure 1.3: Life cycle of T. brucei. Image sourced from (Center for disease control 
(CDC) 2015). Available from: http://www.cdc.gov/parasites/sleepingsickness/biology.html. 
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When taking a blood meal, the tsetse fly punctures the skin of a mammalian 
organism causing blood and lymph to rise and pool at the bite site. If the insect is 
infected with T. brucei, saliva containing the parasite in its highly infectious 
metacyclic trypomastigote (MCT) form can be transferred into this pool with the 
pathogen then gaining accessing to the bloodstream of the host. Once inside the 
vertebrate, the non-dividing MCT differentiates to a long, slender bloodstream form 
(LS-BSF) trypomastigote that start to divided by binary fission and commence 
colonising the various bodily fluids of host. During the initial stages of infection the 
parasites are confined to the blood and lymph systems but as the disease progresses 
they can cross the blood brain barrier and enter the cerebrospinal fluid. While in the 
blood and lymphatic systems, the parasite number fluctuates to generate a 
characteristic “wave of parasitemia” profile. A quorum sensing-like mechanism 
driven by the so-called “stumpy induction factor” operating towards the peak of each 
wave that promotes differentiation of the LS-BSF to a short stumpy form (SSF) 
trypomastigote form, which is pre-adapted for conditions inside the insect (Mony et 
al. 2014; Mony & Matthews 2015). When another tsetse fly takes a blood meal, the 
vector ingests blood or lymph containing LS-BSF and SSF parasites. In the insect’s 
gut, conditions that kill LS-BSF stimulate differentiation of SSF trypanosomes into 
procyclic trypomastigotes (PCF). The PCFs multiply by binary fission, colonize this 
part of the insect’s digestive tract before eventually migrating, possibly via the 
insect’s haemcoel, to the salivary glands of the vector. Once in the salivary glands, 
the PCFs transform into the epimastigote form and using their flagellum, adhere to 
epithelial cells of this organ (Ralston et al. 2009). At this point genetic exchange can 
take place, although this is not an obligatory part of the T. brucei life cycle (Peacock 
et al. 2014). Eventually, in response to unknown conditions and factors, 
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epimastigotes mature into metacyclic trypomastigotes (MCTs) that detach from the 
salivary glands' epithelial layer and enter this duct’s lumen ready to infect a new host 
when the fly feeds. 
 
1.5 Disease staging and pathologies of human African trypanosomiasis. 
The pathologies associated with HAT occur through two distinct stages known as the 
early (or haemolymphatic) stage that then develops into the late (or 
meningoencephalitic) staging (Figure 1.4). For T.b. gambiense infections 
progression from the early to late disease staging takes on average 3 years, although 
recent findings have questioned these values (Jamonneau et al. 2012; Wastling et al. 
2011; Sudarshi et al. 2014), while in the case of T.b. rhodesiense infections this 
usually weeks-months after the initial infection (Brun et al. 2010).  
 
Figure 1.4: Progression of human African trypanosomiasis.Tr:T.b. rhodesiense. 
Tg:T.b. gambiense. Image sourced from Wiser (2011).©2010 from Protozoa and Human 
Disease by Wiser. Reproduced by permission of Garland Science/Taylor & Francis Group LLC. 
      
 
 
(26) 
 
Early stage HAT starts upon infection and continues while the parasites remain 
restricted to the blood or lymphatic systems of the human host (Malvy & Chappuis 
2011). In most cases this disease staging is asymptomatic although for 19% of 
patients harbouring T.b. rhodesiense, a painful, localised skin inflammatory, known 
as a trypanosomal chancre, may develop at the site of the insect bite (Figure 1.5) 
(Brun et al. 2010). As the early stage develops the patient presents with a range of 
symptoms including headaches, adenopathy and characteristically a relapsing fevers, 
with the latter condition directly associated with the fluctuating parasitemia found in 
the patient’s bloodstream (Stuart et al. 2008). Trypanosomes possess immunogenic 
proteins known as variable surface glycoproteins (VSG) with roughly 107 copies per 
cells and estimates suggest that 10% of the trypanosome genome is assigned to vsg 
encoding genes (Berriman et al. 2005; Stuart et al. 2008; Bacchi 2009; Lopes 2010; 
Wiser 2011). The host immune system will mount a specific antibody response 
against trypanosomes expressing one VSG, leading to parasite elimination of those 
expressing that protein. However, parasites that have switched expression to a new 
VSG protein, survive and rapidly replicate until the host mounts an immune response 
against the VSG (Vincendeau & Bouteille 2006; Wiser 2011). This sequence of 
events in repeated.  
 
Figure 1.5: Chancre at the site of the tsetse fly bite in T. b rhodesiense infections. 
Left image sourced from http://www.microbiologybook.org/parasitology/blood-proto.htm and right 
image sourced from Moore et al. (2002) 
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Eventually, trypanosomes cross the blood brain barrier and accesses the CSF with 
the patient entering the late stage of the disease. Here, symptoms include a range of 
neurological conditions such as impaired mental function, weight loss, altered 
sleeping patterns and personality changes with the patient eventually slipping into 
coma and then dying. It is not fully understood how or why the parasites enters the 
CSF, although one current thought could be that the parasite manipulates host 
behaviour in order to aid its transmission: the daytime sleeping patterns displayed by 
patients exhibiting late stage HAT may increase the chance that the host will be 
bitten by the tsetse fly as the person will not react to the pain of an insect bite 
(Wolburg et al. 2012). Interestingly, prostagladin D2 induces sleep if injected into 
the ventricle system and it has been demonstrated this hormone-like compound is 
significantly elevated in the CSF of patients in the late stage HAT with this helping 
to regulate parasite cell density  (Wolburg et al. 2012). 
 
1.6 Current treatments 
Currently, five chemotherapeutic regimens are available for use against HAT with 
treatment determined by which T. brucei sub-species an individual is infected with 
and the presented disease stage (drug structures shown in Figure 1.6). When treating 
the early stage, pentamidine is given as the frontline drug targeting West African 
trypanosomiasis while suramin is used against the East African form of the disease. 
These treatments if appropriately administered are usually effective. However, once 
the pathogen has cross the blood brain barrier and the patient has entered the late 
disease stage, treatment success declines and unfortunately, it is at this point when 
most patients present themselves to a clinician. The therapies available to target the 
late stage HAT consist of melarsoprol, which can be used against both T. 
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bruceivariants, and eflornithine, which although used as a monotherapy, is now 
routinely employed to treat patients infected with T.b. gambiense in a nifurtimox-
eflornithine combinatorial therapy (NECT). Key features of the drug treatments are 
outlined in Table 1.2.  
 
The use of the above therapies is problematic. Most of the available chemotherapies 
require hospitalisation while being administered and for follow up screens aimed at 
determining whether the treatment has worked. This in addition to compound 
synthesis, transportation and storage etc, all contribute to the treatment cost which is 
generally prohibitive to most HAT suffers(Barrett et al. 2003). As a consequence, 
most treatments are administered through the actions of NGO funded mobile 
schemes. Additionally, resistance to some of the treatments, particularly melarsoprol 
and to a lesser extent pentamidine, is on the rise such that these are becoming 
ineffective in certain countries such as Uganda (Matovu et al. 2003; Bernhard et al. 
2007; Nerima et al. 2007; Robays et al. 2008; Pyana et al. 2011; Graf et al. 2013). 
Perhaps the most worrying issue regarding the front line HAT treatments stems from 
their toxicities. For suramin, which can cause problems including nephrotoxicity, 
bone marrow toxicity, anaphylactic shock, skin lesions and neurological 
complications, and pentamidine, which often leads to hypoglycaemia and 
hypotension, these side effects are generally not a major problem with any 
complications generally clearing up after cessation of treatment  (Legros et al. 2002; 
Brun et al. 2010; Wilkinson et al. 2011; Kennedy 2013). However, the use of 
melarsoprol, an arsenic-based compound, is controversial as this can cause reactive 
encephalopathy. This issue arises in 5 to 8% of HAT patients and results in the death 
of 45 to 60% in such individuals (Legros et al. 2002; Burri 2010). This adverse side 
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effects appears to be associated with activation of the melarsoprol prodrug to 
melarsen oxide, with this toxophore responsible for other side effects such as 
convulsions, loss of consciousness, rashes and vomiting (Bouteille et al. 2003; Nok 
2003; Wilkinson & Kelly 2009). 
 
Figure 1.6. Structure of the drugs used against human African trypanosomiasis. 
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Drug  
(class) Mode of action Uses Obstacles References 
Suramin 
 
(Polysulphonated 
napthalene) 
Glycoprotein ISG75 and four lysosomal 
proteins have been linked with efficacy and 
resistance. 
 
Function unclear ‘promiscuous’ inhibitor of an 
array of glycolytic and pentose phosphate 
pathway enzymes 
First line of treatment 
for early stages of T.b. 
rhodesiense infections 
Negatively charged 
cannot cross the blood-
brain barrier; 
 
Administratedintravenou
sly; 
 
Skin reactions, nerve 
damage and 
haematological toxicity. 
Nok 2003; Legros 
et al. 2002; Bacchi 
2009; Wilkinson & 
Kelly 2009; 
Alsford et al. 2012 
Pentamidine 
(Aromatic 
diamidine) 
P2 adenoside transporter 1 (AT1) and an 
aquaglyceroporin (AQP2/3) linked with uptake 
and resistance. 
 
Readily metabolised by human cytochrome 
P450 reductase. Accumulation of drug collapses 
trypanosome mitochondrial membrane 
potential. 
 
Binds to the minor groove of mitochondrial 
DNA minicircles. 
First line of treatment 
for early stages of T.b. 
gambiense infections 
Does not readily pass 
through the blood brain 
barrier; Generally well 
tolerated 
 
Shapiro & 
Englund 1990; 
Wilkinson & Kelly 
2009; Alsford et 
al. 2012; Baker et 
al. 2013 
Melarsoprol 
(trivalent 
arsenical) 
P2 adenoside transporter 1 (AT1) and an 
aquaglyceroporin (AQP2/3) linked with uptake 
and resistance. 
 
Prodrug with activation leading to formation of 
melarsen oxide (MelOx) and hinders adenine 
uptake. 
 
Inhibits a range of glycolytic enzymes and 
forms stable adducts with trypanothione thus 
block activity of trypanothione reductase. 
Second line treatment 
for haemolymphatic 
stages of T.b. 
rhodesiense and T.b. 
gambiense 
 
The only treatment for 
late stages of T.b. 
rhodesiense infections. 
 
Highly toxic causing 
10% of patients to 
develop reactive 
encephalitis; Side effects 
include convulsions, loss 
of consciousness and 
vomiting. 
Fairlamb et al. 
1989; Stich et al. 
2002; Bacchi 
2009; Wilkinson & 
Kelly 2009; 
Schumann Burkard 
et al. 2011Alsford 
et al. 2012; Baker 
et al. 2013 
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Drug  
(class) Mode of action Uses Obstacles References 
Eflornithine 
(Fluorinated 
amino acid) 
Uptake via amino acid transporter (AAT6). 
 
Inhibitor of ornithine decarboxylase 
(ODC),prevents production of putrescine. 
 
Inactivation of ODC transforms the 
trypanosome into forms not capable of 
modifying VSG or dividing allow immune 
clearance 
Early and late stage of 
T.b. gambiense 
infections.  
 
Used for melarsoprol 
refractory cases.  
Poor transport across 
blood-brain barrier; 
 
Costly, complicated and 
difficult to administer;  
 
Side effects include GI 
problems, convulsions 
and fever.  
Steverding 2008; 
Bacchi 2009; 
Vincent et al. 
2010; Wiser 2011; 
Alsford et al. 
2012; Alirol et al. 
2013 
Nifurtimox 
Eflornithine 
combination 
therapy 
(NECT) 
Combination therapy. 
 
Nifurtimox partner is  a drug used to treat 
Chagas disease. 
 
Nifurtimox is a prodrug and activated by a type 
I NTR leading to cytotoxic products. 
Reduction of type I NTR activity linked to 
resistance.   
Replaced melarsoprol in 
late stage T.b. 
gambiense infections.  
 
Gastrointestinal 
disturbances, abdominal 
pain and vomiting 
common. Convulsions, 
tremor and agitation and 
polyneuropathy have 
been reported.  
Checchi et al. 
2007; Wilkinson & 
Kelly 2009; Burri 
2010; Franco et al. 
2012; Alirol et al. 
2013 
Table 1.2:  Summary of drug treatments available to treat human African trypanosomiasis.  
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1.7 Quinones 
Quinone-based compounds encompass a range of chemical moieties characterised by 
the presence of two carbonyl groups linked to a carbocyclic backbone. They can be 
divided into several classes dependent on the relative positions of the carbonyl-
groups on the ring, either in 1,2 (ortho), 1,3 (meta) or 1,4 (para) positions, and 
whether the carbocyclic core is part of another ring system. 
 
Figure 1.7: Examples of basic quinone structures. A corresponds to a 1,2-
benzoquinone, B to a 1,4-benzoquinone, C represents an indolequinone, D a 1,4-
naphthoquinone and E a 9,10-anthraquinone  
 
Quinone compounds are found throughout nature, functioning as electron acceptors 
in crucial oxidoreductase cascades such as in the mitochondrial electron transport 
chain and photosystem II in chloroplasts. Additionally, natural and synthetic 
quinones are of pharmacological interest, functioning either as inhibitors of essential 
redox pathways or as pro-drugs.  In the latter case, the compound must undergo 
activation before mediating its cytotoxic effects, reactions catalysed by quinone 
oxidoreductases (Koster 1991; Danson et al. 2004; Hall et al. 2012). Based on 
oxygen-sensitivity, such enzymes can be divided into two groups (Figure 1.8). Under 
hypoxic conditions, oxygen-sensitive quinone oxidoreductases such as NADH 
cytochrome b5 reductase and cytochrome P450 reductases mediate the 1-electron 
reduction of the quinone to an unstable semiquinone radical (Koster 1991; Long II & 
Jaiswal 2000; Fang & Beattie 2002a; Begleiter et al. 2007; Avendano & Menendez 
2008). This can then be further reduced to the hydroquinone derivative. However, in 
  
the presence of oxygen, formation of the hydroquinon
radical undergoing futile cycling to produce superoxide & regeneration of the parent 
compound. In contrast, the oxygen
NAD(P)H quinone oxidoreductase 1 and 2 (NQO1; (also known 
and NQO2) catalyse the 2
hydroquinone directly.
Figure 1.8: Quinone reduction pathways. 
hydroquinones by two distinct pathways. In one system, enzymes such as 
cytochrome P450 reductase (P450R) & cytochrome b5 reductase (b5R) mediate the 
1e- reduction of the quinone to a semiquinone radical. This then undergoes further 
reduction to the hydroquinone. In the presence of O
futile cycling to form O
the quinone to the hydroquinone occurs directly, via a 2e
by NAD(P)H:quinone oxidoreductase 1 (NQO1).
backbone. 
 
1.7.1 Quinones as anti
Quinones have been extensively studied as potential anticancer agents. This was 
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predominately cytosol
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toxins and mutagens, is low in normal tissues but elevated in cancer cells (Danson et 
al. 2004). This interest resulted in development of several NQO1 activated quinone-
based compounds including EO9, mitomycin C, β-lapachone and gelanamycin, 
agents that show promising antitumor activities although some of these do promote 
unwanted side effects. (Siegel et al. 1990; Berardini et al. 1993; Maliepaard et al. 
1995; Tudor et al. 2005). Through a ping-pong mechanism and utilising NAD(P)H 
as donor of reducing equivalents, NQO1 mediates conversion of the quinone to the 
hydroquinone derivative, resulting in a redistribution of electrons within the 
carbocyclic backbone. Dependent on the initial structure this can then promote 
different downstream effects (Figure 1.9). 
Figure 1.9: Pathways quinone based compounds can take after activation by 
NQO1 to form hydroquinones. Image modified from Siegel et al. (2012). 
 
For compounds such as streptonigin and β-lapachone, the NQO1 generated 
hydroquinone can undergo redox cycling with oxygen leading to the formation of 
reactive oxygen species. If generated at significant levels, these can then cause a cell 
to enter a state of oxidative stress that can lead to cell death (Dzielendziak et al. 
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1990; Siegel et al. 2012; Parkinson et al. 2013). Alternatively, reduction of some 
quinones generates stable hydroquinone metabolites that can exert an inhibitory 
effect on other enzymes. For example the hydroquinones of the ansamycin natural 
products can interact with and bind to the ATP binding pocket of heat shock protein 
90 (hsp90) preventing this enzyme from folding newly synthesized proteins 
including oncoproteins such as HER2 and Raf-1 (Whitesell et al. 1994; Reigan et al. 
2011; Siegel et al. 2012). Finally, some quinones following NQO1 activation 
generate unstable hydroquinones. The resultant electron redistribution within the 
carbocyclic backbone promotes exposure of biological active moieties that lead to 
conjugation of the agent to a target substrate. For azirinidyl agents such as 
mitomycin, EO9 & AZQ (+ analogues), the conjugating moieties remains attached to 
the carbocyclic core whereas in other compounds, such as the phosphoramidate 
mustards & indolequinone-camptothecins, cleavage of specific bonds in the structure 
results in compound fragmentation and release of the adduct forming component. 
 
In addition to NQO1, quinones can undergo bioactivation by other routes. Enzymes 
such as cytochrome P450 reductase (P450R), cytochrome B5 reductase and xanthine 
oxidase can mediate a one electron reduction of the pharmacophore resulting in the 
production of a semiquinone radical (Begleiter & Leith 1990; Maliepaard et al. 
1995; Bolton et al. 2000; Yan et al. 2008; Phillips et al. 2013). In the presence of 
oxygen, the radical can undergo futile cycling, as described above, leading to the 
formation of reactive oxygen species that promote oxidative stress in a cell. 
However, whether this mechanism is responsible for cytotoxicity of a given 
compound cytotoxicity is open for debate as cancerous tissue from lung and breast 
biopsies express P450R at equivalent levels to non-cancerous controls (Lopez 1999). 
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Quinones can also undergo reduction via the activity of the catechol quinone 
reductase, also known as NQO2, an enzyme having 49% identity to NQO1 (Wu et 
al. 1997; Long II & Jaiswal 2000; Dufour et al. 2012). However, in contrast to 
NQO1, NQO2 does not use NAD(P)H as a source of reducing equivalents. At 
present NQO2’s physiological reductant is unknown although it can utilise the 
synthetic compound dihydronicotinamide riboside to catalyse the two electron 
reduction of quinones including RH1, and  nitrobenzamides such as CB1954 (Wu et 
al. 1997; Yan et al. 2008). For indolequinone-based compounds, this activation 
generates derivatives that promote binding to and inhibition of NQO2 itself (known 
as suicide inhibition)(Dufour et al. 2012). This approach has attracted considerable 
interest in relation to various neurodegenerative disorders such as Alzheimer's and 
Parkinson's disease, malaria and leukaemia, all conditions where NQO2 is believed 
to play a role in mediating drug resistance (Long II & Jaiswal 2000; Graves et al. 
2002; Winger et al. 2009; Benoit et al. 2010; Hashimoto & Nakai 2011; Leung & 
Shilton 2013). It is envisaged that development of inhibitors targeting NQO2 may be 
able to reverse the resistance phenotype  
 
1.7.2 Quinones and trypanosomes 
Quinone-based compounds have been screened for their antimicrobial properties 
(Baggish & Hill 2002; Kayser et al. 2003; Tran et al. 2004; Grellier et al. 2010; 
Lizzi et al. 2012; Hall et al. 2012; Lam et al. 2013; Pieretti et al. 2013). The quinone 
pharmacore exhibits redox potential and electrophilicity which makes them ideal 
drug candidates for treating cancers as well as infective agents such as 
Mycobacterium, Plasmodium and Trypanosoma(Tran et al. 2004; Pinto & de Castro 
2009; Grellier et al. 2010; Hall et al. 2012; Lizzi et al. 2012; Pieretti et al. 2013). In 
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the case of trypanosomes, screening programs using natural & synthetic quinones 
have identified a number of lead compounds although how these structures mediate 
their anti-parasitic activity is unclear (Pinto & de Castro 2009; Romas et al. 2009; 
Lizzi et al. 2012; Pieretti et al. 2013). Several theories accounting for their 
trypanocidal properties have been proposed with some postulated to inhibit key 
essential enzymes such as trypanothione reductase or lipoamide dehydrogenase, 
while others are thought to induce oxidative stress within the parasite (Henderson et 
al. 1988; Fang & Beattie 2002a; Fang & Beattie 2002b; Kubata et al. 2002; Romas 
et al. 2009; Garavaglia et al. 2010). These proposals were made based on in vitro 
enzyme studies and the belief that trypanosomes had a limited enzymatic capacity to 
metabolise reactive oxygen species (Boveris et al. 1980; Fairlamb & Cerami 1992). 
However, no direct link between the trypanocidal activity of quinone-based agents & 
a proposed protein target within the parasite itself has been established and it is now 
known that trypanosomatids actually possess a series of novel oxidative defence 
pathways (Rahlfs et al. 2002; Wilkinson & Kelly 2003; Wilkinson et al. 2006; 
Irigoín et al. 2008). 
 
Work conducted in the Wilkinson group has focused on the activity of a type I 
nitroreductase (NTR), a class of oxidoreductase reductase limited to bacteria and 
absent from most eukaryotes, with a subset of protozoan parasites being major 
exceptions (Wilkinson et al. 2008). Analysis of this NADH-dependent, FMN-
containing mitochondrially targeted enzyme has shown that it can readily activate 
the trypanocidal prodrugs nifurtimox and benznidazole, as well as reduce a range of 
nitrofuran-, nitroimidazole-, nitrotriazole- and nitrobenzyl-based  antiparasitic agents 
(Wilkinson et al. 2008; Bot et al. 2010; Hall et al. 2010; Hu et al. 2011; 
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Papadopoulou et al. 2011; Papadopoulou et al. 2012; Yang et al. 2012; Bot et al. 
2013; Papadopoulou et al. 2013; Voak et al. 2013; Voak et al. 2014; Papadopoulou 
et al. 2015). In addition to metabolising nitroaromatic agents the trypanosomal NTR 
was shown to preferentially interact with quinones, particularly benzoquinones, 
leading to the proposal that the biological role for the enzyme was as a ubiquinone 
oxidoreductase (Hall et al. 2012). This hypothesis was supported by analysis of a 
nifurtimox selected population obtained using a whole genome loss of function 
(RNAi) assay where several gene hits that are postulated to encode for proteins 
involved in ubiquinone biology were identified (Alsford et al. 2012). The reactions 
catalysed by the parasite type I NTR appear to be analogous to those outline above 
regarding NQO1 activity (Hall et al. 2012). 
 
1.8 DNA alkylating agents and repair mechanisms 
Alkylating agents are defined as “compounds capable of covalently binding an alkyl 
group (CnH2n+1) to a biomolecule under physiological conditions”(Avendano & 
Menendez 2008). These structures tend to be electrophilic in nature and can readily 
interact with and bind to nucleophilic centres. For more than 60 years aziridine-
containing compounds have formed the basis for the treatment of certain cancers 
with many of these prescribed drugs mediating the covalent attachment of binding 
groups to specific nucleotides, usually guanine, within the DNA backbone. As a 
result, cellular processes such as DNA transcription and DNA replication can be 
blocked, potentially leading to DNA fragmentation when the repair mechanisms 
used to fix such damage do not respond appropriately. Alkylating moieties exhibit 
their highest toxicity during that late G1 and S phases of the cell cycle with any 
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resulting DNA damage promoting cell cycle arrest (Avendano & Menendez 2008; 
Genois et al. 2014). 
 
DNA alkylating agents fall into several types dependent on the number of functional 
groupings present in the compound’s backbone (Figure 1.10). For the so-called 
monofunctional agents, structures that contain a single alkylating substituent, 
specific residues within one strand of the DNA double helix become alkylated such 
that a bulky side grouping is tagged onto the DNA structure. Such lesions can be 
highly mutagenic leading to coding errors with cells evolving repair mechanisms 
such as the base excision repair (BER) or nucleotide excision repair (NER) to fix 
such damage. For example, dacarbazine methylates guanine residues at the oxygen 
of the carbonyl grouping of purine ring resulting in O6-methylguanine derivatives 
(Valavanis et al. 1993; Avendano & Menendez 2008), with the adduct removed by 
O6-methylguanine-DNA alkyltransferase (MGMT) (Drabløs et al. 2004). 
 
Figure 1.10: Different types of DNA alkylating agent. Intrastrand (shown in blue) 
covalently bond to one DNA strand in two places. Interstrand (shown in red) form 
covalent bonds across the double helix. Monofunctional DNA adducts (shown in 
green) only bind to one of the stands.   
In contrast multifunctional agents, structures that contain several alkylating 
substituents, can interact with and covalently bind to multiple (usually two) residues 
within a single strand of the DNA double helix leading to formation of intrastrand 
cross links or bond to nucleotides on opposing strands to generate interstand cross 
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links (ICLs) (Figure 1.10). The latter are a particularly dangerous lesion as they 
physically link the two complementary strands within the DNA double helix 
together. This blocks essential cellular process that require DNA strand separation, 
including DNA replication and transcription, leading to chromosomal breakage, 
rearrangements, or cell death (Dronkert & Kanaar 2001; McHugh et al. 2001; Deans 
& West 2011; Sengerová et al. 2011). Estimates indicate that a single ICL can kill a 
unicellular microbe with as few as 20 being fatal to a mammalian cell (Magaña-
Schwencke et al. 1982; Lawley & Phillips 1996).  
 
One substituent that is effective at promoting DNA alkylation is the aziridine 
grouping, a three-membered heterocycle containing one amine group (-NH-) bound 
to two methylene bridges. As these moieties are highly reactive they must be 
attached to an electron withdrawing backbone to be of any medicinal value. This 
attachment functions to reduce the overall reactivity of the pharmacore while still 
preserving their DNA alkylating capabilities (Avendano & Menendez 2008). For 
prodrugs such as RH1 and CB1954, the two electron reduction reaction mediated by 
enzymes such as NQO1 or type I NTRs results in an increase in the pKa of the 
aziridine nitrogen to restore the reactiveness of the aziridinyl group (Figure 1.11). 
The resultant hydroquinone facilitates protonation of the aziridine nitrogen, thus 
forming an aziridinium cation, which then acts as an electrophilic centre targeting 
the nucleobase guanine. Interaction between the cation and the nucleophile causes 
the aziridinyl ring to open, thus releasing the strain within this moiety, with the now 
linear alkyl side chain binding covalently binding to the N7 position of purine ring 
on guanine. If a compound contains a single aziridinyl grouping then a 
monoalkylation will occur while structures that have multiple aziridinyl substituents 
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can be generated intra- or inter-strand DNA cross links (Avendano & Menendez 
2008). 
 
Figure 1.11: Schematic of DNA alkylation by the aziridinyl 1,4-benzoquinone 
AZQ (Image sourced from Avendano & Menendez 2008). Available from: 
http://store.elsevier.com/Medicinal-Chemistry-of-Anticancer-Drugs/Carmen-Avendano/isbn-
9780080559629/Copyright © 2015 Elsevier B.V 
 
In order to preserve the integrity and functionality of their genomes, all eukaryotic 
cells have evolved a series of complementary and overlapping pathways to function 
in the repair of ICLs. However, the exact enzymatic makeup of these systems are not 
fully understood (Deans & West 2011). In yeast many of the major DNA repair 
pathways (NER, mismatch repair, post-replication repair/translesion synthesis and 
homologous recombination) have been implicated in fixing ICL damage although 
only a few proteins specifically involved in this repair have been identified (Barber 
et al. 2005; Lehoczký et al. 2007; Daee et al. 2012; Ward et al. 2012). The best 
characterised of these are members of the Pso2p/SNM1 family of enzymes as cells 
lacking this activity are specifically and highly susceptible to ICL-inducing agents, 
such as the nitrogen mustards and aziridines, but not to any other forms of DNA 
damage (Henriques & Moustacchi 1981): note Pso2p (sensitive to PSORalen) refers 
to the yeast enzyme with SNM1 (Sensitive to Nitrogen Mustard) being the name 
given to plant/mammalian homologues. The role played by Pso2p/SNM1 in these 
repair systems remains unknown although biochemical studies have shown that it 
displays a 5' exonuclease activity (Dronkert & Kanaar 2001; Li et al. 2005). This 
coupled with the observation that pso2Δ cells exposed to ICL-inducing compounds 
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tend to accumulate DNA double stranded breaks indicates that Pso2p does not 
function in the initial identification/incision events, which in yeast occurs via the 
NER pathway, but may be involved in the processing of DNA ends created during 
the generation of ICL-associated DNA double stranded breaks (Li & Moses 2003; Li 
et al. 2005; Barber et al. 2005; Dudáš et al. 2007). Intriguingly, Pso2p also displays 
a structure-specific DNA hairpin opening endonuclease activity providing evidence 
that it may have other functions outside ICL repair (Tiefenbach & Junop 2012). 
 
All members of the Pso2p/SNM1 family contain a non-canonical metallo-ß-
lactamase (MBL) domain containing four motifs including a characteristic HxHxDH 
signature, which cooperate to facilitate zinc co-factor binding (Figure 1.12) (Cattell 
et al. 2010). Additionally, and in contrast to other MBL-containing proteins, 
Pso2p/SNM1 members also contain a characteristic β-CASP (named after its 
representative member CPSF, Artemis, SNM1 and PSO2) region, which in addition 
to possessing elements that function in metal binding, also harbours regions which 
are important in substrate interactions and specificity. In silico studies have shown 
that a range of protozoan parasite including Plasmodium, Leishmania and 
Trypanosoma, all possess a member of the Pso2p/SNM1 family of nucleases 
(Bonatto et al. 2005; Sullivan et al. 2015). For the T. brucei homologue, the function 
of this enzyme was established using yeast complementation with gene deletion 
studies demonstrating that the Pso2p/SNM1 activity was non-essential to the 
medically relevant life cycle stage (Sullivan et al. 2015). As with yeast pso2 null 
mutants, trypanosomes lacking SNM1 were specifically more susceptible to DNA 
alkylating agents that promote ICL formation, a phenotype that could be readily 
complemented by ectopic expression of Tbsnm1.  
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Figure 1.12.  Schematic of representatives from the SNM1/PSO2 family of 
proteins. Alignment of the yeast (yPSO2) and three human (SNM1A, 
SNM1B/Apollo and SNMC/Artemis) proteins are shown revealing the conserved 
MBL (blue/purple) and β-CASP (yellow/orange) domains. Adapted from Cattell et 
al. (2010). Available from http://onlinelibrary.wiley.com/doi/10.1002/em.20556/abstract. 
Copyright © 1999-2016 John Wiley & Sons, Inc. 
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1.9 Research aims 
The treatment regimes for the treatment of HAT are controversial as they are toxic 
and have limited efficacy. This, coupled with the emergence of resistant/non-
responsive parasite strains, has led to an urgent need for new, safer therapies 
targeting this infection. Quinone based compounds represent a group of moieties that 
are being exploited and/or evaluated in treating infectious diseases and hypoxic 
cancers. Here, I explore whether these agents could signify a new group of 
treatments for trypanosomatid diseases, focusing on HAT.   
 
The specific aims were to: 
1. Determine the anti-trypanosomatid properties of selection of compounds 
containing benzo-, indole- or naphtho-quinone backbones. 
2. Investigate the mode(s) of action of the most potentagents, assessing whether 
they function as prodrugs and/or promote DNA damage 
3. Understand how T. bruceimight gain resistance towards the most active 
quinone. 
4. Explore the mechanism of action of the nitroaromatic trypanocidal agents 
CB1954 and BG-M2 
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Chapter 2: Materials and Methods 
2.1 Stocks 
2.1.1 Cell stocks 
The wild type organisms and cell lines used in this study are listed in Table 2.1. 
 
Table 2.1: Organisms used in this study 
Organism name Source 
Leishmania major MHOM/IL/80/Friedlin D. Smith,  
University of York 
Trypanosoma brucei brucei  Lister 427; clone 
221a  
D. Horn, 
University of Dundee 
Trypanosoma brucei brucei  Lister 427; clone 
2TAG1 (2T1) 
Alsford & Horn (2008) 
Trypanosoma brucei brucei  single marker 
bloodstream (SMB) 
Wirtzet al. (1999) 
Trypanosoma cruzi CL-Brener J. Kelly, LSHTM 
Escherichia coli XL-1 Blue Laboratory stock 
Human acute monocytic leukaemia line 
 (THP-1) 
K. Seifert, LSHTM 
BALB/c mice K. Seifert, LSHTM 
 
2.1.2 Quinone based compounds used in this study 
The quinone-based compounds (1-4; 6-36; 47-51) used in this study were obtained 
from the Drug Synthesis and Chemistry Branch, Developmental Therapeutics 
Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute 
with the exception of RH1 (compound 5) and the 1,4 benzoquinone mustards (52-
56), which were donated by Frank Guziec, Jr. (Southwestern University, 
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Georgetown, TX), and the napthoquinones (37-46) which were supplied by 
Mohammed Jaffar (Morvus Technology Ltd, UK). Compounds were resuspended in 
dimethyl sulfoxide (DMSO) (Sigma Aldrich) at a concentration of 10 mM unless 
otherwise stated. The structures and chemical/physical properties of the compounds 
are listed in the Appendices. 
 
2.1.3 Non-quinone based compounds used in this study 
LH37 and LH33 were obtained from Longqin Hu (Rutgers, The State University of 
New Jersey, New Jersey, USA) and nifurtimox supplied by Simon Croft (LSHTM, 
UK). Megazol and DFMO were obtained from Mike Barrett (University of Glasgow, 
Glasgow, UK). BG-M2, KS90 and KS900 supplied by Phillip Penketh (Yale, 
Connecticut, USA) and NH10 was donated by Nuala Helsby (University of 
Auckland, Auckland, New Zealand). Nitrofurazone and CB1954 were purchased 
from Sigma-Aldrich while G418, phleomycin, puromycin, blasticidin and 
hydromycin were sourced from PAA Laboratories Ltd or Melford Laboratories Ltd. 
 
2.2 Cell culture and storage 
2.2.1 Maintenance of Trypanosoma brucei brucei 
The bloodstream form (BSF) of T. brucei was grown in HMI-11 which consists of 
HMI-9 media (Invitrogen) supplemented with 3 g L-1 sodium bicarbonate, 0.014% 
(v/v) β-mercaptoethanol (both from Sigma-Aldrich) and 10% (v/v) heat-inactivated 
foetal calf serum (PAA Laboratories Ltd) at 37ºC in a 5% (v/v) CO2 atmosphere 
(Hirumi and Hirumi, 1989). Derivatives of this cell line (designated 2T1 and SMB) 
that constitutively express the tetracycline repressor protein, were grown in this 
medium supplemented with 1 µg mL-1 phleomycin (2T1) or 2 µg mL-1 G418 (SMB). 
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T. brucei 2T1 parasites transformed to express elevated levels of TbNTR (a type I 
nitroreductase), TbCPRII or TbCPRIII (both cytochrome P450 reductase enzymes) 
and T. brucei SMB parasites transformed to undergo inducible RNA interference 
towards various genetic targets were further selected by the addition of 2.5 µg mL-1 
hygromycin (Wilkinson et al. 2008; Bot et al. 2013). T. brucei (wild type and 2T1) 
null mutant cells lacking the nuclease TbSNM1 were cultured in medium 
supplemented with 10 µg mL-1 blasticidin and 2 µg mL-1 puromycin (Sullivan et al. 
2015). In over expression and complementation experiments, wild type and 
TbSNM1 null mutant parasites expressing elevated levels of TbSNM1 were grown 
in the presence of 2 µg mL-1 phleomycin (Sullivan et al. 2015). T. brucei 
heterozygous cells expressing lowered levels of the type I nitroreductase TbNTR 
were cultured in HMI-11 containing10 µg mL-1 blasticidin (Wilkinson et al. 2008). 
To select T. brucei lines displaying resistance to the quinone RH1 (5), parasites in 
the logarithmic phase of growth were continually cultured in the presence of 
compound starting at 5 nM and increasing in a stepwise fashion over a period of 3 
months to 40 nM. 
 
2.2.2 Maintenance of Leishmania major 
The promastigote form of L. major MHOM/IL/80/Friedlin was cultured at 25°C in 
modified M199 medium (Invitrogen) supplemented with 4 mM sodium bicarbonate, 
40 mM HEPES pH 7.4, 0.1 mM adenine, 0.005% (w/v) haemin (all Sigma-Aldrich), 
25000 U L-1 penicillin, 25 mg L-1 streptomycin (both PAA Laboratories Ltd) and 
10% (v/v) heat-inactivated foetal bovine serum (PAA Laboratories Ltd). The 
medium was filter sterilized and stored at 4°C.  
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2.2.3 Maintenance of Trypanosoma cruzi 
The epimastigote form of T. cruzi was cultured in RPMI-1640 medium (PAA 
Laboratories Ltd) supplemented with 5 g L-1 trypticase, 5 g L-1  HEPES pH 8.0, 20 
mg L-1 haemin, 0.34 g L-1 sodium glutamate, 0.22 g L-1 sodium pyruvate, 2500 U L-1 
penicillin, 0.25 g L-1 streptomycin (all Sigma-Aldrich) and 10% (v/v) heat-
inactivated foetal calf serum (PAA Laboratories Ltd) and incubated at 25°C (Kendall 
et al., 1990). 
 
2.2.4 Maintenance of Escherichia coli 
Escherichia coli XL-1 blue strains were maintained at 37°C in NZCYM (10 g L-1 
enzymatic casein digest, 1 g L-1 casamino acids, 5 g L-1 yeast extract, 5 g L-1 NaCl, 
0.98 g L-1 MgSO4) (Sigma-Aldrich or Melford Laboratories Ltd), supplemented with 
100 µg mL-1 ampillicin (Sigma-Aldrich) where appropriate. In some experiments, 
the growth medium was solidified with 1.5% (w/v) Agar no.1 (Oxoid). 
 
2.2.5 Mammalian cells 
The THP-1 cell line was grown at 37°C under a 5% (v/v) CO2 atmosphere in RPMI-
1640 medium (PAA Laboratories Ltd.) supplemented with 2 mM pyruvate, 2 mM 
sodium glutamate, 25000 U L-1 penicillin and 2.5 mg L-1 streptomycin, 20 mM 
HEPES (pH 8.0) (all Sigma-Aldrich) and 10% (v/v) foetal calf serum (PAA 
Laboratories Ltd).  
 
2.2.6 Cell storage 
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For long term storage, cells were deposited as frozen stocks in liquid nitrogen 
(parasite lines) or at -80ºC (prokaryotic strains) in growth medium containing 20% 
(v/v) glycerol (Sigma-Aldrich). Bacterial strains were frozen directly at -80ºC in 1.2 
mL cryogenic vials (Nunc). Parasite lines, in 1.2 mL cryogenic vials (Nunc), were 
frozen slowly (1-2 days) to -80ºC using a Cryo 1°C Freezing Container (Nalgene) 
containing isopropanol (VWR International), then transferred to liquid nitrogen for 
long-term storage. Mammalian (THP-1) cells were frozen in fresh growth medium 
containing 20% (v/v) DMSO (Sigma-Aldrich) at a density of 1 x 105 cells mL-1. 
Frozen stocks were generated as described for parasite lines using the Cryo 1°C 
Freezing Container (Nalgene). 
 
Eukaryotic cell lines were revived by quickly thawing the contents of the frozen vial. 
Thawed cells were pelleted by centrifugation for 5 minutes (parasites at 1640 xg, 
mammalian cells at 400 x g) and washed in 10 mL of the appropriate medium. Cells 
were then re-suspended in fresh medium as per normal culturing. 
 
2.3 Anti-parasitic and toxicity screens 
2.3.1 Bloodstream form Trypanosoma brucei brucei 
All growth inhibition assays were carried out in 96-well plates (PAA Laboratories 
Ltd). T. brucei BSF parasites in the logarithmic phase of growth were seeded at 1 x 
104 cells mL-1 in 200 µL of HMI-11 medium containing various concentrations of 
the compound under study. Other assays performed included culturing cells grown in 
the absence of drug (100% growth) and a medium background control. After 
incubation at 37°C for 3 days, resazurin (Sigma Aldrich) was added to each well at a 
final concentration of 12.5 mg L-1 (or 2.5 µg resazurin per well). The plates were 
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further incubated for 8-24 hours at 37°C before measuring the fluorescence using a 
Gemini Fluorescent Plate reader (Molecular Devices) at λEX =530 nM and λEM =585 
nM with a filter cut off at 550 nM. The colour change (and subsequent fluorescence) 
is a result of the reduction of the dye by living cells therefore the change is 
proportional to the amount of cells present. Therefore, the highest fluorescence was 
observed in untreated cells, whereas the lowest was observed in the absence of cells.  
 
To calculate the fluorescence value at each compound concentration (flv) the 
following calculation was used: 
   equation 1: flv = flraw - flbackground   
where flraw  is the raw fluorescence value at a given compound concentration and 
flbackground is the average background fluorescence value of the medium control. 
 
The fluorescence value at a given compound concentration (flv) was then expressed 
as % growth relative to the average fluorescence value at a compound concentration 
equal to 0 (fldrug=0) (i.e. no drug control) 
 
  equation 2: % growth at given [compound] = flv/fldrug=0 x 100  
 
The % growth data at a given compound concentration was then expressed as % 
growth inhibition at a given compound concentration 
 
 equation 3: % growth inhibition = 100 - % growth at given [compound]  
 
Data expressed as % growth or % growth inhibition was used to construct dose 
response curves and establish the compound concentration that inhibits cell growth 
by 50% (IC50) using the non-linear regression tool on GraphPad Prism (GraphPad 
Software Inc). 
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2.3.2 Leishmania major promastigotes 
L. major promastigotes in the logarithmic phase of growth were seeded at 5 x 105 
cells mL-1 in 200 µL M199 growth medium containing various concentrations of the 
compound under study. Other assays performed included culturing cells grown in the 
absence of drug (100% growth) and a medium background control. After incubation 
at 27°C for 6 days, resazurin (Sigma-Aldrich) was added to each well at a final 
concentration of 12.5 mg L-1 (or 2.5 µg resazurin per well). The plates were further 
incubated for 8-24 hours at 27°C before measuring the fluorescence using the 
Gemini Fluorescent Plate reader as previously described and growth inhibition 
curves were calculated as described. 
 
2.3.3 Trypanosoma cruzi promastigotes 
T.cruzi epimastigotes in the logarithmic phase of growth were seeded at 5 x 105 cells 
mL-1 in 200 µL of modified RPMI growth medium containing various concentrations 
of the compound under study. Other assays performed included culturing cells grown 
in the absence of drug (100% growth) and a medium background control. After 
incubation at 27°C for 12-14 days, resazurin (Sigma Aldrich) was added to each well 
at a final concentration of 12.5 mg L-1 (or 2.5 µg resazurin per well). The plates were 
further incubated for 24-48 hours at 27°C before measuring the fluorescence using a 
Gemini Fluorescent Plate reader (Molecular Devices) and calculating IC50 values as 
described. 
 
2.3.4 Mammalian cells 
THP-1 cells were seeded at 2.5 x 104 cells mL-1 in 200 μL modified RMPI-1640 
growth medium and incubated at 37°C in a 5% (v/v) CO2 atmosphere for 3 days in 
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the presence of 20 ng mL-1 phorbol 12-myristate 13-acetate (Sigma Aldrich). On day 
4, the medium was carefully removed, the cells washed in pre-warmed medium 
lacking PMA and the cells treated with growth medium various concentrations of the 
compound under study. The plates were incubated for a further 3 days at 37°C under 
a 5% (v/v) CO2 atmosphere before addition of resazurin to a final concentration of 
12.5 mg L-1 (or 2.5 µg per well) to each culture. Plates were incubated for a further 
8-12 hours before determining the fluorescence of each culture as described. 
 
Peritoneal macrophages isolated from mice were used in growth inhibition assays. 
Briefly, macrophages seeded at 4 x 105 mL-1 in mammalian growth medium were 
incubated overnight at 37°C in a 5% (v/v) CO2 atmosphere to facilitate attachment of 
the cells onto a slide in a 16-well chamber slide. The following day the medium was 
carefully removed, the cells washed in pre-warmed RPMI-1640, then treated with 
various concentrations of the compound under study diluted in the growth medium. 
The plates were incubated for a further 5 days at 37°C under a 5% (v/v) CO2 
atmosphere before washing the slide in 100% (v/v) methanol for 2 minutes, briefly 
rinsing in 100% (v/v) methanol and then air drying. The slide was then washed with 
10% (w/v) Giemsa stain diluted in tap water for 10 minutes before briefly rinsing in 
tap water and air drying. The above cell isolation, drug treatments and cell staining 
were all performed by Karin Seifert (LSHTM, UK). Slides were visualized with 
Leica DMRA2 light microscope with Retiga EXi Fast 1394 digital camera and 
Velocity software package using at x100 oil immersion objective and the number of 
cells per field of view determined. A minimum of 10 fields of view per drug 
treatment were examined and the average number of cells per field of view 
calculated. The values obtained for each drug-treated culture were then expressed as 
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a % growth relative to untreated controls. Photographs of the slides were taken using 
the same microscope with a x20 objective. 
 
2.4 Nucleic acid extraction techniques 
2.4.1 Parasite genomic DNA 
Parasite genomic DNA (gDNA) was extracted using two methods. In the first 
protocol, gDNA was harvested using a sodium dodecyl sulfate (SDS)-based 
lysis/phenol:chloroform protocol adapted from Kelly et al(1993). Parasites in the 
logarithmic phase of growth were pelleted (1640 g for 10 minutes), washed in 
phosphate buffered saline (PBS) (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 
1.76 mM KH2PO4, pH 7.6) and resuspended in TEN lysis buffer (50 mM Tris-Cl pH 
8.0, 50 mM EDTA, 50 mM NaCl) containing 100μg mL-1 proteinase K  (Sigma-
Aldrich). SDS was then added to a final concentration of 1% (w/v) and the mixture 
incubated at 54oC for 2 hours. An equal volume of phenol:chloroform (1:1) was 
added to the lysate, the contents mixed by inversion of the tube and the 
aqueous/organic phased partitioned by centrifugation (3,500 g for 10 minutes). The 
upper aqueous layer was carefully removed, dispensed into a fresh tube and if 
required, the phenol/chloroform step repeated. The ‘cleaned’ nucleic acid-containing 
aqueous phase was finally transferred to a fresh tube. A few drops (~20-30 µL) of 1 
M MgCl2 was then added and the chromosomal DNA precipitated using an equal 
volume of isopropanol. The resultant fibrous material was collected, transferred to a 
fresh 1.5 mL centrifuge tube, washed with 70% (v/v) ethanol and left to air dry. The 
gDNA was then dissolved in low salt buffer (10 mM Tris HCl,1 mM EDTA pH8.0) 
      
 
 
(54) 
 
containing 30 μg mL-1 heat-treated (100ºC for 10 minutes) RNase A (Sigma-
Aldrich). 
 
The second gDNA extraction method was carried out using the DNeasy Blood and 
Tissue Kit (Qiagen) following the manufacturer’s protocol. Briefly, parasites in the 
logarithmic phase of growth were pelleted (1640 g for 10 minutes) then resuspended 
in PBS containing 1-2 mg mL-1 proteinase K. An equal volume of RNase-containing 
lysis buffer was then added to the mixture and the mixture incubated at 60°C for 10 
minutes. A volume of ethanol (96-100 % (v/v)) equal to that used to initially 
resuspend the cells was added to the lysate, the contents mixed and passed through a 
QIAprep spin column by centrifugation (20,238 g for 1 minute), such that the 
genomic DNA binds to the silica membrane of the column. The DNA was then 
washed using an ethanol-based buffer, removing any residual salts and other 
precipitates, with the gDNA finally eluted off the silica membrane in 50-200 µL a 
low salt buffer (10 mM Tris HCl,1 mM EDTA pH8.0). The gDNA was stored at 4°C 
until use. 
 
2.4.2 Total RNA extraction 
Total RNA was extracted from L. major promastigotes or BSF T. b. brucei in the 
logarithmic phase of growth using the RNeasy Extraction kit (Qiagen) as per the 
manufacturer's instructions. Parasite cultures were pelleted by centrifuged (1,640 g 
for 10 minutes) and any residual growth media removed. The pellet was resuspended 
and cells disrupted using a guanidinium thiocyanate (GTC)-containing lysis buffer 
before being passed through QIAshredder spin column (Qiagen) by centrifugation 
(20,238 g for 2 minutes). The flow through was collected to which ethanol (70% 
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(v/v)) was added and the homogenized lysate passed through an RNeasy Mini 
Column by centrifugation (20,238 g for 15 seconds) such that the RNA binds and 
becomes entrapped in the silica membrane of the column. The RNA sample was then 
washed with GTC, the column dried by centrifugation (20,238 g for 15 seconds) and 
any contaminating DNA removed by digestion with on column DNase I (Qiagen) for 
15 minutes at room temperature. The column was then washed again firstly with the 
GTC-containing buffer then twice using an ethanol based buffer before eluting the 
total RNA into 30-50 µL RNase-free water. The RNA is stored at -20°C until use. 
 
2.4.3 Plasmid DNA 
Small scale plasmid DNA (5-20 μg) extractions from E. coli were performed using 
the QIAprep Spin Miniprep kit (Qiagen) according to the manufacturer’s 
instructions. Briefly, NZCYM broth supplemented with 100 µg ml-1 ampillicin was 
inoculated with the desired E. coli strain and grown overnight at 37°C with aeration.  
The bacteria were harvested (20,238 g for 1 minutes), residual growth medium 
removed and the cells resuspended then lysed in an RNase A-containing alkali 
buffer. The pH of the lysate was adjusted using a neutralisation buffer and the 
resultant cell debris/chromosomal DNA removed by centrifugation (20,238 g for 10 
minutes). The supernatant was passed through to QIAprep spin column by 
centrifugation (20,238 g for 1 minute) such that the plasmid DNA binds to the silica 
membrane of the column. The DNA was then washed using an ethanol-based buffer, 
removing any residual salts and other precipitates with the plasmid DNA finally 
eluted off the silica membrane in 40-60 µL a low salt 10 mM Tris HCl, 1 mM EDTA 
pH 8.0 buffer. Plasmid DNA was stored at -20°C until use. 
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2.5 DNA manipulation techniques 
2.5.1 cDNA synthesis 
Complementary DNA (cDNA) was synthesized from total RNA using the 
Superscript® VILOTM cDNA synthesis kit (Invitrogen). A typical 20 µL reaction 
contained 1X VILO reaction mix (formulation includes random hexamers, MgCl2, 
dNTPs), 2.5 ng uL-1 total RNA and 1X SuperScript® enzyme mix (formulation 
includes Superscript III reverse transcriptase, RNase OUTTM, Recombinant 
Ribonuclease Inhibitor, and a proprietary helper protein). Using a Techne TC-412 
thermocycler, a single cycle at 25°C for 10 minutes followed by 42°C for 60 minutes 
was performed and the reaction halted by an 85°C treatment for 5 minutes. Samples 
were then stored at -20ºc until use. 
 
2.5.2 DNA amplification 
DNA fragments were amplified using primers purchased from Sigma-Aldrich (see 
Appendix) with dNTPs and DNA polymerases (plus associated buffers) sourced 
from New England Biolabs. In a typical 50 µL amplification the reaction contained 
1x Thermopol buffer (20 mM Tris-HCl, 10 mM (NH4)2SO4, 10 mM KCl, 0.1% (v/v) 
Triton X-100, 1.5 mM MgSO4), 200 µM dNTPs, 0.1 ng µL-1 template DNA, 0.5 µM 
forward & reverse primers and 20 U mL-1 DNA polymerase (Taq or Vent pfu were 
used dependent on whether the fragment required proof reading). On occasions 
additional MgSO4 was added to the reaction. 
 
Using a Techne TC-412 thermocycler, a standard PCR program consisted of one 
cycle at 96 °C for initial melting, followed by 30 cycles of: 96°C for 30 seconds 
(denaturing step), 55°C for 30 seconds (annealing) and 72°C for 60 seconds 
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(extension time). A further extension of 10 minutes at 72°C was usually added at the 
end of the 30th cycle. The temperatures and times were dependent on the 
oligonucleotide primer properties, therefore these conditions were varied as 
necessary. 
 
2.5.3 Quantitative real time PCR (qRT-PCR) 
DNA fragments were amplified from cDNA employing the QuantiTect® SYBR® 
Green PCR kit (Qiagen) and primers obtained from Sigma-Aldrich (see Appendix 3). 
A typical 10 µL reaction contained 1X QuantiTect® SYBR® Green PCR buffer (20 
mM Tris-HCl, 10 mM (NH4)2SO4, 10 mM KCl, 0.1% (v/v) Triton X-100, 2.5 mM 
MgSO4, 200 µM dNTPs and HotStarTaq® DNA polymerase), 1000 ng µL-1 template 
cDNA and a pre-determined amount of forward & reverse primers. Samples were 
loaded onto 384 well plates and sealed using an adhesive qPCR seal (both donated 
by Dr M.Struebig). 
 
Using an Applied Biosystems 7900HT system, a standard PCR program consisted of 
one cycle at 95°C for 15 minutes to activate the HotStarTaq® DNA polymerase 
followed by 40 cycles of 95°C for 10 seconds (denaturing), 60°C 10 seconds 
(annealing) and 72°C for 10 seconds (extension). Following completion of the 
amplification step a dissociation curve analysis was carried out to ensure target 
specificity. Fluorescence data collected during the amplification was analyzed using 
SDS version 2.4 software (Applied Biosystems) and exported into Excel 2007 
(Microsoft). From the resultant sigmoidal curves, the cycle threshold (CT) value was 
determined and normalized against standardized control (TbTERT)(Brenndörfer 
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&Boshart 2010) using the comparative CT method as described by Schmittgen & 
Livak (2008).   
2.5.4 DNA purification 
DNA fragments were purified using a GeneJET™ DNA gel extraction kit 
(Fermentas Life Science) in accordance with the manufacturer’s protocols. For DNA 
samples in liquid, a high salt buffer containing chaotropic salts was applied to the 
sample before passing it through a GeneJET™ purification column by centrifugation 
(20,238 g for 1 minute) such that the nucleic acid binds to the column’s silica 
membrane: the chaotropic salts promote binding of DNA to the silica membrane as 
well as denaturing associated proteins. Following a series of ethanol washes and 
centrifugation steps, the DNA was eluted from the silica membrane using 30-60 µL 
low salt elution buffer. The DNA is stored at -20°C until use. 
 
To purify DNA fragments embedded in agarose, the weight (and hence volume) of 
the DNA-containing agarose slice was determined to which an equal volume 
ofsolubilisation buffer was added. The mixture was then incubated at 60°C for 10 
minutes or until the agarose had completely dissolved. An equal volume of 
isopropanol was added to the DNA-containing solution and the mixture applied to a 
GeneJET™ purification column. The binding/wash steps were carried out as 
described as above.  
 
2.5.5 DNA ligation  
DNA ligation reactions were varied dependent on the ratio of insert to vector present. 
The relative amounts of each DNA sample was judged following visualization of an 
ethidium bromide stained agarose gel. A typical ligation reaction was set up as 
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follows: in a 30 µL reaction, varying amounts of purified DNA (vector & insert) and 
3 µL 10X T4 DNA ligation buffer (500 mM Tris-HCl pH 7.5, 100 mM MgCl2, 10 
mM ATP, 100 mM dithiothreitol (DTT)) (Biolabs New England) were mixed and 
the volume of the ligation reaction adjusted to 29 µL with sterile distilled H20. T4 
DNA ligase (1 μL: 400 units) was added to the reaction, the mixture consolidated 
then incubated at room temperature for 2-4 hours or at 4°C overnight. 
 
In some cases, ligations were carried out using the pGEM®-T-Easy vector system 
(Promega). Here, a typical 20 µL reaction was set up containing 1 µL pGEM®-T-
Easy vector (50 ng), 10 µL 2X Rapid Ligation Buffer (60 mM Tris-HCl pH 7.8, 
20mM MgCl2, 20mM DTT, 2mM ATP, 10% (w/v) polyethylene glycol MW8000), 1 
µL pGEM®-T-Easy T4 DNA ligase (3 U) and 8 µL insert DNA. The ligation mix 
was consolidated then incubated at room temperature for 2-4 hours or at 4°C 
overnight. 
 
2.5.6 DNA restriction digests 
The restriction enzymes (Table 2.2) used in this study were purchased from New 
England Biolabs or Thermo Fisher Scientific. A typical plasmid restriction digestion 
was set up as follows: in a total volume of 20 µL, plasmid DNA (10 µL) was mixed 
with 2 µL 10X restriction enzyme buffer appropriate for the restriction enzyme(s) 
being used and the volume adjusted to 19 µL with sterile distilled H2O. In some 
cases bovine serum albumin was added to the reaction to a final concentration of 100 
µg mL-1. Restriction enzyme (1 μL: 10-20 units) was then added to the reaction and 
the contents consolidated by centrifugation. The reaction mixture was incubated at 
the recommended temperature for the restriction enzyme, generally 37°C, for 1-2 
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hours. The reaction was halted by addition of 6X DNA loading dye (10 mM 
Tris.HCl pH 7.6, 0.03% (w/v) bromophenol blue, 0.03% (w/v) xylene cyanol FF, 
60% (v/v) glycerol, 60 mM EDTA) (Thermo Fisher Scientific) and the DNA 
fragments fractionated on an agarose gel. 
 
Table 2.2:Restriction enzymes used in this study. The cleavage site for each 
enzyme indicated by ‘/’ 
Enzyme Restriction site  Enzyme Restriction site 
ApaI GGGCC/C  NotI GC/GGCCGC 
BamHI G/GATCC  SacI GAGCT/C 
EcoRI G/AATTC  XbaI T/CTAGA 
HindIII A/AGCTT  XhoI C/TCGAG 
 
Restriction digestion analysis of gDNA (generally for Southern hybridization 
studies) was set up as described above except a larger total reaction volume (100 µL) 
and more DNA (30-60 µL) were used. Generally, multiple aliquots of the restriction 
enzyme were added to each reaction to ensure that the digestion had gone to 
completion. 
 
2.5.7 Bacterial DNA transformation 
Competent E. coli were prepared as follows: a bacterial stock culture was diluted 
1:20 into fresh NZCYM medium (generally 0.5 mL stock in 10 mL fresh medium) 
and the new culture grown with aeration at 37°C for two hours: at this point the 
optical density at 600 nm of the culture was between 0.6-1.0). Aliquots (generally 1 
mL) of the bacterial cells were pelleted (20,238 g for 1 minute), resuspended in an 
equal volume (generally 1 mL) ice cold 0.1 M CaCl2 and then incubated on ice for 10 
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minutes. The bacteria were harvested (20,238 g for 1 minute) and the pellet 
resuspended in a 1/10th volume (generally 0.1 mL) ofice cold 0.1 M CaCl2. The 
DNA to be transformed (15- 30 µL of a ligation or 1 µL of pure plasmid DNA) was 
added to the CaCl2  resuspended competent cells, the mixture held on ice for 10-30 
minutes then heat shocked at 42°C for 2 minutes before being immediately returned 
to ice for a further 2 minutes. The transformed bacteria were plated onto NZCYM 
agar plates containing an appropriate antibiotic for plasmid selection and left to 
incubate overnight at 37°C to allow growth of colonies. 
 
2.5.8 Parasite DNA transformation 
T. brucei were transformed using the Amaxa® nucleofection system (Lonza). 
Parasites (~2x107 per transfection) in the exponential phase of growth were 
harvested by centrifugation (1,640 x g for 10 minutes at room temperature), residual 
growth medium removed and the pellet resuspended in 100 µL Human T-cell 
Nucleofector® solution (Lonza): this solution was made no more than 5 minutes 
before use by combining 82 µL of reagent A with 18 µL reagent B in the Human T-
cell Nucleofector® kit. The cell suspension was immediately transferred to a 
nucleofection cuvette containing ~10 µg DNA (in 10µL) to be transformed and 
parasite electroporation performed using the Amaxa Nucleofector® device set to 
programme X-001. The cells were then transferred into pre-warmed HMI-11 
(generally 48 mL) medium and left at 37°C. After at least 6 hours, selective 
antibiotics (see section 2.2.1) were added to the transformed culture, aliquots 
(generally 2 mL) transferred into the wells of a 24 well plate and the parasites 
incubate at 37°C under a 5% (v/v) CO2 atmosphere. In some cases 1:10 and 1:100 
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dilutions of the transformed culture were set up prior to addition of the selective 
antibiotics. Drug-resistant T.brucei were usually apparent 5-7 days post-transfection. 
 
2.5.9 DNA sequencing 
For custom DNA sequencing Eurofins MWG operon (for single reads) or the Beijing 
Genome Institute (BGI) (for high throughput multi-read sequences) were used. 
Samples such as PCR products or plasmids were sent at a concentration of 50-100 ng 
µL-1 whilst the corresponding oligonucleotides were sent at a final concentration of 
10 pmol µL-1. Results were usually received within 48 hours where single sequence 
reads were performed or 2 months for high throughput multi-read sequencing. 
 
2.5.10 Bioinformatic analysis 
The primer prediction algorithm RNAit (Redmond et al. 2003) was used to predict 
specific regions of opening reading frames suitable for RNAi. Trypanosomal and 
LeishmaniaDNA/protein sequences were identified following text or BLAST 
searches using algorithms housed at the Kinetoplastid genome resource TritrypDB 
(http://tritrypdb.org/tritrypdb/) or NCBI (http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
PSORT (http://psort.hgc.jp/) was used as a predictor of localisation. Analysis of high 
throughput multi-read sequencing data was carried out by Dr Sam Alsford (LSHTM) 
as described (Glover et al. 2015). 
 
2.6 Nucleic acid separation and hybridization 
2.6.1 DNA by conventional gel electrophoresis 
Conventional agarose gel electrophoresis was used to fractionate DNA molecules 
between 200 bp to 10 kbp. The size of the gel, agarose concentration, voltage and 
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times were optimized to achieve the desired result. A standard agarose gel 0.8-1.2% 
(w/v) was made by dissolving agarose powder (Bioline) in 1X TAE (40 mM Tris 
base, 40 mM acetic acid, 1 mM EDTA) by boiling using a microwave. After the 
agarose had cooled, ethidium bromide (0.1 mg L-1) was added.  Once gels were cast, 
the solidified agarose was placed into a gel electrophoresis tank containing 1X TAE 
supplemented with 0.1mg L-1 ethidium bromide. DNA samples (containing DNA 
loading dye) and a 1 kb GeneRuler™ (Thermo Fischer Scientific) were loaded onto 
the gel and the samples fractionated through the gel by applying a constant voltage 
(70-100 V) across the gel for 40 minutes to 2 hours. Migration of the samples 
through the agarose matrix was followed by monitoring the bromophenol blue and 
xylene cyanol dye fronts present in the samples loading buffer. When the DNA had 
migrated the desired distance, the agarose gel was visualized on a UV transluminator 
and documented (Syngene). 
2.6.2 DNA blotting 
DNA-containing agarose gels were depurinated for 10-15 minutes, bathed in 
denaturation buffer (0.5 M NaOH, 1.5 M NaCl (Sigma Aldrich)) for 30 minutes and 
washed again in distilled water. The gel was transferred into neutralisation buffer 
(0.5 M Tris-HCl, 1.5 M NaCl at pH 7.5) for an hour before washing again in distilled 
water. 
 
The nucleic acids were transferred onto MAGNA nylon membrane (MSI 0.45µ) by 
capillary action using 20X SSC solution (3M NaCl; 0.3M sodium citrate) using the 
method described by Southern (Southern 1975). 3MM filter paper was wrapped 
around a support (usually a gel casting tray) and placed in a large plastic container. 
The filter paper was then soaked with 20X SSC onto which the gel containing the 
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nucleic acid to be transferred was placed. The gel was wetted with 20X SSC, 
covered with nylon membrane on top of which were place additional pieces of dry 
3MM filter paper, a paper towel ‘wicks’, a flat tray and finally a weigh. The large 
plastic container was then filled with 20X SSC and the whole arrangement left 
overnight. Following transfer, the nucleic acids were cross linked to the nylon 
membrane using a UV cross-linker (Stratagene) set at a pre-determined algorithm, 
with the nucleic acid side of the membrane positioned toward the UV blubs. The 
fixed membrane was put into pre-hybridisation solution or stored in 3MM paper at 
room temperature.  
 
2.6.3 DNA probe synthesis 
Non-radioactive DNA were synthesized using the PCR DIG Probe Synthesis Kit 
(Roche) according to the manufacturer’s protocol. For a 50 µL reaction, 5 µL 10X 
PCR buffer (containing 15 mM MgCl2) and 5 µL PCR DIG probe synthesis mix (2 
mM dATP, dGTP and dCTP; 1.3 mM dTTP; 0.7 mM DIG labelled dUTP) were 
added to a 0.2 ml tube containing the template DNA and the forward/reverse primers 
(0.5 µM each). The reaction volume was adjusted to 49.25 µL with sterile distilled 
water to which 0.75 µL (2.6 units) of DNA polymerase was added. Using a Techne 
TC-412 thermocycler, a standard PCR program consisting of one cycle at 96°C for 
initial melting followed by 30 cycles of 96°C for 30 seconds (denaturing), 55°C for 
30 seconds (annealing) and 60°C for 60 seconds (extension), was performed. A 
further extension 10 minutes at 72°C was usually added to the program. The 
temperatures and times used were varied dependent on the oligonucleotide primer 
combinations and template. After the amplification, the reactions products were 
fractionated on a 0.8% (w/v) agarose gel and bands of the expected size gel purified. 
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The probe was then stored at -20°C or denatured at 95°C for 5 minutes then used 
immediately for hybridization.  
2.6.4 DNA hybridization 
Nylon membranes containing immobilized DNA were incubated in pre-hybridization 
solution (5X SSC buffer; 0.5% (w/v) SDS, 1X Denhardts solution (200 mg L-1 
Ficoll® 400, 200 mg L-1 polyvinylpyrrolidone, 200 mg L-1 bovine serum albumin) 
containing 0.2 g L-1 sonicated denatured salmon sperm DNA (Sigma Aldrich) at 
65°C for a minimum of 1 hour. The denatured probe was immediately added to the 
pre-hybridization solution and then membrane incubated at 65°C overnight. The 
following morning, the membrane was copiously washed with 2X SSC containing 
0.2% (w/v) SDS at room temperature for 15 minutes then twice with 0.1X SSC 
containing 0.2% (w/v) SDS for 15 minutes at 65°C. 
 
Detection of the hybridizing probe was carried out using the DIG Luminescent 
Detection Kit (Roche) as per the manufacturer’s instructions. Briefly, the membrane 
was washed with Blocking Solution (1% (w/v) Blocking Reagent (Roche) in 0.1 M 
maleic acid, 0.15 M NaCl pH 7.5) before challenging for 30 minutes with an alkaline 
phosphatase conjugated anti-DIG antibody diluted 1:10 000 in Blocking Solution. 
Following two 15 minute washes in Wash Buffer (0.1 M maleic acid, 0.15 M NaCl, 
pH 7.5, 0.3% (v/v) Tween 20) and equilibration in Detection Buffer (0.1 M Tris-
HCl, 0.1 M NaCl, pH 9.5), the DNA side of the membrane was covered with CPSD® 
solution diluted 1:100 with Detection Buffer and incubated firstly for 5 minutes at 
room temperature then for 5 to 15 minutes at 37°C.  In a dark room, the membrane 
was then placed in an X-Ray cassette and exposed to X-Ray film (SLS). The film 
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was washed in RG Universal Ready to Use Developer and Fixer solutions 
(Champion Photochemistry) and water before being documented. 
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Chapter 3: Screening quinone-based compounds for 
anti-parasitic activity 
 
Parasites belonging to the order Trypanosomatida cause three of the seventeen 
infections referred to as neglected tropical diseases (NTDs) (Molyneux et al. 
2005; World Health Organisation 2015). Because this collection of maladies 
primarily affect people living in the poorest regions of the World, such ailments 
are not deemed commercially viable by pharmaceutical companies in terms of 
drug development: the developmental costs required to bring a new drug to 
market outweigh any potential finacial return (Feasey et al. 2010). As such only 
16 of the 1393 new drugs coming to market between 1975 and 1999 actually 
target NTDs (Pécoul 2004). In the case of trypanosomatid diseases, existing 
chemotherapies are problematic as they are costly, generally require medical 
supervision for their administration, often cause numerous severe side effects 
and may have limited efficacy (Wilkinson & Kelly 2009). Because of these 
issues the recommended drug regimens are frequently not completed resulting in 
the selection of parasite strains refractory to certain front-line drugs (Barrett et 
al. 2003; Wilkinson & Kelly 2009; Baker et al. 2013; Mohapatra 2014). Against 
this backdrop there is an urgent need for cheap, safe agents that can be 
administrated orally towards NTDs in general. 
 
Quinone-based compounds encompass a range of molecules characterised by 2 
carbonyl-groups linked to a carbocyclic backbone. They can be divided into 
several classes dependent on the number/type of ring(s) present in the basic 
structure & the relative positions of the carbonyl-groups on the ring (Figure 3.1). 
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Figure 3.1: Examples of basic quinone structures. A shows a 1,4-benzoquinone, B 
a 1,2-benzoquinone, C is a 1,4-naphthoquinone, D a 9,10-anthraquinone & E an 
indolequinone.  
 
Widely distributed in nature, quinones participate in a number of crucial biological 
cascades serving as electron acceptors and donators in the photosynthesis 
(plastoquinone, phylloquinone) and aerobic respiration (ubiquinone) electron 
transport chains and in blood coagulation and bone formation (vitamin K1 and K2) 
(Figure 3.2). Additionally, several natural & synthetic quinones have been used or 
are undergoing clinical evaluation in medicine as antimicrobial & anticancer agents. 
These usually function as inhibitors of essential redox pathways or as pro-drugs. For 
example, atovaquone, used as part of malarone combinational therapy to treat 
malaria, binds to and blocks the cytochrome bc1 complex in the Plasmodium 
mitochondrial electron transport chain while the anti-cancer drug mitomycin C 
following bioreductive activation, covalently binds to DNA strands leading to 
formation of inter- and intra-strand crosslinkages  (Figure 3.2) (Iyer & Szybalski 
1963; Mather et al. 2005). 
 
Figure 3.2: Examples of biologically active quinone-based molecules 
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Here, we report the antimicrobial screening of several different types of quinone-
based molecules against the protozoan parasites L. major, T. brucei and T. cruzi and 
for one group of compounds evaluate their toxicity toward mammalian cells.  
 
3.1 Anti-parasitic and toxicity properties of aziridinyl 1,4-benzoquinones 
Aziridinyl 1,4-benzoquinones lacking substitutions on the aziridinyl ring are of 
pharmacological interest because these compounds are reported to have potent 
anticancer activities (Lin et al. 1972; Lusthof et al. 1989). For RH1 (5) and AZQ 
(20) this has resulted in these agents undergoing clinical evaluation for use as 
treatments to target hypoxic solid malignancies including tumours associated with 
the breast, liver and colon (Schilsky et al. 1982; Tan et al. 1984; Falletta et al. 1990; 
Danson et al. 2011). In these situations, the cancerous cells have been shown to 
express elevated levels of the enzyme NADPH quinone oxidoreductase 1 (NQO1; 
also known as DT-diaphorase). In the absence of oxygen, this enzyme catalyses the 2 
electron reduction of the ABQ prodrug to generate metabolites that then mediate 
their cytotoxic effect by promoting DNA damage through the formation of DNA 
cross links (Danson et al. 2004; Dehn et al. 2005; Danson et al. 2007).  
 
Recently, the anti-microbial activities of ABQs towards the Plasmodium falciparum 
and Trypanosoma brucei parasites have been investigated with several potential lead 
compounds identified (Grellier et al. 2010; Hall et al. 2012). Here, we have 
expanded on these initial screens to evaluate the anti-kinteoplastid activities of 22 
ABQs (compounds 1-22; appendix 1) against T. brucei, T. cruzi and L. major. As an 
initial step a series of primary screens were performed aimed at determining the 
growth inhibitory activity of a fixed concentration of compound (10 µM) against 
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BSF T. brucei, T. cruzi epimastigotes or L. major promastigotes (Materials and 
Methods). In these assays a fixed number of parasites (1 x 104T. brucei ml-1; 5 x 
105T. cruzi or L. major ml-1) were grown for three (T. brucei), fourteen (T. cruzi) or 
six (L. major) days at 37 ºC (T. brucei) or at 27 ºC (T. cruzi and L. major) and then 
the cell number determined using the vital dye resazurin as reporter. All treatments 
were performed in quadruplicate. The resultant fluorescence values for each 
compound treated culture was transformed (subtraction of a background medium-
control florescence) and the data for each treatment expressed as % growth inhibition 
relative to untreated parasites analysed in parallel (data not shown). To demonstrate 
the validity of this assay system the growth inhibitory effects of nifurtimox on all 
three parasites was also determined. Based on these initial screens twelve, nine and 
twelve structures yielded high or moderate fluorescence values indicating they 
exhibited no or low growth inhibitory activity against T. brucei, T. cruzi and L. 
major, respectively. These were excluded from further studies.  
 
To further evaluate the anti-microbial activities of the remaining ABQs a series of 
secondary screens were performed aimed at determining the growth inhibitory 
activities of a range of compound concentrations (typically 3 nM to 10 µM for T. 
brucei and L. major, and 1 to 500 nM for T. cruzi). The resultant fluorescence values 
were transformed as previously described and compared against untreated parasites 
grown in parallel, with the finalised data expressed as % cell growth. Dose response 
curves for each agent were drawn (Figure 3.3) from which compound IC50 
valueswere determined (Table 3.1). Together the data demonstrated the ABQs to be 
a potent anti-parasitic class of compounds. Of those compounds tested MeDZQ (2), 
RH1 (5), 6 and 8 all yielded IC50 values<100 nM against BSF T. brucei with DZQ 
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(1), 3, TZQ (21) and 22 exhibitingvalues <500 nM. For T. cruzi, three agents (DZQ 
(1), RH1 (5) and TZQ (21)) displayed extremely potent activity against the 
epimastigote stage yielding IC50’s <10 nM with a further two (MeDZQ (2) and 22) 
and three (4, 6 and 14) generating values <100 and <500 nM, respectively. Against 
L. major promastigotes TZQ (21) exhibited an IC50 of <10 nM with DZQ (1) and 
RH1 (5) generating values of <100 nM with 3 and 22 yielding IC50’s <500 nM. Of 
all the ABQs analysed RH1 (5) was the most potent agent tested against all three 
parasite yielding IC50 values of 19 ± 1, 3 ± 1 and 68 ± 1 nM against T. brucei, T. 
cruzi and L. major, respectively. 
 
Figure 3.3: Dose response curvesof trypanosomatid parasites towards selected 
aziridinyl 1,4-benzoquinone compounds. The growth inhibitory effects ofDZQ (1), 
RH1 (5), 6 and 21 towards wild type bloodstream form T. brucei (circles, black solid 
line), L. major promastigote (squares, black dotted line) or T. cruzi epimastigote 
(diamonds grey solid line) cells was evaluated. Dose response curves were 
constructed from which the IC50 was calculated using non-linear regression analysis. 
Data points are averages from experiments performed in triplicate (T. brucei and L. 
major) or quadruplicate (T. cruzi) ± standard deviation. 
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Compound IC50 values (µM) ±  standard deviation 
T. brucei T. cruzi L. major 
Nifurtimoxa 2.700 ± 0.100 2.600 ± 0.400  6.280 ± 0.040 
 
7, 9-12, 16-19 
 
>10.000 >10.000 >10.000 
DZQ (1) 0.272 ± 0.001 0.005 ± 0.001 0.060 ± 0.001 
MeDZQ (2) 0.018 ± 0.001 0.055 ± 0.002 0.560 ± 0.139 
3 0.400 ± 0.03 6.200 ± 1.160 0.199 ± 0.004 
4 1.180 ± 0.160 0.106 ± 0.025 0.663 ± 0.006 
RH1 (5) 0.019 ± 0.001 0.003 ± 0.001 0.068 ± 0.001 
6 0.066 ± 0.002 0.205 ± 0.053 0.664 ± 0.002 
8 0.058 ± 0.001 1.300 ± 0.108 1.870 ± 0.184 
13 >10.000 5.550 ± 0.240 >10.000 
14 >10.000 0.445 ± 0.030 2.270 ± 0.017 
15 >10.000 3.310 ± 0.200 >10.000 
AZQ (20) 8.233  ± 0.272 6.000 ± 0.283 >10.000 
TZQ (21) 0.179 ± 0.001 0.003 ± 0.001 0.009 ±0.001 
22 0.148 ± 0.001 0.055 ± 0.002 0.218 ± 0.02 
Table 3.1: Anti-parasitic activity of aziridinyl 1,4-benzoquinones. Data represent 
the growth-inhibitory effect as judged by the IC50 values of aziridinyl 1,4-
benzoquinones on wild-type BSF T. brucei, L. major promastigotes and T. cruzi 
epimastigotes. All values are means ± standard deviation from three or four 
independent experiments. aT. brucei and T. cruzi IC50 towards nifurtimox were 
obtained from Wilkinson et al. (2008).  
  
To evaluate whether those ABQs that displayed anti-parasitic activity against all 
three kinteoplastid parasitesexhibited toxicity to mammalian cells we determined the 
cell killing properties of each agent against differentiated THP-1 cells: note this 
assay is not a growth inhibitory experiment as THP-1 cells once differentiated into 
macrophage-like cells are unable to divide. As for the parasite growth assays 
resazurin was used as reporter with the mammalian fluorescence values transformed 
as described previously and expressed as % viable cells relative to untreated control 
cultures. Values were then used to plot dose responses curves (Figure 3.4) from 
which the compound concentration that kills 50% of the mammalian cells (LD50) 
was determined (Table 3.2).  
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Figure 3.4: Dose response curves of differentiated THP-1 cells towards 
aziridinyl 1,4-benzoquinones compounds.The growth inhibitory effects 
ofselectedaziridinyl 1,4-benzoquinones (DZQ (1), MeDZQ (2), 3, 4, RH1 (5) and 22) 
towards differentiated THP-1 cells was evaluated. Dose response curves were 
constructed from which the LD50 was calculated using non-linear regression 
analysis. Data points are averages from experiments performed in triplicate ± 
standard deviation. Experiments were conducted by Ms J. Szular, QMUL.    
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Compound LD50(µM) ±  standard 
deviation 
DZQ (1) 0.181 ± 0.005 
2 0.885 ± 0.023 
3 63.170 ± 0.176 
4 6.633 ± 0.176 
RH1 (5) <0.100 
6 1.067 ± 0.159 
8 2.950 ± 0.770 
TZQ (21) <0.100 
22 0.138 ± 0.025 
Nifurtimoxa >100.000 
 
Table 3.2: Toxicity of aziridinyl 1,4-benzoquinones towards cultured 
mammalian macrophages. Data represent the growth-inhibitory effect as judged by 
their IC50’s of selected aziridinyl 1,4-benzoquinones on differentiated THP-1 
macrophage cells. All values are means ± standard deviation from three independent 
experiments. aDifferentiated THP-1 LD50 valuetowards nifurtimox taken from Voak 
et al (2013). 
 
Under these conditions eight of the ABQs tested showed significant toxicity in vitro 
yielding LD50's <10 µM with two compounds, including RH1 (5), being extremely 
toxic yielding values <100 nM. Comparison of the mammalian toxicity LD50 data 
with the IC50 values observed against the parasites allowed a crude measure of that 
agents’ selectively toward the pathogen(Table 3.3). In many cases the ABQ 
displayed a higher potency against the mammalian cell line relative to the parasite: 
the observed LD50 value towards the differentiated THP-1 line was lower than the 
calculated IC50 value against the parasite resulting in a selective toxicity value <1. Of 
those that did display preferential activity toward the parasite the observed selective 
toxicity (<50) was equivalent to that noted using nifurtimox, an agent who use in 
humans is problematic (Wilkinson & Kelly 2009). Only compound 3 showed 
reasonable selectivity against BSF T. brucei and L. major promastigotes yielding 
selective toxicity values of 158 and 317, respectively.  
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Compound Selective toxicity (LD50 THP-1/IC50 parasite) 
T. brucei T. cruzi L. major 
DZQ (1) <1 36 3 
2 49 16 2 
3 158 10 317 
4 6 63 10 
RH1 (5) 5 <33 1 
6 16 <1 <1 
8 51 <1 <1 
TZQ (21) <1 <33 <11 
22 <1 3 <1 
Nifurtimox >37 >38 >16 
Table 3.3: Selective toxicity of aziridinyl 1,4-benzoquinones 
 
As THP-1 cells are an immortal human monocytic cell line derived from an acute 
monocytic leukaemia patient and that ABQs have potent activity against cancerous 
cells (AZQ was trialled as a treatment against leukaemia) (Tan et al. 1984; Lee et al. 
1986; Moore et al. 1997), it was decided that selected compounds should be 
screened for their toxicity against non-cancerous mouse peritoneal macrophages. The 
compounds (TZQ (1), RH1 (5), TZQ (21) and 22) analysed all displayed potency 
against all parasites screened with three of the four agents differing only in the 
number of aziridinyl groups attached to the benzoquinone ring thus allowing a crude 
structure activity relationship study to be performed: DZQ (1) contains two 
aziridinyl substituents, TZQ (21) contains three and 22 has four. Peritoneal 
macrophages obtained from BALB/c mice (Dr Karin Seifert, LSHTM) were adhered 
onto a microscope slide, treated with different concentrations (100 to 1000 nM) of 
the selected ABQ and incubated at 37ºC. The cells were then fixed, Giemsa stained 
and the average number of cells per field of view determined (Figure 3.5): routinely 
10 fields of view were counted. For each drug treated sample the % of stained cells 
relative to untreated controls was determined and plotted as a dose response curve 
(data not shown) from which the LD50 was calculated. Under these conditions TZQ 
  
(1), RH1 (5), TZQ (21
nM, respectively.  
Figure 3.5: Susceptibility of primary spleen macrophages to aziridinyl 1,4
benzoquinones. Peritoneal macrophages extracted from BALB/c mice were adhered 
onto microscope slides then treated with different concentrations of selected ABQs. 
Cells were Giemsa stained and visualized by light microscopy. A typical field using 
a x20 objective is shown.
 
Our data clearly demonstrates that ABQs are extremely toxic to primary cells thus 
confirming our THP-
be beneficial in targeting systemic trypanosomal and leishmanial infections. 
However, they may still be useful in the therapy of cutaneous lesions. As such our 
focus on ABQs switched from exploiting these 
as chemical tools to understand their mechanisms of action against the pathogen.
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1 studies and shows that this class of compound are unlikely to 
as potential treatments to using them 
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3.2 Trypanocidal and leishmanicidal properties of methyl substituted aziridinyl 
1,4-benzoquinones 
Searches of the PubChem database (http://pubchem.ncbi.nlm.nih.gov/) identified 
several additional ABQs that all contained mono- or di-methyl substitutions on the 
aziridinyl groups attached to the 1,4-benzoquinone core which were freely available 
from the National Cancer Institute. In this study these agents represent a second class 
of compounds referred to as methyl aziridinyl 1,4-benzoquinones (MeABQs). Many 
of these chemicals were originally synthesised while searching for anti-cancer 
agents, screens in which many were deemed to be inactive.  
 
Here, a total of 12 MeABQs (23-34) were assayed for anti-parasitic activity using the 
primary and secondary screening procedures outlined previously. From the primary 
screens, five, five and four compounds failed to display any activity against BSF T. 
brucei, T. cruzi epimastigotes or L. major promastigotes, respectively (Table 3.4). 
Subsequent secondary screening generating dose response curves (Figure 3.6) from 
which IC50 values were determined (Table 3.4). Generally, these compounds 
appeared to be less toxic to the parasites than the non-methylated ABQ group of 
compounds with no chemical yielding an IC50 value of <500 nM against T. brucei, 
one (24) against T. cruzi and six (23-25, 27, 29 and 30) against L. major. In light of 
the cytotoxicity displayed by ABQs to mammalian cells and because no one 
MeABQ agent displayed activity against all three parasite lines, this class of 
compound was not analysed further. 
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Figure 3.6: Susceptibility of trypanosomatid parasites towards selected methyl 
and di-methyl substituted aziridinyl 1,4-benzoquinones. The growth inhibitory 
effects of 25, 27 and 29 towards wild type bloodstream form T. brucei (circles, black 
solid line), L. major promastigote (squares, black dotted line) or T. cruzi 
epimastigote (diamonds grey solid line) cells was evaluated. 25 did not show activity 
against T. cruzi epimastigotes at 10 µM therefore was not screened further. Dose 
response curves were constructed from which the IC50 was calculated using non-
linear regression analysis. All data points are averages from experiments performed 
in triplicate ± standard deviation 
 
Compound IC50 values (µM) ±  standard deviation 
T. brucei T. cruzi L. major 
23 >10.000 2.180 ± 0.670 0.348 ± 0.166 
24 >10.000 0.037  ± 0.001 0.473 ± 0.123 
25 0.920 ± 0.050 - 0.080 ±0.006 
26 >10.000 8.638 ± 0.736 2.360 ± 0.230 
27 0.540 ± 0.040 0.620 ± 0.180 0.210 ± 0.01 
28 2.850 ± 0.260 >10.000 >10.000 
29 2.160 ± 0.079 0.975 ± 0.025 0.175 ± 0.005 
30 0.700 ± 0.053 0.980 ± 0.025 0.174 ± 0.01 
31 >10.000 >10.000 >10.000 
32 2.873 ± 0.042 >10.000 >10.000 
33 >10.000 >10.000 8.157 ± 0.080 
34 2.923 ± 0.065 >10.000 >10.000 
 
Table 3.4: Anti-parasitic activity of methyl substituted aziridinyl 1,4-
benzoquinones. Data represent the growth-inhibitory effect as judged by their IC50’s 
of methylated aziridinyl 1,4-benzoquinones on wild-type BSF T. brucei, L. major 
promastigotes and T. cruzi epimastigotes. All values are means ± standard deviation 
from three or four independent experiments. 
 
3.3 Trypanocidal and leishmanicidal properties of naphthoquinone. 
Naphthoquinone-based compounds are of biological importance playing key roles in 
process requiring oxidoreductase shuttles or as enzyme cofactors (e.g. the K 
vitamins). Additionally, they have been exploited as antimicrobial agents primarily 
as inhibitors of the above systems (e.g.atovaquone is used to treat malaria) 
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(Srivastava et al. 1997; Srivastava et al. 1999). In the search for anti-kinetoplastid 
agents approximately 100 publications detailing the synthesis and evaluation of 
naphthoquinone derivatives have been reported with such compounds targeting a 
range of different biological processes within the parasites including energy 
production, generators of mitochondrial oxidative stress, ergosterol biosynthesis, 
cytoskeleton assembly, protein metabolism and biosynthesis and  chaperones 
modulation (Menna-Barreto et al. 2010; Pieretti et al. 2013; Salomão et al. 2013). 
Here, we evaluated a series of naphthoquinones (35-51), many of which contained 
nitrogen mustard and aziridinyl groupings that may promote DNA damage, for their 
trypanocidal and leishmanicidal properties. After conducting growth inhibition 
screens, dose response curves were drawn (Figure 3.7) from which IC50 values 
calculated (Table 3.5). Out of the seventeen compounds tested, fifteen (36-45 and 
47-51) were active against T. brucei yielding IC50’s ranging from ~0.1 to ~2.7 µM 
while fourteen (36-44 and 47-51) displayed potency against L. major, generating 
IC50’s from ~0.3 to 8.7 µM. Invariably, compounds that exhibited trypanosomal 
growth inhibitory properties were active against the leishmanial species. Only 45 did 
not follow this trend although this agent displayed a relatively low activity against T. 
brucei (IC50 of 1.91 ± 0.21 µM) while no having an effect on L. major at 10 µM. In 
contrast, T. cruzi was generally less susceptible to this class of quinone with only 
five (35, 36, 38, 40 and 41) agents displaying anti-Chagasic properties producing 
IC50’s ranged from to 0.7 to 7.7 µM).  
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Figure 3.7: Dose response curvesof trypanosomatid parasites towards selected 
naphthoquinones. The growth inhibitory effects of 38, 40 and 41 towards wild type 
bloodstream form T. brucei (circles, black solid line), L. major promastigote 
(squares, black dotted line) or T. cruzi epimastigote (diamonds grey solid line) cells 
was evaluated. Dose response curves were constructed from which the IC50 was 
calculated using non-linear regression analysis. All data points are averages from 
experiments performed in triplicate ± standard deviation. 
 
Compound  IC50 values (µM) ± standard deviation 
T. brucei T. cruzi L. major 
Menadione (35) >10.000 7.710 ± 0.090 >10.000 
Plumbagin (36) 0.640 ± 0.015 2.360 ± 0.310 0.410 ± 0.040 
37 2.170 ± 0.070 >10.000 8.700 ± 1.050 
38 2.700  ± 0.100 7.090 ± 0.730 0.730 ± 0.020 
39 1.890 ± 0.030 >10.000 7.600 ± 0.030 
40 0.200 ± 0.040 0.700 ± 0.070 0.288 ± 0.010 
41 0.300 ± 0.067 7.000 ± 0.180 1.780 ± 0.130 
42 0.630 ± 0.010 >10.000 1.300 ± 0.040 
43 0.107 ± 0.149 >10.000 0.650 ± 0.006 
44 0.670 ± 0.010 >10.000 0.900 ± 0.006 
45 1.910 ± 0.210 >10.000 >10.000 
Lapachol (46) >10.000 >10.000 >10.000 
47 0.197 ± 0.030 >10.000 5.667 ± 0.379 
48 0.721± 0.004 >10.000 6.717 ± 0.029 
49 0.660 ± 0.070 >10.000 2.000 ± 0.080 
50 6.333± 0.247 >10.000 6.310 ± 0.277 
51 0.198 ± 0.010 >10.000 1.187 ± 0.018 
 
 
Table 3.5:Anti-parasitic activity of naphthoquinones. Data represent 
the growth-inhibitory effect as judged by their IC50’s of naphthoquinones 
on wild-type BSF T. brucei, L. major promastigotes and T. cruzi 
epimastigotes. All values are means ± standard deviation from three or 
four independent experiments. 
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3.4 Trypanocidal and leishmanicidal properties of benzoquinone nitrogen 
mustards 
Nitrogen mustard-containing compounds such as chlorambucil, mechlorethamine, 
cyclophosphamide, melphalan, prednimustine, bendamustine etc have been trialled 
and used extensively to treat a range of cancers (Mouridsen et al. 1980; Dighiero et 
al. 1998; Moreau et al. 1999; Skinner et al. 2004; Tashkin et al. 2006; Leoni et al. 
2008). In most cases, the biologically active N(CH2CH2Cl)2 grouping is attached to a 
cyclic structure such as a benzyl (chlorambucil, melphalan, prednimustine), 
oxazaphosphorine (cyclophosphamide) or benzimidaozle (bendamustine) ring. 
Previous work conducted in the Wilkinson lab has shown that 
nitrobenzylphosphoramide-containing nitrogen mustards are potent trypanocidal and 
leishmanicidal compounds with the activities of such agents dependent on type I 
NTR(Hall et al. 2010; Hu et al. 2011; Voak et al. 2014). Based on the above lines of 
evidence we evaluated a small collection of 1,4-benzoquinone nitrogen mustards 
(52-56) for their anti-parasitic properties (Figure 3.8; Table 3.6). Out of the five 
compounds tested, one (54) failed to display activity against any of the parasites 
screened at 10 µM. From the remaining agents four (52, 53, 55 and 56) showed 
activity against both T. brucei and L. major with only one (52) displaying anti-T. 
cruzi effects. Where an anti-microbial property was observed the leishmanial 
parasite was generally more susceptible to a given agent than the trypanosome e.g. 
based on IC50 values L. major was 7.5- and 2.8-fold more susceptible to 52 as 
compared to T. brucei and T. cruzi, respectively.  
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Figure 3.8: Dose response curvesof trypanosomatid parasites towards 1,4-
benzoquinone nitrogen mustards. The growth inhibitory effects of 51, 52 and 53 
towards wild type bloodstream form T. brucei (circles, black solid line), L. major 
promastigote (squares, black dotted line) or T. cruzi epimastigote (diamonds grey 
solid line) cells was evaluated. Dose response curves were constructed from which 
the IC50 was calculated using non-linear regression analysis. All data points are 
averages from experiments performed in triplicate ± standard deviation 
 
Compound IC50 values (µM) ± standard deviation 
T. brucei  T. cruzi L. major 
52 5.433 ± 0.764 2.023 ± 0.080 0.720 ± 0.030 
53 4.483 ± 0.993 >10.000 2.270 ± 0.090 
54 >10.000 >10.000 >10.000 
55 2.023 ± 0.008 >10.000 0.610 ± 0.020 
56 1.727 ± 0.096 0.668 ± 0.050 0.668 ± 0.050 
 
Table 3.6: Anti-parasitic activity of 1,4-benzoquinone nitrogen mustards. Data 
represent the growth-inhibitory effect as judged by their IC50’s of 1,4-benzoquinone 
nitrogen mustards on wild-type BSF T. brucei, L. major promastigotes and T. cruzi 
epimastigotes. All values are means ± standard deviation from three or four 
independent experiments. 
 
3.5 Trypanocidal and leishmanicidal properties of other aziridinyl-containing 
quinones 
Several other classes of quinones that contain aziridinyl groupings have been used or 
are under clinical evaluation as therapeutic agents. One of the best known is 
mitomycin C, an indolequinone being used to treat a range of tumours including 
cancers of the bladder, breast, lung, liver and stomach (see 
http://www.cancerresearchuk.org/about-cancer/cancers-in-general/treatment/ cancer-
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drugs/mitomycin-c) and its derivatives porfiromycin and apaziquone which have or 
are undergoing clinical evaluation to treat hypoxic tumours (Keyes et al. 1985; Puri 
et al. 2006; Phillips et al. 2013; Guise et al. 2014). The compounds all function as 
prodrugs undergoing NQO1-mediated activation that results in products which 
promote DNA damage (Iyer & Szybalski 1964; Siegel et al. 2012). Interestingly, 
novel indolequinone prodrugs have been developed that function to inhibit NADPH 
quinone oxidoreductase 2 (NQO2), an enzyme of unknown  function whose 
expression is upregulated in some cancers (Yan et al. 2011; Dufour et al. 2012). In 
this case, activation of these prodrugs occurs via NQO2 bioreduction to produce 
metabolites that actually alkylate and inhibit NQO2 itself (Dufour et al. 2012). 
 
Here, we evaluated the efficacy of three further aziridinyl-containing quinones 
including mitomycin C (57) and two benzimidazoles (58 and 59) against T. brucei, 
T. cruzi and L. major (Figure 3.10; Table 3.7). Mitomycin C (57) displayed growth 
inhibitory activity against all three parasites displaying a particularly high degree of 
potency towards T. brucei (IC50 of 20 nM). As with this indolequinone, the two 
benzimidazoles were extremely effective against T. brucei with 58 and 59 yielding 
IC50 values of 211and 6 nM, respectively but less so against T. cruzi and L. major. 
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Figure 3.9: Dose response curvesof trypanosomatid parasites towards other 
aziridinyl-containing quinones. The growth inhibitory effects of 57, 58 and 59 
towards wild type bloodstream form T. brucei (circles, black solid line), L. major 
promastigote (squares, black dotted line) or T. cruzi epimastigote (diamonds grey 
solid line) cells was evaluated. Dose response curves were constructed from which 
the IC50 was calculated using non-linear regression analysis. All data points are 
averages from experiments performed in triplicate ± standard deviation.  
 
Compound IC50 values (µM) ± standard deviation 
T. brucei T. cruzi L. major 
Mitomycin c 
(57) 0.020 ± 0.015 2.063 ± 0.380 4.200 ± 0.029 
58 0.211 ± 0.005 >10.000 2.800 ± 0.200 
59 0.006 ± 0.001 0.773 ± 0.128 0.680 ± 0.060 
 
Table 3.7: Anti-parasitic activity of other aziridinyl containing quinones. Data 
represent the growth-inhibitory effect as judged by their IC50’s of the remaining 
aziridinyl containing quinones on wild-type BSF T. brucei, L. major promastigotes 
and T. cruzi epimastigotes. All values are means ± standard deviation from three or 
four independent experiments. 
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Chapter 3 summary 
This chapter has focused on evaluating the trypanocidal and leishmanicidal activities 
of a small (59) compound library made up of chemicals that all contain a quinone-
containing backbone. We demonstrated that: 
1. Most compounds tested displayed anti-parasitic activity at 10 µM, with ~1/3rd 
(21/59) exhibiting growth inhibitory effects against all three parasites 
studied. 
2. Several compounds yielded very low IC50 values (<100nM) indicating that 
these were of promise in treatment development targeting trypanosomiasis 
and leishmaniasis: six compounds (MeDZQ (2), RH1 (5), 6, 8, mitomycin C 
(57) and 59) generated IC50’s <100 nM against T. brucei, five (DZQ (1), 
MeDZQ (2), RH1 (5), TZQ (21) and 22) against T. cruzi and four (DZQ (1), 
RH1 (5), TZQ (21) and 25) against L. major. 
3. As a class the aziridinyl 1,4 benzoquinones that lacked methyl substituents 
on their aziridinyl groupings were the most effect against all three parasites 
tested, with RH1 (5) being the most effective of all. 
4. When tested against primary and secondary mammalian cell lines 
(macrophages and macrophage-like cells) all the compounds tested, including 
RH1 (5), displayed significant toxicity. 
5. In light of the observed toxicity, aziridinyl 1,4 benzoquinones are unlikely to 
be beneficial in targeting systemic trypanosomal and leishmanial infections 
although may still be of use in treating cutaneous lesions. 
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6. The focus on ABQs in this thesis should switch from exploiting these as 
potential anti-parasitic treatments to using them as chemical tools to 
understand their mechanisms of action against the pathogen.  
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Chapter 4: Unravelling the trypanocidal mode of 
action of the aziridinyl benzoquinones 
 
Understanding how various compounds may mediate their cytotoxic effects has 
helped in deciphering key biological and biochemical process within a given cell 
or organism. This information has not only informed future drug design but also 
allows for the identification of potential resistance mechanisms. In 
trypanosomes, one way in which a compound’s mode of action can be identified 
is through the generation of genetically modified parasites that express altered 
levels of a given gene with the susceptibility of the resultant recombinant lines 
evaluated against the chemical understudy. One drawback of this approach is 
that certain assumptions about the compound’s mode of action are required at 
the onset thus potentially biasing the study. Recently, the application of high 
throughput whole genome loss of function (RNAi) and whole genome gain of 
function (over expression) screening strategies for use in T. brucei have been 
described with these approaches partially circumventing the above issue 
(Alsford et al. 2012; Begolo et al. 2014). Here, using an RNAi library screening 
technique we evaluate whether the trypanocidal benzoquinone-based compounds 
described in Chapter 3 function as prodrugs that forms metabolites which go on 
to promote DNA damage through a mechanism that can be repaired by a 
trypanosomal nuclease belonging to the SNM1/PSO2 family, enzymes that are 
only implicated in the repair of interstrand crosslinks (ICLs). 
 
4.1 Identifying the RH1 activation mechanism. 
In conjunction with Dr Sam Alsford (LSHTM) a whole genome loss of function 
assay was conducted on BSF T. brucei using RH1, the archetypal ABQ, as selective 
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agent. The library consists of a population of T. brucei parasites which have been 
genetically modified to contain a tetracycline inducible RNAi construct plus a 
fragment of the T. brucei genome. The library exhibits > 5 times coverage of the T. 
brucei genome (Alsford et al 2011). The whole loss-of-function library screens have 
been used to identify key proteins which confer resistance towards a particular agent. 
Previous work by Horn and Alsford groups have identified AAT6 as a key uptake 
mechanism for eflornithine resistance whilst NTR was identified as a mediator of 
nifurtimox resistance (Baker et al, 2011; Alsford et al, 2014).  
 
To summarise the experiment, an aliquot of the T. brucei RNAi library stock was 
induced to undergo RNAi by addition of tetracycline (1 µg ml-1) one day (-1 day) 
prior to setting up the selection. At day 0, 30 nM RH1 (a concentration 1.5 times the 
IC50 (see Table 3.1)) was added to a culture containing 2 x 105 T. brucei ml-1 and 
over the course of the next 12 days the cell density of the treated culture followed 
(Figure 4.1): When appropriate the culture was diluted to 2 x 105T. brucei ml-1 in 
medium containing fresh tetracycline (1 µg ml-1) and RH1 (30nM). The above 
treatment initially resulted in a reduced growth rate as compared to non-induced and 
non-RH1 controls, followed by an outgrowth from day 8 onwards of an RH1 
resistant population, a pattern has been previously observed using other selective 
conditions (Baker et al. 2011; Alsford et al. 2013; Alsford et al. 2014). The 
outgrowth represents theparasites which contain a fragment of the genome, which 
under RNAi conditions confers resistance towards the selective agent.  
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Figure 4.1: Screening for RH1 resistant determinants using a genome wide T. 
brucei RNAi library. The BSF T. brucei RNAi library (Alsford et al. 2012; Glover 
et al. 2015) was co-treated with tetracycline (1 µg ml-1) to induce RNAi, and RH1 
(30 nM) with the cumulative cell growth of the culture followed. The arrows 
correspond to culture dilution and addition of fresh RH1 (30 nM) and tetracycline (1 
µg ml-1). Genomic DNA (as indicated by stars) was extracted from parasites at days 
9 and 12. The above data was collected by Dr S. Alsford, LSHTM.  
 
 
Towards the end of the selection, at days 9 and 12, genomic DNA was extracted 
from the RH1 selected parasite population and used as template in a PCR-based low 
resolution screen. This screen was carried out in accordance to Baker et al (2011). 
To summarise this low resolution screen, the genomic DNA was used in a standard 
PCR reaction (30 cycles of 95ºc for 30s, 57ºc for 30s and 72ºc for 130s) containing 
the primers LIB2f and LIB2r (See Appendix 3). These primers are designed to 
amplify the fragment found in the RNAi construct. The PCR products were 
separated on a 1% agarose gel (Figure 4.2). The hits that are pulled out of a low 
resolution screen are those that yield the highest amounts of reads from the high 
throughput sequencing of the genomic DNA.  
 
Analysis of the resultant amplification products identified one major fragment of 
~1.1 kbp and a background non-descript smear. Sequence analysis of the major band 
and comparison against the reference genome database revealed that the RH1-
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resistance-associated fragment mapped to a region that spanned the 5’ 
untranslated/5’ coding sequence of the type I nitroreductase (Tbntr) gene (Gene ID: 
Tb927.7.7230 on TriTRypDB). This was not unexpected given that the encoded 
protein, TbNTR, had been previously associated with the activation of trypanocidal 
nitroheterocyclic-based prodrugs nifurtimox and benznidazole (Wilkinson et al. 
2008; Baker et al. 2011; Hall et al. 2011; Hall & Wilkinson 2011) and been 
postulated to function as a NADH dependent quinone oxidoreductase (Wilkinson et 
al. 2008; Alsford et al. 2012; Hall et al. 2012).  
 
 
 
Figure 4.2: Identification of RH1 resistance determinants. (A) Amplification of 
the RNAi target from the RH1 screen using gDNA extracted on day 9 of the 
selection and different primer concentrations produced several bands with the major 
fragment mapping to the type I nitroreductase (Tbntr) loci. M indicates a size marker 
in bp. (B) The position of the DNA fragment recovered from the RH1 RNAi screen, 
mapping to the Tbntr loci is indicated by grey box. 
 
In addition to facilitating the low resolution PCR screens, the extracted template 
genome DNA can also serve as starting material for a more in-depth analysis.Such 
analysiscan reveal other genes associated with conferring resistance towards the 
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selecting agent. For example the in-depth analysis of nifurtimox resistant library 
carried out by Alsford et al (2012) identified putative flavokinases which convert 
riboflavin to FMN, the cofactor for the nifurtimox prodrug activator NTR.   This 
would involve the high throughput sequencing of the PCR products to generate any 
hits coupled with extensive bioinformatics used to map such hits against the 
reference genome sequence. Prior to conducting such a study the inducibility of the 
RNAi screen needs to be determined. The percentage inducibility effectively 
functions as a measure as to how much of the outgrowth observed for a given 
selection is actually due to the RNAi effect and not as a result of some other process 
such as selection of background mutations. This value can be readily calculated by 
firstly comparing the cumulative growth of non-induced (i.e. not undergoing RNAi) 
parasites grown in the presence of drug treatment against non-induced parasites 
grown in the absence of drug treatment (equation 4): 
Equation 4: 
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Next, the cumulative growth of parasites induced to undergo RNAi grown in the 
presence of drug treatment is compared the cumulative growth of parasite induced to 
undergo RNAi grown in the absence of drug treatment (equation 5): 
Equation 5:  	
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Then, the two above equations are compared against each other and transformed by 
subtraction form 1 (equation 6); 
Equation 6: 1-   
 
  
 
 
 
For RH1 a % inducibility value of 12% was observed (Figure 4.3). This figure is low 
in comparison to most other selective challenged used against the RNAi library 
screen with compounds such as eflornithine and pentamidine yielding 
      
 
 
(92) 
 
inducibilityvalues >80% (Alsford et al 2012). However, for the nifurtimox screens 
reported by Alsford et al (2012) an inducibility value of <20% was recorded 
(Alsford et al. 2012). This value reflects how much of the observed phenotype is 
down to the effect of RNAi. Low values suggest that background mutations are 
responsible for the resistance rather than the effect of RNAi. One possible 
explanation for such low values could reflect a possible mode of action for RH1 and 
nifurtimox. Potentially both agents may promote the formation of mutations in the 
genome of the T. brucei RNAi library parasites such that these resultant mutants are 
resistant to the selective pressure producing the observed outgrowth. 
 
 
Figure 4.3: Inducibility of the RH1 
resistance phenotype of the selected 
library. Data was collected by Dr S. 
Alsford, LSHTM. 
4.2 Validating TbNTR as an activator of RH1  
To conclusively demonstrate that TbNTR is the key activator of RH1 we evaluated 
the susceptibility of T. brucei cells engineered to express reduced levels of the 
encoding gene. Initially, we developed two DNA constructs that facilitate RNAi 
targeting the Tbntr transcript. In one vector, based on p2T7TA, formation of double 
strand RNA that drives the RNAi process is driven by two head to head promoters 
(see Chapter 6) (Wilkinson et al. 2003), while in the other, based on pRPaSL, 
formation of double strand RNA is caused by 
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expression from a single promoter of repeat sequences from the target gene that form 
a stem loop structure (Alsford & Horn 2008). Despite it being documented that the 
TbNTR activity is essential for BSF T. brucei viability (Wilkinson et al. 2008), 
RNAi targeting the Tbntr transcript using either system had no effect on parasite 
growth or on the susceptibility of the parasite to nifurtimox or RH1. To overcome 
this we used a T. brucei line (Tbntr+/-) where one of the Tbntr alleles had been 
replaced with a puromycin resistance cassette (Wilkinson et al. 2008). When the 
susceptibility of these recombinant parasites towards RH1 was assessed the 
heterozygote cells displayed an IC50 approximately 2.5-fold greater than that 
observed towards wild type cells (Figure 4.4). Likewise, parallel studies involving 
nifurtimox displayed a similar result with the Tbntr+/- line being more resistant to 
this 5-nitrofuran than controls (data not shown) and is in keeping with previous 
observations (Wilkinson et al 2008). This confirmed that reduction of Tbntr 
expression through loss of one of the alleles encoding for TbNTR is sufficient to 
generate resistance to RH1. 
 
Figure 4.4: Susceptibility of T. brucei Tbntr heterozygotes to RH1.  (A) Dose 
response curve of wild type T. brucei (solid line) and parasites that are haploid for 
Tbntr (dotted line) to RH1. (B) Susceptibility of wild type T. brucei (white bar) and 
TbNTR heterozygotes (grey bar) to RH1 as judged by the IC50 values (in nM). All 
data are means for experiments performed in quadruplicate ± standard deviation. The 
differences in susceptibility of wild type and TbNTR over expressing cells to RH1 
was statistically significant (P <0.01), as assessed by Student's t test. 
 
      
 
 
(94) 
 
As reduction of TbNTR activity leads to RH1 resistance it is implicit that gain of 
function via over expression of the oxidoreductase should have the converse effect, 
generating cells that are more susceptible to the ABQ. To determine if this is the 
case, the sensitivity of a T. brucei line engineered to express elevated levels of the 
enzyme towards the quinone was evaluated (Wilkinson et al. 2008; Hall et al. 2011; 
Bot et al. 2013). This demonstrated that parasites over expressing Tbntr were 
hypersensitive (approximately 4-fold) to this aziridinyl agent as compared to 
controls. 
 
Figure 4.5: Susceptibility of T. brucei expressing elevated levels of TbNTR to 
RH1. (A). Dose response curve of wild type T. brucei (solid line) and parasites 
engineered to express elevated levels of TbNTR (dotted line) to RH1. (B). 
Susceptibility of wild type T. brucei (white bar) and TbNTR over expressing line 
(grey bar) to RH1 as judged by the IC50 values (in nM). All data are means for 
experiments performed in quadruplicate ± standard deviation. The differences in 
susceptibility of wild type and TbNTR over expressing cells to RH1 was statistically 
significant (P < 0.01), as assessed by Student's t test. 
 
Together, the above functional genomic data clearly demonstrate that TbNTR is a 
key activator of RH1. 
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4.3 Does TbNTR activate other aziridinyl benzoquinones? 
To determine whether TbNTR plays a role in activating other ABQs the 
susceptibility of the Tbntr over expressing parasites towards a selected group of 
these compounds was tested (Figure 4.6; Table 4.1). Out of the additional 
compounds screened, six (DZQ, MeDZQ, 3, 6, 8 and TZQ) all showed the same 
hypersensitivity profile as RH1, being between 1.5 and 3.5-fold more susceptible to 
the aziridinyl agents than controls. Intriguingly, one compound (22), a tetra-
aziridinyl ABQ, did not follow this pattern with the TbNTR over expressers 
exhibiting an IC50 equivalent to that observed against control cells. 
 
 
Figure 4.6: Susceptibility of T. brucei expressing elevated levels of TbNTR to 
ABQs. Dose response curves evaluating the sensitivity of wild type T. brucei (white 
bars) and parasites engineered to express elevated levels of TbNTR (grey bars) 
toward selected ABQs were plotted and the IC50 values (in nM) determined. 
Nifurtimox were used as control. All data are means for experiments performed in 
quadruplicate ± standard deviation. The differences in susceptibilities of control and 
TbNTR over expressing cells to all compounds except compound 22 was statistically 
significant (P <0.01), as assessed by Student's t test. 
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Compound IC50 values (µM) ± standard deviation Ratio 
control over expressers 
Melarsoprol 3.750 ± 0.200 4.100 ± 0.500 0.9 
Nifurtimox 2.980 ± 0.030 0.315 ± 0.015 9.5 
DZQ (1) 0.318  ± 0.038 0.090  ± 0.003 3.5 
3 0.449 ± 0.010 0.297 ± 0.073 1.5 
RH1 (5) 0.012 ± 0.002 0.003 ± 0.001 4.0 
6 0.310 ± 0.040 0.140 ± 0.020 2.2 
8 0.670 ± 0.030 0.460 ± 0.010 1.5 
TZQ (21) 0.184 ± 0.010 0.060 ±0.009 3.1 
22 0.121 ± 0.021 0.148 ± 0.009 0.8 
 
Table 4.1: The growth inhibitory effect of ABQ compounds towards T. brucei 
expressing elevated levels of TbNTR. Data represents the IC50 values of parasites 
expressing wild type and elevated levels of TbNTR. All values are means ± standard 
deviation of four independent experiments. The fold difference in IC50 values 
between the two treatments are given. 
 
The above findings are further supported by in vitro studies where ABQs such as 
DZQ, MeDZQ, 3, RH1, 6, 8 and TZQ were shown to be substrates for purified 
recombinant TbNTR whereas 22 was not metabolised by parasite enzyme (Hall et al 
2012). Therefore, based on our observations 22 is not activated by TbNTR.  
 
4.3Assessing other aziridinyl benzoquinone activation mechanisms 
The ABQs can undergo activation to form hydroquinone derivatives by two distinct 
pathways. As shown in figure 1.8, enzymes such as cytochrome P450 reductase 
(CPR) mediate the 1e- reduction of the quinone to a semiquinone radical with the 
fate this reduction product dependent on oxygen levels. Under hypoxic conditions 
this radical can then undergo further reduction to the hydroquinone while in the 
presence of O2, the semiquinone can undergo futile cycling to form O2.- and the 
parental quinone. In the second pathway, reduction of the quinone to the 
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hydroquinone occurs directly viaa 2e- reduction event as typified by NQO1. As 
TbNTR shares many biochemical characteristics with NQO1 it appears that the 
major ABQ trypanocidal mechanism for most compounds involves the second of the 
above pathways. However, to evaluate whether the anti-parasitic ABQs reported in 
Chapter 3 can undergo activation by the first pathway, the susceptibility of T. brucei 
lines engineered to express ectopic copies of the TbCPR isoforms 2 (TbCPR2) or 3 
(TbCPR3) (Bot et al. 2013)to RH1, TZQ and 22 was evaluated (Figures 4.7). When 
using RH1 and TZQ, both TbCPR over expressing lines exhibited IC50’s similar to 
that observed against control cells indicating that for these ABQs the 1e- quinone 
reduction pathway plays no role in their trypanocidal activities. When the T. brucei 
line expressing elevated levels of TbCPR2 or TbCPR3 were tested against 22, both 
recombinant lines were hypersensitive (>20-fold) to this tetra-aziridinyl agent than 
control cells.  
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Figure 4.7: Susceptibility of T. brucei expressing elevated levels of TbCPR2 to 
ABQs. Panels on the left hand side show the dose response curve of wild type T. 
brucei (solid line) and parasites engineered to express elevated levels of TbCPR2 
(dotted line) to RH1, TZQ and 22.The panels on the right hand side show the 
susceptibility of wild type T. brucei (white bar) and TbCPR2 over expressing 
parasites (grey bar) to RH1, TZQ and 22 as judged by the IC50 values (in nM). All 
data are means for experiments performed in quadruplicate ± standard deviation. The 
differences in susceptibility of wild type and CRP2 over expressing cells to 22 was 
statistically significant (P < 0.01), as assessed by Student's t test.  
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Figure 4.8: Susceptibility of T. brucei expressing elevated levels of TbCPR3 to 
ABQs. Panels on the left hand side show the dose response curve of wild type T. 
brucei (solid line) and parasites engineered to express elevated levels of TbCPR3 
(dotted line) to RH1, TZQ and 22.The panels on the right hand side show the 
susceptibility of wild type T. brucei (white bar) and TbCPR3over expressing 
parasites (grey bar) to RH1, TZQ and 22 as judged by the IC50 values (in nM). All 
data are means for experiments performed in quadruplicate ± standard deviation. The 
differences in susceptibility of control and TbCRP3 over expressing cells to 22 was 
statistically significant (P < 0.01), as assessed by Student's t test. 
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Based on the above observations, it appears that 22, the only ABQ whose 
trypanocidal activity is not dependent on TbNTR, functions as a prodrug that 
undergoes activation via a mechanism in which the trypanosomal CPRs play a role. 
Whether other enzymes can catalyse this activity was not established here. 
Chapter 4 summary 
In this Chapter we have explored how the ABQs can mediate their cytotoxic effect 
against T.brucei. Specifically we have shown that: 
1. Screening of the RNAi library using RH1 as selective agent determined that 
reduction in type I nitroreductase activity generates resistant parasites. 
2. T.brucei Tbntr heterozygote parasites are resistant to RH1. 
3. T. brucei cells engineered to express an ectopic copy of Tbntr are more 
susceptible to RH1 and most other ABQs tested, with compound 22 being the 
exception. 
4. Compound 22, a tetra aziridinyl ABQ, still functions as a prodrug and is 
activated by a reaction catalysed by cytochrome P450 reductase isoforms.  
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Chapter 5: Investigating the potential role of ABQs 
in promoting DNA damage in trypanosomes. 
 
In most cells ABQs ultimately mediate their toxicity through the formation of ICLs 
that block processes which require separation of the DNA double helix (i.e. 
replication and transcription) (Berardini et al. 1993; Alley et al. 1994; Yan et al. 
2008; Pierce et al. 2011). To combat the deleterious effects of such lesions several 
DNA repair pathways cooperate to recognise and then fix this damage. Of the 
enzymes that function in these systems, members of the so-called SNM1/Pso2p 
family are of particular interest as cells lacking this activity are specifically and 
highly susceptible to ICL-inducing agents including psoralen, cisplatin and 
mechlorethamine but not to any other forms of DNA damage (Henriques & 
Moustacchi 1980; D Bonatto et al. 2005). Recently, an SNM1 homologue has been 
identified in T. brucei(Sullivan et al. 2015). Gene disruption of the Tbsnm1 gene has 
revealed that this activity was non-essential to the medically relevant T. brucei life 
cycle stage although null mutant cells were more susceptible than wild type to bi- 
and tri-functional DNA alkylating agents, a phenotype that could be readily 
complemented by ectopic expression of Tbsnm1. Here, using T. brucei lines 
expressing altered levels of Tbsnm1 we evaluated whether the trypanocidal ABQs 
identified in Chapter 3 mediate their anti-parasitic activities by promoting DNA 
damage following NTR or CPR activation.  
 
5.1 Susceptibility of T. brucei expressing altered levels of Tbsnm1 to aziridinyl 
benzoquinones. 
Functional studies aimed at investigating the role Tbsnm1 plays in T. brucei resulted 
in a series of parasites lines engineered to express different levels of this DNA repair 
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enzyme (Sullivan et al. 2015). As part of the characterisation of these lines we 
conducted hybridisation and PCR-based techniques to confirm the nature of the 
TbSNM1 null mutant background: Southern hybridisation confirmed that both 
copies of the Tbsnm1 had been successfully disrupted in the parasite genome while 
RT-PCR and qPCR showed that null mutant cells were not expressing a full length 
Tbsnm1 mRNA transcript (data not shown). 
 
To evaluate whether deletion of both copies of Tbsnm1 from the T. brucei genome 
altered the cells sensitivity to the ABQs null mutant trypanosomes were grown in the 
presence of DZQ, RH1, TZQ or 22 and the IC50 values for each compound 
determined (Figure 5.1; Table 5.1). For all agents tested null cells were ~3 to 7-fold 
more susceptible to the ABQ under study than control parasites analysed in parallel. 
When these growth assays were extended to look at the trypanocidal agents 
nifurtimox anddifluoromethylornithine (DFMO), no difference was observed in the 
IC50’s exhibited by the engineered and control lines. 
 
Compound 
IC50 values (µM) ± standard deviation Ratio 
Wild Type Tbsnm1-/- 
DZQ 0.157 ± 0.023 0.043 ± 0.002 3.7 
RH1 0.015 ± 0.001 0.005 ± 0.001 3.0 
TZQ 0.202 ± 0.006 0.076 ± 0.004 2.7 
22 0.138 ± 0.025 0.021 ± 0.005 6.6 
DFMO 27.500 ± 0.108 27.100 ± 0.850 1.0 
Nifurtimoxa 2.850 ± 0.020 2.250 ± 0.090 0.8 
 
Table 5.1: Susceptibility of T. brucei lines to ABQ compounds. Data represents 
the IC50 values in µM of T. brucei (wild type) and T. brucei Tbsnm1-/- null mutants 
(Tbsnm1-/-) to selected ABQ compounds. All values are means ± standard deviation 
of four independent experiments. The fold difference in IC50 values between the two 
treatments are given. The differences in susceptibility of wild type and Tbsnm1-/-
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lines to DZQ, RH1, TZQ or 22 was statisticallysignificant (P < 0.01), as assessed by 
Student's t test. 
 
 
Figure 5.1: Susceptibility of T. brucei Tbsnm1-/- null mutant cells to ABQs. 
Panels on the left show the dose response curves of wild type T. brucei (solid line) 
and Tbsnm1-/- null mutant (dotted line) parasites to RH1, 22 and DFMO. The panels 
on the right show the susceptibility of wild type T. brucei (white bar) and Tbsnm1-/- 
null mutant (grey bar) parasites to RH1, 22 and DFMO as judged by the IC50 values 
(in nM or µM). All data are means for experiments performed in quadruplicate ± 
standard deviation. The differences in susceptibility of wild type and Tbsnm1-/- null 
mutants to RH1 and 22 was statistically significant (P < 0.01), as assessed by 
Student's t test. 
 
To conclusively demonstrate that the above altered susceptibility phenotype was 
solely due to lack of TbSNM1 activity a complementation strategy was used. In 
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these experiments a vector targeted to one of the parasite’s tubulin arrays and that 
facilitates constitutive expression of an ectopic copy of Tbsnm1 was introduced into 
null mutant and wild type trypanosomes. Southern hybridisation and PCR 
approaches were used to demonstrate integration of the ectopic Tbsnm1 into a 
tubulin array and gene expression (data not shown). 
 
The susceptibility of the null mutant cells expressing an ectopic copy of Tbsnm1 
towards DZQ, RH1, TZQ or 22 was then evaluated (Figure 5.2; Table 5.2). When 
the sensitivity of the complemented line to all four ABQs was tested the resultant 
dose response curves and IC50 values were distinct from those obtained using 
TbSNM1 null mutant cells and were similar to the plots and values observed using 
wild type parasites and wild type T. brucei engineered to express elevated levels of 
TbSNM1. 
Compound 
IC50 values (µM) ± standard deviation 
wild type Tbsnm1-/- Tbsnm1-/- 
Tbsnm1RV 
Tbsnm1RV 
DZQ 0.157 ± 0.023 0.043 ± 0.002 0.204 ± 0.022 0.206 ± 0.017 
RH1 0.019 ± 0.001 0.005 ± 0.001 0.012 ± 0.001 0.011 ± 0.001 
TZQ 0.253 ± 0.033 0.046 ± 0.001 0.376 ± 0.006 0.300 ± 0.023 
22 0.091 ± 0.008 0.012 ± 0.001 0.069 ± 0.007 0.056 ± 0.007 
DFMO 24.150 ± 3.940 24.240 ± 6.710 26.960 ± 1.400 25.410 ± 6.440 
 
Table 5.2: Susceptibility of T. brucei lines expressing altered levels of Tbsnm1 to 
ABQ compounds. Data represents the IC50 values in µM of T. brucei wild type, 
Tbsnm1-/- null mutants (Tbsnm1-/-), Tbsnm1-/- expressing an ectopic copy of Tbsnm1 
(Tbsnm1-/- Tbsnm1RV) and T. brucei wild type expressing elevated levels of Tbsnm1 
(Tbsnm1RV) to selected ABQs. All values are means ± standard deviation of four 
independent experiments. The fold difference in IC50 values between the two 
treatments are given. The differences in susceptibility of wild type and Tbsnm1-/- 
lines to DZQ, RH1, TZQ or 22 was statistically significant (P < 0.01), as assessed by 
Student's t test. Ratios are shown in Appendix 3.  
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Figure 5.2: Susceptibility of T. brucei lines expressing altered levels of Tbsnm1 
to ABQs. Panels on the left hand side show the dose response curve of wild type T. 
brucei (black solid line), Tbsnm1-/- null mutants (grey solid line), Tbsnm1-/- 
expressing an ectopic copy of Tbsnm1 (grey dashed line) and T. brucei wild type 
expressing elevated levels of Tbsnm1 (black dashed line) to RH1, 22 and DFMO. 
The panels on the right hand side show the susceptibility of wild type T. brucei 
(white bar), Tbsnm1-/- null mutants (light grey bar), Tbsnm1-/- expressing an ectopic 
copy of Tbsnm1 dark (grey bar) and T. brucei wild type expressing elevated levels of 
Tbsnm1 (dark grey bar) to RH1, 22 and DFMO as judged by the IC50 values (in nM 
or µM). All data are means for experiments performed in quadruplicate ± standard 
deviation.  
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The above data clearly shows that DZQ, RH1, TZQ and 22 all promote a form of 
DNA damage, which by analogy to other organisms is through the formation of 
ICLs, in the T. brucei genome with TbSNM1 playing a key role in the repair of such 
lesions.  
 
5.2 Linking aziridinyl benzoquinone activation with DNA damage 
To establish whether there was a link between activation of the trypanocidal 
aziridinyl benzoquinones and TbSNM1-mediated DNA damage pathways both 
copies of the Tbsnm1 gene were deleted from the genome of puromycin sensitive 
T.brucei parasites previously engineered to inducibly overexpress carboxyl terminal 
tagged ectopic copies of Tbntr, Tbcpr2 or Tbcpr3(Wilkinson et al. 2008; Hall et al. 
2011). Using a combination of Southern hybridisation, comparative CT analysis of 
the qPCR data and western blot we confirmed that: 1. the two Tbsnm1 alleles had 
been successfully disrupted in the genome of the final recombinant lines, 2. the RNA 
transcripts of Tbntr, Tbcpr2 or Tbcpr3 were ~13-, ~3- and ~6-fold higher, 
respectively, in the final recombinant lines than in wild type cells, and 3. the epitope 
tagged version of TbNTR, TbCPR2 or TbCPR3 were expressed within the final 
recombinant parasites (data not shown). 
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Figure 5.3: Southern hybridisation of Mlu1 digested genomic DNA extracted 
from TbSNM1 samples. Lanes1 and 5: Wild type 221, Lanes 2 and 6: Tbsnm1-/-, 
Lanes 3 and 4: Tbsnm1-/-  Tbntr, Lane 7:Tbsnm1-/-  Tbcpr2 and Lane 8: Tbsnm1-/-  
Tbcpr3. Autoradiographs of samples hybirdized with the 3’ UTR region of TbSNM1 
resulting in two fragments corresponding to the differences in fragment size after the 
addition of a puromycin and blasticidin resistance cassette.  
 
The susceptibility of snm1 null trypanosomes expressing elevated levels of 
TbNTRtowards RH1 and TZQ was measured. Likewise, trypanosomes expressing 
elevated levels of TbCPR2 or 3 in the same background were challenged against 
22to establish a link between prodrug activation and Tbsnm1-mediated DNA repair 
pathways. 
 
When TbSNM1 null mutant parasites or cells engineered to just express an ectopic 
copy of Tbntr were treated with RH1 and TZQ an increased susceptibility when 
compared against wild type T. brucei was observed (Figure 5.4; Table 5.3): Tbsnm1-
/-
 cells and T. brucei over expressing Tbntr were 3.0- and 5.0-fold more susceptible 
to RH1, respectively, with a 2.7- and 3.4-fold increase in sensitivity noted towards 
TZQ. For TbSNM1 null parasites induced to express an ectopic copy of Tbntr this 
increase in potency was magnified further with these cells showing a 15.0-fold 
increase in susceptibility towards both compounds, when as compared against wild 
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type. This alteration was specific to the ABQs as all lines tested exhibited equivalent 
susceptibilities to DFMO. 
 
 
 
Figure 5.4:Susceptibility of T. brucei snm1-/- null mutants over expressing 
TbNTR to RH1. Panels on the left hand side show the dose response curve of wild 
type T. brucei (black solid line), Tbsnm1-/- null mutants (black dotted line), T. brucei 
expressing elevated levels of Tbntr (grey solid line) and Tbsnm1-/- null mutants 
expressing elevated levels of Tbntr (grey dotted line) to RH1 and DFMO. The panels 
on the right hand side show the susceptibility of wild type T. brucei (white bar), 
Tbsnm1-/- null mutants (light grey bar), T. brucei expressing an ectopic copy of Tbntr 
dark (grey bar) and Tbsnm1-/- null mutants expressing elevated levels of Tbntr (dark 
grey bar) to RH1and DFMO as judged by the IC50 values. All data are means for 
experiments performed in quadruplicate ± standard deviation.   
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Compound IC50 values (µM) ± standard deviation 
Wild Type Tbntr Tbsnm1-/- Tbsnm1-/- 
Tbntr 
RH1 0.015 ± 0.001 0.003 ± 0.001 0.005 ± 0.001 0.001 ± 0.001 
TZQ 0.202 ± 0.006 0.060 ± 0.009 0.076 ± 0.004 0.013 ± 0.001 
DFMOa 27.500 ± 0.108 30.720 ± 1.330 27.100 ± 0.850 26.710 ± 2.060 
 
Table 5.3: The growth inhibitory effects of selected ABQ compounds on T. 
brucei snm1-/- null mutants over expressing TbNTR.Data represents the IC50 
values in µM of T. brucei wild type, T. brucei expressing elevated levels of TbNTR 
(Tbntr), TbSNM1 null mutants (Tbsnm1-/-) and TbSNM1 null mutants expressing an 
ectopic copy of Tbntr (Tbsnm1-/- Tbntr) to RH1, TZQ and DFMO. All values are 
means ± standard deviation of four independent experiments. a valve for DFMO 
taken from Sullivan et al (2015).Flow diagrams and ratios can be found in Appendix 
4. 
 
When these studies were extended to investigate the susceptibility of TbSNM1 null 
mutant parasites engineered to express an ectopic copy of Tbcpr2 or Tbcpr3 towards 
22a similar effect was observed (Figures 5.5 and 5.6; Tables 5.4 and 5.5). For the 
Tbsnm1-/- cells and T. brucei over expressing Tbcpr2 or Tbcpr3, all three lines 
displayed a ~7-fold increase in susceptible towards this ABQ. This fold difference 
increased in TbSNM1 null parasites induced to express an ectopic copy of Tbcpr2 or 
Tbcpr3 such that these cells showed a 12.5- and 13.8-fold increase in susceptibility, 
respectively, when as compared against wild type. Again, this alteration was specific 
to this particular ABQs as all lines tested exhibited equivalent susceptibilities to 
DFMO. 
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Figure 5.5: Susceptibility of T. brucei snm1-/- null mutants over expressing 
TbCPR2 to 22. Panels on the left hand side show the dose response curve of wild 
type T. brucei (black solid line), Tbsnm1-/- null mutants (black dotted line), T. brucei 
expressing elevated levels of Tbcpr2 (grey solid line) and Tbsnm1-/- null mutants 
expressing elevated levels of Tbcpr2 (grey dotted line) to 22 and DFMO. The panels 
on the right hand side show the susceptibility of wild type T. brucei (white bar), 
Tbsnm1-/- null mutants (light grey bar), T. brucei expressing an ectopic copy of 
Tbcpr2 dark (grey bar) and Tbsnm1-/- null mutants expressing elevated levels of 
Tbcpr2 (dark grey bar) to these compounds and DFMO as judged by the IC50 values. 
All data are means for experiments performed in quadruplicate ± standard deviation.  
 
Compound 
IC50 values (µM) ± standard deviation 
wild type Tbcpr2 Tbsnm1-/- Tbsnm1-/- 
Tbcpr2 
22 0.138 ± 0.025 0.020 ± 0.003 0.021 ± 0.001 0.011 ± 0.004 
DFMO 27.500 ± 0.108 33.250 ± 5.123 27.100 ± 0.850 29.250 ± 3.862 
 
Table 5.4: The growth inhibitory effects of selected ABQ compounds on T. 
brucei snm1-/- null mutants over expressing TbCPR2. Data represents the IC50 
values in µM of T. brucei wild type, T. brucei expressing elevated levels of TbCPR2 
(Tbcpr2), TbSNM1 null mutants (Tbsnm1-/-) and TbSNM1 null mutants expressing 
an ectopic copy of Tbcpr2 (Tbsnm1-/- Tbcpr2) to 22 and DFMO. All values are 
means ± standard deviation of four independent experiments. . Flow diagrams and 
ratios can be found in Appendix 4.  
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Figure 5.6: Susceptibility of T. brucei snm1-/- null mutants over expressing 
TbCPR3 to 22. Panels on the left hand side show the dose response curve of wild 
type T. brucei (black solid line), Tbsnm1-/- null mutants (black dotted line), T. brucei 
expressing elevated levels of Tbcpr3 (grey solid line) and Tbsnm1-/- null mutants 
expressing elevated levels of Tbcpr3 (grey dotted line) to 22 and DFMO. The panels 
on the right hand side show the susceptibility of wild type T. brucei (white bar), 
Tbsnm1-/- null mutants (light grey bar), T. brucei expressing an ectopic copy of 
Tbcpr3 dark (grey bar) and Tbsnm1-/- null mutants expressing elevated levels of 
Tbcpr3 (dark grey bar) to these compounds and DFMO as judged by the IC50 values. 
All data are means for experiments performed in quadruplicate ± standard deviation.  
 
Compound 
IC50 values (µM) ± standard deviation 
wild type Tbcpr3 Tbsnm1-/- Tbsnm1-/- 
Tbcpr3 
22 0.138 ± 0.025 0.019 ± 0.003 0.021 ± 0.001 0.010 ± 0.001 
DFMO 27.500 ± 0.108 36.500 ± 3.697 27.100 ± 0.850 39.125 ± 2.170 
 
Table 5.5: The growth inhibitory effects of selected ABQ compounds on T. 
brucei snm1-/- null mutants over expressing TbCPR3. Data represents the IC50 
values in µM of T. brucei wild type, T. brucei expressing elevated levels of TbCPR3 
(Tbcpr3), TbSNM1 null mutants (Tbsnm1-/-) and TbSNM1 null mutants expressing 
an ectopic copy of Tbcpr3 (Tbsnm1-/- Tbcpr3) to 22 and DFMO. All values are 
means ± standard deviation of four independent experiments. Flow diagrams and 
ratios can be found in Appendix 4.  
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Here, we have explored the effect of ABQ compounds on parasites null in the DNA 
repair enzyme Tbsnm1. We observe a 3.0 and 2.7 fold increase in susceptibility of 
these parasites when compared to wild type. We have expanded ours studies to 
investigate the effect of the introducing the quinone prodrug activators (ntr, cypr2, 
cypr3) into this cell line. Parasites null in repair enzyme and expressing ectopic 
copies of the activators are fivefold more sensitive than the snm1 null parasites. We 
can therefore conclude that once the quinone based compound is activated, the 
activated moiety goes onto cause DNA damage through the formation of ICLs.     
Concluding points of Chapter 5 
In this Chapter we have explored how the ABQs can mediate their cytotoxic effect in 
the parasite T. brucei. From this we have demonstrated that: 
1. ABQ compounds mediate DNA damage and cells null in the DNA repair 
protein snm1display a 2-6 fold increase in susceptibility, 
2. The Tbsnm1 phenotype can be rescued using an ectopic copy of Tbsnm1. 
Two of the four screened ABQ compounds screened against these lines show 
complete restoration of the phenotype and resistance whereas two ABQ 
compounds only showed a partial restoration of the Tbsnm1 phenotype. 
3. When the Tbsnm1 gene is deleted from the cell line expressing increased 
amounts of the quinone reductases (Tbntr/Tbcypr2/Tbcypr3), the cells 
become between two and five fold more sensitive to ABQ compounds.  
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Figure 5.7: Flow diagrams to summarise the susceptibility of T. brucei lines discussed in this chapter.IC50 values± standard deviation for wild type, 
snm1-/- null mutants, NTR/CPR2/CPR3 overexpressing lines and NTR/CPR2/CPR3 overexpressing lines in a snm1-/- null background. These values can be 
found in Tables 5.3, 5.4 and 5.5 as well as Figures 5.4, 5.5 and 5.6. 
      
 
 
(114) 
 
Chapter 6: Unravelling the mechanism RH1 
resistance 
Selection of trypanosomes lines that display resistance to clinically used 
trypanosomal therapies has been extensively used to provide information as to how a 
given agent mediates its cytotoxic effects (Carter & Fairlamb, 1993; Berger et al 
1995; Wilkinson et al. 2008; Vincent et al. 2010; Sokolova et al 2010). Here we take 
a non-bias approach to select T. brucei cells that display resistance to RH1, the 
archetypal ABQ. As described in Chapter 3, RH1 is active against all three of the 
parasites studied in this thesis generating IC50 values of <100 nM. The IC50 values 
towards bloodstream form T. brucei, T. cruzi epimastigotes and L. major 
promastigotes are 19, 3 and 68 nM, respectively. The data presented in this section 
complements the observations previously outlined in Chapter 4.  
 
6.1 Selection of RH1 resistant T. brucei 
To further investigate its mechanism of action we continuously cultured BSF T. 
brucei in the presence of RH1 to generate cells that display resistance to this ABQ. 
In preliminary selections performed in triplicate, T. brucei cultures containing 1 x 
104 cells ml-1 were treated with RH1 at its wild type IC50 level (20 nM) and cell 
growth monitored. When the parasite density approached 1 x 106 cells ml-1, the 
culture was diluted to 1 x 104 cells ml-1 in medium containing fresh RH1 (20 nM). In 
these initial screens, between 10 and 20 days into the selection process, the cell 
Figure 6.1: Structure of RH1 
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numbers crashed such that no viable cells were visible under light microscopy (data 
not shown) and when cultures were incubated further showed no signs parasite 
growth were observed. From this we concluded that the exposure of the cultures to 
IC50 levels of RH1 generates a trypanocidal effect that the parasite is unable to 
recover from.  
 
To overcome this a second selection protocol based on that reported by Vincent and 
colleagues (2010) whilst obtaining eflornithine resistant T. brucei, was followed. In 
these experiments, T. brucei cultures seeded at 1 x 104 cells ml-1 were initially 
treated with an amount of RH1 roughly equivalent to the concentration that inhibits 
parasite growth by 10% (5 nM), with the level of the selective agent gradually 
increased firstly to 10 nM (IC25), approximately 1 week into the selection, and then 
to 20 nM (IC50) two weeks into the experiment, with the cumulative cell density 
monitored throughout (Figure 6.2). Of the three replica cultures analysed, two 
stopped growing as soon as the selective pressure was increased to 20 nM. In 
contrast, the remaining culture was still viable even when the RH1 concentration had 
been increased to 30 and then 40 nM, the later value being twice the IC50 value 
observed against wild type parasites. 
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Figure 6.2: RH1 resistance selection in T. brucei. Selection of RH1 resistant T. 
brucei was performed by the stepwise increase of the ABQ starting at 5 nM 
eventually going up to 40 nM. The concentration of RH1 is the culture is displayed 
by the solid black line.  The cumulative cell density of three independent cultures 
was monitored throughout the experiment: cultures 1, 2 and 3 are represented by the 
grey solid line, dashed grey line and dotted grey line, respectively. Cultures 2 and 3 
failed to grow when the treatment was increased to 20 nM. 
 
Throughout the selection process the susceptibility of the parasite population to RH1 
was regularly monitored. For cultures maintained in low RH1 concentrations (5 or 
10 nM) a susceptibility phenotype, as judged by their IC50 values, similar to that of 
the wild type was observed: wild type and selecting lines displayed IC50’s of ~20 
nM. When the selecting line was cultured in a higher level of ABQ, a stepwise 
increase in the resistance phenotype was noted such that trypanosome populations 
cultured in the presence of 20 nM RH1 exhibited an IC50 of ~35 nM while parasites 
grown in 40 nM RH1 displayed an IC50 of ~80 nM. This jump in the IC50 suggests 
that resistance to RH1 may be multifactorial. When the selective pressure was 
increased to beyond 40 nM, parasite numbers crashed such that no viable cells were 
visible under light microscopy and cultures failed to grow when incubated further 
(data not shown). Based on this we postulated that we were unable to go above 40 
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nM in our selection assay. In light of this, the polyclonal cell lines grown in 40 nM 
RH1 was cloned by limited dilution while still maintaining selective pressure and 
two lines, designated as RH1R C1 and RH1R C2, were analysed further. 
 
6.2 Characterisation of T. brucei RH1R clonal lines 
Firstly, we investigated the growth properties of two RH1R clones (Figure 6.3). In 
the absence of RH1, the doubling time of the two clones was comparable to the 
parental line (doubling time of ~7½ hrs). When grown in medium containing RH1 
(40 nM), the doubling time of the resistant lines increased ~1.5-fold (doubling time 
of ~10½  hours). In comparison, no growth of wild type T. brucei maintained in 40 
nM ABQ was detected after 24 hrs. 
 
Figure 6.3: Cumulative cell growth of T. brucei RH1R parasites. The cumulative 
cell density of wild type T. brucei (black lines) and a laboratory-generated RH1-
resistant clone (RH1R C1)(grey lines) grown in medium lacking (solid lines) or 
containing 40 nM RH1 (dashed lines). Data pointsare averages from experiments 
performed in quadruplicate T. brucei cumulative growth average ± standard 
deviation.A second RH1-resistant clone (RH1R C2)analysed in parallel displayed 
similar growth properties (data not shown).  
 
To confirm that the cloning process had not altered the susceptibility of the RH1R  
lines to the ABQ, the dose response of the two clones towards RH1 was evaluated 
(Figure 6.4). Analysis of the IC50’s extrapolated from the resultant plots 
demonstrated that RH1R C1 and C2 displayed values ~3.5-fold higher than that 
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observed against the wild type, being equivalent to that noted for the polyclonal RH1 
selected parasites: RH1 exhibited IC50’s of 25.25 ± 6.13, 82.75 ± 1.71 and 92.13 ± 
0.85 nM against wild type cells, RH1R C1 and RH1R C2, respectively. 
 
 
Figure 6.4:Susceptibility of the T. bruceiRH1Rclones to RH1. (A) Dose response 
curve of wild type T. brucei (circles, black solid line) and two RH1 resistant clones, 
RH1R C1 (squares, black dashed line) and RH1R C2 (diamonds, grey solid line) to 
RH1. (B) Susceptibility of wild type T. brucei (white bar) and RH1R C1 (light grey 
bar) and RH1R C2 (dark grey bar) to RH1 as judged by the IC50 values (in nM). Data 
points are averages from experiments performed in quadruplicate ± standard 
deviation. The differences in susceptibility of wild type and the RH1R clones to RH1 
was statistically significant (P <0.01), as assessed by Student's t test.  
  
When analysing certain trypanosomatids, particularly Leishmania, that have been 
selected for resistance to a given drug or compound, removal of the selective agent 
from the growth medium for a prolonged period of time can result in a complete or 
partial loss of the phenotype generating revertant lines (Sereno & Lemesre 1997; 
Perez-Victoria et al. 2001; Pérez-victoria et al. 2003; Leprohon et al. 2009; Kumar et 
al. 2013; Ritt et al. 2013; Mukherjee et al. 2013). This suggests that whatever 
event(s) that promoted resistance is unstable and can be readily lost or replaced by a 
complementary pathway. To investigate the stability of the resistance phenotype 
displayed by the two RH1R lines, the trypanosomes were cultured for 50 and 100 
generation in the absence of the ABQ and at each generation interval the 
susceptibility of each clone towards RH1 evaluated (Figures 6.5 and 6.6). Even when 
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cultured for 100 generations in medium lacking RH1 both RH1R clones still 
displayed the resistance phenotype being 3.5- to 6-fold less sensitive than wild type 
indicating that the mechanism which leads to RH1 resistance is stable in the absence 
of selection pressure.   
 
Figure 6.5: Susceptibility of T. bruceiRH1RC1 cultured in the presence and 
absence of selective pressure. Dose response curve of wild type T. brucei (circles, 
black solid line), RH1R C1 continuously cultured in RH1 (40 nM) (diamonds, grey 
solid line) and RH1R C1 cultured for 100 generations in medium lacking RH1 
(squares, black dashed line) to RH1 were plotted. Data points are averages from 
experiments performed in quadruplicate ± standard deviation. RH1R C1 parasites 
cultured in the absence of RH1 for 50 generations and the RH1R C2 line (cultured in 
the absence of the ABQ for 50 and 100 generations) analysed in parallel displayed 
similar susceptibility profiles (Figure 6.5). 
 
 
Figure 6.6: Susceptibility of T. bruceiRH1Rclones cultured in the absence of 
selective pressure. The IC50 values (in nM) extrapolated from dose response curves 
demonstrate that RH1R C1 (C1) and RH1R C2 (C2) parasites remain RH1 resistant in 
comparison to wild type T. brucei (wt) even when cultured in the absence of 
selective agent for 50 and 100 generations. Data points are averages from 
experiments performed in quadruplicate ± standard deviation. The differences in 
susceptibility of wild type and the RH1R clones to RH1 was statistically significant 
(P < 0.01), as assessed by Student's t test. 
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6.3 Cross resistance of RH1R lines to trypanocidal agents 
Trypanosomatid parasites that have been selected for resistance to one compound 
often display reduced sensitivity to other agents (Carter & Fairlamb 1993; Berger et 
al. 1995; Wilkinson et al. 2008; Sokolova et al. 2010). To determine whether the 
RH1R clones behave similarly, our susceptibility studies on the RH1 selected lines 
were extended to include a range of compounds, with many of the chemicals tested 
being ICL forming agents and/or type I NTR activated prodrugs (Table 6.1). For 
those ICL promoting compounds that contained an aziridinyl- (including other 
ABQs) or nitrogen mustard-moiety at their core, the RH1R cells displayed a ~2- to 
3.5-fold increase in resistance towards such agents as compared to the parental line. 
The only DNA damaging compound class that did not follow this trend were the 
nitrosoureas. This may be because: 1. these chemicals do not promote sufficient ICL 
damage to have a deleterious effect on the growth of T. brucei and actually may 
mediate their trypanocidal effect via some other mechanism(s) or 2. the pathway(s) 
invoked in RH1R cells leading to RH1 resistance do not play a role in fixing any 
damage caused by these agents. Interestingly, the T. brucei TbSNM1 null mutants 
described by Sullivan et al. (2015) displayed the same susceptibilities to nitrosoureas 
as wild type parasites. This further suggests that if these compounds do promote ICL 
formation an SNM1-independent pathway functions to repair any resulting DNA 
damage generated by these agents and is in contrast to the SNM1-dependent 
mechanisms used to fix the lesions generated by aziridinyl and nitrogen mustard-
based compounds.  
 
When our susceptibility studies were extended to investigate how RH1R cells 
responded to trypanocidal agents, cross resistance was observed towards nifurtimox 
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and megazol but not towards DFMO (Table 6.1). It has been postulated that both 
nifurtimox and megazol may mediate at least part of their anti-parasitic effects by 
promoting DNA damage although this mechanism is unlikely to occur via the 
formation of ICL lesions (Poli et al. 2002; Enanga et al. 2003; Buschini et al. 2009; 
Wilkinson & Kelly 2009). Additionally, these two nitroheterocyclic structures along 
with several of the ICL-inducing compounds (e.g. RH1, DZQ, carboquone, CB1954 
and LH17) that RH1R cells also display cross resistance towards, also function as 
prodrugs with the type I NTR catalysing the activation of such agents (Wilkinson et 
al. 2008; Hall et al. 2010; Bot et al. 2010; Hall et al. 2012). Based on the above 
phenotypic screens it is tempting to speculate that the mechanism(s) invoked in 
RH1R cells that leads to reduced RH1 sensitivity may involve components of the ICL 
repair pathway and/or modulation of the type I NTR activity. 
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Compound 
IC50 values (µM) ± standard deviation 
wild type RH1R C1 ratio 
Aziridines     
DZQ 0.191 ± 0.008 0.374 ± 0.043 1.9 
RH1 0.025 ± 0.006 0.083 ± 0.002 3.3 
Carboquone 0.023 ± 0.001 0.066 ± 0.014 2.8 
CB1954 5.275 ± 0.556 11.275  ± 1.441 2.1 
Triethylenemelamine   1.970 ± 0.743 3.975 ± 0.119 2.0 
ThioTEPA 37.825 ± 1.729 83.525 ± 2.401 2.2 
 
   
Nitrogen mustards    
Mechlorethamine  54.750 ± 3.775 95.250 ± 0.957 1.8 
Melphalan  9.650 ± 0.370 18.900 ± 0.455 1.9 
LH17 5.438 ± 0.444 17.998 ± 1.106 3.6 
 
   
Nitrosoureas    
Lomustine (µM) 16.650 ± 0.443 15.463 ± 0.665 0.9 
Semustine (µM) 15.025 ± 3.457 17.100 ± 3.619 1.1 
 
   
Other agents    
DFMO  16.763 ± 2.691 22.177 ± 0.383 1.3 
Nifurtimox  1.688 ± 0.386 7.050 ± 0.311 3.6 
Megazol 0.166 ± 0.001 0.454 ± 0.004 2.7 
 
Table 6.1: Susceptibility of T. bruceiRH1R cells to various trypanocidal agents.  
Data represent the growth-inhibitory effect as judged by their IC50’s of various 
agents on BSF T. brucei wild type and RH1R cells. All values are means ± standard 
deviation from independent experiments preformed in quadruplicate. The ratio 
represent the fold difference in IC50 value between the RH1R and wild type lines to a 
given compound. 
 
6.4 Evaluating the ABQ activation mechanism in RH1R cells 
Based on the cross resistance profiles displayed by the RH1R clones towards a range 
of compounds and the stepwise increase in IC50 values noted during the selection 
process, we hypothesis that resistance to RH1 is multifactorial. As many of the 
agents tested are type I NTR metabolised prodrugs and/or promote some form of 
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DNA damage, we evaluated whether the activation mechanism identified in Chapter 
4 and downstream DNA repair pathways eluded to in Chapter 5 are somehow 
affected within the RH1R clones, leading to the phenotypic changes noted in these 
resistant cells. 
 
Reduction in gene copy number and the acquisition of mutations in ntr is now 
regarded as a key marker displayed by laboratory T. cruzi cells selected for 
resistance to nifurtimox and benznidazole (Wilkinson et al. 2008; Mejía-Jaramillo et 
al. 2011; Mejia et al. 2012; Campos et al. 2014). To examine whether Tbntr is 
implicated in mediating RH1 resistance, we analysed the sequence, copy number and 
mRNA expression levels of this gene in RH1R cells. Initially, we amplified the 
region of Tbntr (~720 bp) that encodes for the enzymes catalytic domain from the 
selected line using a high fidelity DNA polymerase. Following A-tailing, the 
resultant fragments were cloned into the pGEM-T-easy vector and the inserts 
sequenced (a total of 5 sequences were analysed from 4 independent PCRs). 
Examination of the nucleic acid and deduced amino acid sequences indicated that 
Tbntr expressed by RH1R cells was identical to that in wild type (sequences on the 
TriTryp database and as generated in the Wilkinson laboratory). Therefore, the RH1 
resistance phenotype displayed RH1R cells is not due to acquisition of mutations in 
the Tbntr catalytic domain. Here, we did not investigate whether alterations to the 
nucleic acid sequence in the 5’ region of Tbntr lead to resistance as analysis of Tcntr 
from T. cruzi nifurtimox or benznidazole resistant cells has have never shown any 
difference in this part of the gene. 
 
To determine whether T. brucei RH1R parasites exhibited any changes to the Tbntr 
copy number we conducted quantitative PCRs on genomic DNA extracted from wild 
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type and RH1 selected lines, targeting internal fragments within Tbntr and Tbtert; 
Tbtert was used as a standardized control (described by Brenndörfer & Boshart 
(2010)). Using the comparative CT method, the resultant fluorescence profiles 
obtained from each reaction for each DNA fragment and from each parasite line 
were compared with the relative levels of Tbntr normalized with respect to 
Tbtert(Figure 6.7). This demonstrated that the copy number of Tbntr from the RH1R 
line was not significantly different from that in wild type parasites.  
 
Figure 6.7: Tbntr copy number in RH1R cells. Quantitative PCR profiles targeting 
Tbntr and Tbtert from wild type (white bar) and RH1R (grey bar) cells were 
compared using thecomparative CT method. The values shown are the average 2-(ΔΔC
T
)
 from reactions performed in triplicate ± standard deviation.  
 
As described in Chapter 4, reduction of Tbntr expression in heterozygous lines leads 
to resistance towards RH1 and many other ABQs. To establish whether changes in 
the expression level of this prodrug activator promotes resistance in the selected line, 
we conducted qRT-PCR on cDNA generated from total RNA extracted from both 
wild type and RH1R lines. As with the qPCR described above, amplifications 
targeting internal fragments within Tbntr and Tbtert were performed with the 
resultant fluorescence profiles obtained from each reaction for each DNA fragment 
and from each parasite line compared using the comparative CT method (Figure 6.8). 
Following normalization of the Tbntr signal with respect to Tbtert, the level of the 
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NTR mRNA transcript was ~2-fold lower in the RH1R line compared to wild type. 
This strongly suggests that reduction in Tbntr expression in selected cells leads to 
RH1 resistance with this data complementing the data presented in Chapter 4. 
 
 
Figure 6.8: Tbntr expression is lower in RH1R cells. Quantitative RT-PCR profiles 
targeting Tbntr and Tbtert from wild type (white bar) and RH1R (grey bar) cells were 
compared using thecomparative CT method and the average fold difference (as 
judged by 2-(ΔΔCt)from reactions performed in triplicate ± standard deviation) plotted 
as a measure of the relative expression level of Tbntr. The difference in relative 
expression levels between the two lines was judged to be statistically significant (P 
<0.01), as assessed by Student's t test.  
 
6.5Are DNA repair pathways implicated with the RH1r phenotype? 
As the RH1R selected line shows cross resistance to a range of compounds including 
several ICL forming agents that do not function as NTR activated prodrugs, it is 
implicit that additional factors besides TbNTR are involved in generating the 
phenotype observed. In Chapter 5, it was shown that in T. brucei RH1 to promote 
DNA damage that can be repaired by a pathway involving TbSNM1.To evaluate 
whether DNA repair enzymes play a role in generating RH1 resistance, the gene 
copy number and mRNA expression levels of Tbsnm1, Tbmre11 and Tbrad51 was 
investigated. Initial amplification reactions using genomic DNA indicated that the 
copy number of these open reading frames were equivalent in resistant and wild type 
cells (data not shown).
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When these studies were extended to look at mRNA expression, there was no 
apparent difference in any transcript abundance. These preliminary studies indicate 
that TbSNM1, TbMRE11 and TbRAD51 are not involved in mediating resistance to 
RH1 although a more in-depth analysis, possibly involving transcriptomic or 
proteomic approaches, would shed more light on what factors are responsible for the 
observed RH1 resistance phenotype. 
 
Figure 6.9: Selected DNA repair enzymes appear not be involved in mediating 
RH1 resistance. Quantitative RT-PCR profiles targeting Tbsnm1, 
Tbmre11,Tbrad51 and Tbtert from wild type (white bar) and RH1R (grey bar) cells 
were compared using thecomparative CT method and the average fold difference (as 
judged by 2-(ΔΔCt)from reactions performed in triplicate ± standard deviation) plotted 
as a measure of the relative expression level of Tbsnm1, Tbmre11 andTbrad51. 
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Chapter 6 summary 
In this Chapter we have explored how RH1 resistance may arise in T. brucei. 
Specifically we have shown that: 
1. T. brucei resistant to RH1 can be selected in vitro. 
2.  The resultant RH1R lines display a ~4-fold increase in resistance to this 
particular ABQ. 
3. The RH1 resistance phenotype is stable and can be maintained for up to 100 
generations in the absence of selective pressure. 
4. The RH1R lines displays cross resistance to a number of other compounds 
including aziridinyl- and nitrogen mustard-based compounds, and the 
trypanocidal nitroheterocyclic compounds nifurtimox and megazol. 
5. Based on the phenotypic screens, the mechanism(s) underlying this resistance 
appears to be multifactorial. 
6. One mechanism underlying RH1 resistance involves reduction in Tbntr 
expression. 
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Chapter 7: Investigating the mechanism of action of 
trypanocidal nitroheterocycles 
 
A number of nitroaromatics have been reported to display anti-trypanosomatid 
properties (reviewed by Raether & Hänel 2003; Wilkinson et al. 2011; Patterson & 
Wyllie 2014).  Unravelling how such compounds actually go about exerting their 
toxic affects represents a major challenge in bringing a potential compound from the 
bench to the bedside. In this thesis we have previously described how biological 
approaches can be used to dissect the function of a given antimicrobial agent with 
the application of high throughput strategies speeding up this process. Techniques 
that have facilitated such studies in T. brucei are the development of whole genome 
loss of function (RNAi) and gain of function (over expression) screening strategies 
with the former being  extremely informative in understanding how all the clinically 
used anti-HAT drugs work (Baker et al. 2011; Alsford et al. 2011; Alsford et al. 
2012; Begolo et al. 2014).  
 
Using the whole genome loss of function assay coupled, where appropriate, with 
next generation sequencing (Baker et al. 2011; Alsford et al. 2011; Alsford et al. 
2012), we explored the mechanism(s) of action of the aziridinyl dinitrobenzamide 
CB1954 (also known as Tretazicar), a compound closely related to RH1 (Figure 6.1) 
and BG-M2, a nitroaromatic derivative of O6-benzylguanine (Zhu et al. 2011). To 
confirm whether any of the “hits” identified are genuinely involved in mediating 
resistance to the selective agent, RNAi constructs specifically targeting the “hit” 
transcript were generated, cell lines established and growth studies and phenotypic 
screens performed to 1) determine whether the target is essential for viability of BSF 
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trypanosomes and 2) validate if reduction of target gene expression confers 
resistance to the selective agent. 
 
7.1. CB1954 and its antiparasitic activity 
CB1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide) (Figure 7.1) was initially 
developed as an anti-cancer prodrug therapeutic in the ChesterBeatty Laboratories 
that, following activation, generates cytotoxic metabolites that promote ICL 
formation (Helsby et al. 2003). Preliminary studies revealed that this 
dintrobenzamide was efficiently metabolised by rat NQO1 although this activity did 
not translate across to its human counterpart (Chen et al. 1997; Prosser et al. 2010). 
As such, interest in CB1954 as an anti-cancer agent waned although it has been 
patented as a rodenticide (US 8785428 B2). However, at the beginning of the 21st 
century, CB1954 as an anti-cancer agent has been revisited following observations 
that bacterial type I NTRs can interact with this compound (Prosser et al. 2010). As a 
result, strategies termed gene-directed or antibody-directed enzyme prodrug therapy 
were been developed that involve targeting anti-cancer cells with a DNA construct 
containing E. coli or a tumour specific antibody conjugated to the NTR protein prior 
to treatment with the prodrug (Chung-Faye et al. 2001; Palmer et al. 2003; Helsby et 
al. 2004; Patel et al. 2009; Prosser et al. 2010). Again initial in vitro studies using 
either system were encouraging although when transferred into an in vivo situation, 
off targeting was observed resulting in unwanted side effects (Knox et al. 1993). 
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Figure 7.1: Structure of CB1954  
 
Recently, it has been shown that CB1954 also exhibits antimicrobial activities 
against BSF T. brucei, T. cruzi amastigotes and L. major amastigotes (Bot et al. 
2010; Sokolova et al., 2010; Voak et al. 2013). In all cases, significant potency was 
observed with the prodrug active at concentrations lower than 3 µM: the IC50 of 
CB1954 towards T. brucei, T. cruzi and L. major was calculated to be 2.97 ± 0.25, 
0.57 ± 0.05 and 0.05 ± 0.02 µM respectively (Bot et al. 2010; Voak et al. 2013). In 
constrast, little/no toxicity was observed in the Chinese hamster fibroblasts (V79), 
African green monkey kidney epithelial (Vero) or human macrophage-like (THP-1) 
mammalian cells: IC50 values of 543, > 250 and > 100 µM were recorded, 
respectively (Helsby et al 2005;Bot et al. 2010; Voak et al. 2013).  
 
7.2 Evaluating the mechanism of CB1954’s trypanocidal activity 
Using a similar approach as discussed in Chapter 4, collaborators at the London 
School of Hygiene and Tropical Medicine performed a whole genome loss of 
function assay using CB1954 as selective agent. A T. brucei RNAi library stock 
population was treated with tetracycline (1 µg ml-1) one day (-1 day) prior to 
challenging the parasites with the dinitrobenzamide (3 µM) (day 0). Cell numbers 
were then monitored over a 16 day period with the cultures passaged as appropriate 
into T. brucei growth medium containing the fresh inducer tetracycline and CB1954. 
Over the first 3 days of selection, the parasites grew at a rate equivalent to that of 
      
 
 
(131) 
 
non-induced and non-CB1954 treated controls (Figure 7.2). This was then followed 
by a dramatic fall in the cumulative cell density as the selective agent killed off the 
trypanosomes, followed by an outgrowth from day 12 onwards of a CB1954 resistant 
T. brucei population.  
 
 
Figure 7.2:Screening for CB1954 resistant determinants using a genome wide T. 
brucei RNAi library. The BSF T. brucei RNAi library (Alsford et al. 2012; Glover 
et al. 2015) was co-treated with tetracycline (1 µg ml-1) to induce RNAi, and 
CB1954 (3 µM) with the cumulative cell growth of the culture followed. The arrows 
correspond to culture dilution and addition of fresh CB1954 (3 µM) and tetracycline 
(1 µg ml-1). Genomic DNA (as indicated by stars) was extracted from parasites at 
days 15 and 16. The above data was collected by Dr S. Alsford, LSHTM.  
 
 
On days 15 and 16 genomic DNA was extracted from the CB1954 selected parasite 
population and used as template in a PCR-based low resolution screen (Figure 7.3A). 
Analysis of the resultant amplification products identified one major fragment of 
~1.1 kbp, comparable to the major band size observed in the RH1 RNAi library 
screen. Sequence analysis of this fragment and comparison against the TriTryp 
genome database revealed that this mapped to a region that spanned the 3' region of 
the type I nitroreductase (Tbntr) gene (Gene ID: Tb927.7.7230) (Figure 7.3B). This 
result was unsurprising given that previous studies have shown that 
dinitrobenzamidine readily undergoes activation by this type of oxidoreductase 
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enzyme (Bot et al 2010; Voak et al 2014). In addition to the Tbntr-containing 
fragment, several other bands were also observed in amplification reactions 
especially when using higher concentration of the oligonucleotide primers (Figure 
7.3A). Sequencing of these identified a series of non-specific DNA sequences (e.g. 
vsg genes, telomere associated regions) that were not analysed further. 
 
 
 
Figure 7.3: Identification of CB1954 resistance determinants. (A) Amplification 
of the RNAi target from the CB1954 screen using gDNA extracted on days 15 or 16 
of the selection using PCR conditions described (Alsford et al. 2012; Glover et al. 
2015). M indicates the size markers (in bp). Arrow indicate the DNA fragmented 
obtained from the screen (image contributed by Dr S Alsford, LSHTM). (B) The 
position of the DNA fragments recovered from the CB1954 RNAi screen relative to 
the genome location is shown by the grey box.   
 
To confirm that TbNTR was the key activator of CB1954 we evaluated the 
susceptibility of T. brucei cells engineered to express reduced levels of the encoding 
gene.  Initially, an RNAi based approach was used to down regulate gene expression. 
However as noted in Chapter 4, cells undergoing RNAi were viable, in contrast to 
reports that the TbNTR activity is essential for BSF T. brucei growth (Wilkinson et 
al 2008), and displayed the same susceptible to CB1954 as controls: when these the 
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studies were extended to nifurtimox no effect on parasite susceptibility was 
observed. Based on these observations we hypothesize that under the conditions used 
here, RNAi does not sufficiently reduced the Tbntr transcript to a level that affects 
the sensitivity of T. brucei to CB1954 (RH1 or nifurtimox). In contrast, when the 
susceptibility of the T. brucei Tbntr heterozygote line towards CB954 was assessed, 
the recombinant line displayed an IC50 approximately 3-fold greater than that 
observed towards wild type cells (Figure 7.4). This confirmed that reduction of 
TbNTR expression through loss of one of the Tbntr encoding alleles is sufficient to 
generate resistance to CB1954. 
 
Figure 7.4: Susceptibility of T. brucei Tbntr heterozygotes to CB1954. (A). Dose 
response curve of wild type T. brucei (solid line) and parasites that are haploid for 
Tbntr (dotted line) to CB1954. (B). Susceptibility of wild type T. brucei (white bar) 
and TbNTR heterozygotes(grey bar) to CB1954as judged by the IC50 values (in µM). 
All data are means for experiments performed in quadruplicate ± standard deviation. 
The differences in susceptibility of wild type and TbNTR over expressing cells to 
CB1954 was statistically significant (P < 0.01), as assessed by Student's t test. 
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7.3 High resolution screening of CB1954 selected cells 
As discussed in Chapter 4, the DNA template used in the low resolution PCR screens 
can also be used for a more in-depth analysis to potentially identify addition 
determinants that may play a role in mediating CB1954’s trypanocidal mode of 
action. Using the criteria previously outlined, the inducibility of the CB1954 selected 
RNAi library was determined and shown to be 67%. This value indicates that the 
resistance phenotype displayed by the selected parasite population was most likely 
due to an RNAi effect rather than the acquisition and selection of background 
mutations. Given this, amplification reactions were sent for high throughput DNA 
sequencing carried out at Beijing Genome Institute and bioinformatic analysis of the 
resultant data performed by Dr S Alsford (LSHTM) in accordance to Glover et al. 
(2015). 
 
Out of the ~450,000 total sequence reads, of which ~80,000 were deemed to be 
tagged reads (i.e. reads where one of the “signature” primer sequence used in the 
initial PCR was identified), 96% of the total number of reads and 82% of the tagged 
number of reads identified three distinct DNA fragments that all mapped to Tbntr 
(Table 7.1). This represented the only open reading frame generated from this 
analysis that meets the “at least 2 tagged hit per gene” criteria laid out by Glover et 
al (2015) for the identification of a valid hit. 
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In addition to Tbntr, several other potential hits that did not meet the “at least 2 
tagged hit per gene” criteria were taken forward for further analysis. These were 
selected on the basis that >100 total reads were obtained and/or they constituted >1% 
tagged number of reads. Based on the TriTryp database most of these hits 
(designated TbORFa-g) encode for hypothetic proteins, several of which have a 
predicted nuclear localisation, with Tb927.9.9600 and Tb927.9.11760 coding for 
sequences annotated as Tbmcm9 and Tbrad2, respectively (Table 7.2). 
 
Gene ID Study name 
Reads/kbp/cds 
Tagged 
hits/CDS Total Reads 
Tagged 
Reads 
Tb927.7.7230 Tbntr 439624 63501 3 
Tb927.11.6370 TbORFa 5661 4919 1 
Tb927.7.7310 TbORFb 3217 2828 1 
Tb927.3.3670 TbORFc 2281 2044 1 
Tb927.10.3130 TbORFd 2876 1250 1 
Tb927.8.8070 TbORFe 1229 900 1 
Tb927.8.8110 TbORFe 975 862 1 
Tb927.8.4050 TbORFf 1165 535 1 
Tb927.10.3910 TbORFg 403 363 1 
Tb927.9.9600 Tbmcm9 290 101 2 
Tb927.9.11760 Tbrad2 136 44 --- 
Table 7.1: The hits identified in the next generation sequencing sequence analysis 
of CB1954 RNAi library screen and the frequency of reads.  
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Table 7.2: Description of the hits obtained from the high throughput sequence analysis of CB1954 RNAi library screen. The 
information presented was obtained from the TriTryp database. Protein localisation was determined using PsortII where M: 
mitochondria; C: cytoplasm; N: nucleus; ER: Endoplasmic reticulum; V: vacuole; PM: Plasma membrane. Protein features and 
functional domains were identified using BlastP.  
 
 
Study 
name 
chromosome Molecular 
mass (kDa) 
Predicted 
localisation 
Protein features and functional domains 
TbORFa 11 96 35% C 
30% N 
1. Ribonuclease inhibitor (RI)-like domains with leucine-rich repeats  
2. 28% identity to Capsaspora  hypothetical protein.  
TbORFb 7 25 44% PM 
26% V 
1. A signal peptide  
2. 2 transmembrane  domains located towards the amino-terminal 
3. 37% identity towards DNA mismatch repair protein MutS from Dethiobacter alkaliphilus 
TbORFc 3 67 70% N 1. 3 RNA recognition motifs (RRMs) involved with RNA processing (Wurst et al. 2009).   
TbORFd 10 87 74% N 1. Calponin-homology domain, CH-domain towards the amino-terminal 
2. 3-PAP Myotubularin-associated protein domain 
3. No significant identity to proteins from other organisms 
TbORFe 8 56 
 
52% M 
39% N 
 
 
1. 2 coding sequences are almost identical  
2. 4 phosphorylation sites on 56-kDa protein/3 on the 62 kDa protein 
3. 32-35% identity to Eurpyga (bird) and Zootermopsis (termite) hypothetical proteins TbORFe 8 62 70% M 
22% N 
TbORFf 8 83 33% V 
33% ER 
 
1. 2 transmembrane domains at either end of protein sequence.  
2. YWTD domain maybe involved in lipid metabolism and/or transport  
3. No significant identity to proteins from other organisms 
TbORFg 10 53 44% ER 1. 6 transmembrane domains 
2. Homology to thiol:disulfide interchange proteins from marine bacteria and beta-
lactamase like proteins from fungi. 
Tbmcm9 9 85 57% N Mini chromosome maintenance complex (MCM) protein (Tiengwe et al. 2012; Tiengwe et 
al. 2014) 
Tbrad2 9 82 44% ER 
35% M 
XPG (Machado et al 2014).     
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To assess whether a reduction in activity of any of the above “hits” plays a role in 
resistance to CB1954, an RNAi based approach was taken. Using the RNAit 
algorithm, DNA fragments containing sequences internal to each of the open reading 
frames were amplified from T. brucei genomic DNA and the resultant fragments 
cloned into the p2T7Ti RNAi vector. Each construct was then linearized before being 
transfected into T. bruceiSMB. Following selection, the growth of each RNAi cell 
line was monitored to determine whether RNAi targeting a given transcript affected 
parasite viability (Figure 7.5). In all cases, cells induced to undergo RNAi were 
viable and grew at the same rate as non-induced controls, with most having a 
doubling time of around 8 hours: for cells where the TbORFa or Tbrad2 mRNA was 
targeted, an increase in doubling time to ~10 and ~13 hours, respectively, was 
observed although this property was shown by tetracycline treated and untreated 
parasites.  
 
Figure 7.5: Growth of selected T. brucei RNAi lines. The growth of tetracycline 
induced (dashed line) and noninduced (solid line) BSF T. brucei was monitored daily 
over a 10-day period. For all the transformed lines, cell counts were performed on 
three independent cultures from which the mean cell density ± standard deviation 
was determined. All other RNAi lines behaved similarly. 
 
The susceptibility of each of the cell lines towards CB1954 while undergoing RNAi 
was evaluated. From the resultant dose response curves (Figure 7.6), the IC50 of each 
cell line to dinitrobenzamidine was determined (Figure 7.7). In all cases, cells 
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undergoing RNAi, irrespective of which transcript was being targeted, exhibited a 
similar sensitivity to CB1954 as wild type cells. This suggests that loss of function of 
any lesser “hit” identified from the high throughput sequence analysis does not lead 
to resistance to the dinitrobenzamidine. 
 
 
Figure 7.6: Susceptibility of selected T. brucei RNAi lines to CB1954. Dose 
response curve of tetracycline induced (dashed line) and noninduced (solid line) BSF 
T. brucei to CB1954. All data are means for experiments performed in quadruplicate 
± standard deviation. All other RNAi lines behaved similarly. 
 
 
Figure 7.7: Susceptibility of T. brucei RNAi lines to CB1954. Susceptibility of 
wild type T. brucei and parasites undergoing RNAi targeting various transcripts to 
CB1954 as judged by the IC50 values (in µM). All data are means for experiments 
performed in quadruplicate ± standard deviation. The differences in susceptibility of 
wild type and recombinant lines was not judged to be statistically significant, as 
assessed by Student's t test. 
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7.4 Trypanocidal activity of BG-M2 
O6-Alkylguanine-DNA alkyltransferase (MGMT) is a ubiquitous DNA repair protein 
that plays a key role in mediating resistance to guanine O-6 chloroethylating agents 
in certain types of tumour cell (Pegg & Byers 1992; Pegg et al. 1993). This enzyme 
removes alkyl groups from guanine residues added by alkylating agents, thus 
reversing the action of the drug. To prevent this enzymatic response, several 
inhibitors including O6–benzylguanine and its derivatives (Figure 7.8) have been 
developed to inhibit the function of MGMT(Zhu et al. 2011).  
 
 
Figure 7.8: Structures of O6-alkylguanine DNA alkytransferase inhibitors. 
KS90, KS900 and BG-M2 are 4-nitrobenzyloxycarbonyl derivatives of the MGMT 
inhibitor O6–benzylguanine (Zhu et al 2011) 
 
Here, the nitrobenzyl prodrug BG-M2 and two compounds, KS90 and KS900, used 
in its synthesis, were tested for trypanocidal activity (Zhu et al. 2011). For each 
agent, dose response curves against wild type BSF T. brucei were plotted (Figure 
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7.9) from which each compound’s IC50 value was determined. This demonstrated 
that KS90 and KS900 did not display anti-trypanosomal at concentrations up to 10 
µM and were not studied further.In contrast, BG-M2 displayed growth inhibitory 
activity against BSF T. brucei yielding an IC50 value of 1.96 ± 0.01 µM. 
 
Figure 7.9: Dose response of T. brucei to MGMT inhibitors. The susceptibility of 
wild type BSF T. brucei to KS90 (black circles), KS900 (black squares) and BG-M2 
was evaluated. All data points are means for experiments performed in quadruplicate 
± standard deviation. 
 
7.4.1 Evaluating BG-M2 as a trypanocidal prodrug 
As BG-M2 is designed to function as a prodrug and contains a nitrobenzyl 
substituent, we initially postulated that this compound could undergo TbNTR 
mediated activation. To determine whether this was the case the susceptibility of 
Tbntr over expressing parasites towards this structure was tested (Figure 7.10). From 
the resultant dose response curves and IC50 values it was clear that BG-M2 displayed 
equal potency against the Tbntr over expressing line as towards wild type. This 
indicates that contrary to our initial hypothesis BG-M2 is not activated by TbNTR 
within the parasite itself.  
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Figure 7.10: Susceptibility of T. brucei expressing elevated levels of TbNTR to 
BG-M2. (A) Dose response curve of wild type T. brucei (solid line) and parasites 
engineered to express elevated levels of TbNTR (dotted line) to BG-M2. (B) 
Susceptibility of wild type T. brucei (white bar) and TbNTR overexpressing line 
(grey bar) to BG-M2 as judged by the IC50 values (in µM). All data are means for 
experiments performed in quadruplicate ± standard deviation. The difference in IC50 
values was not statistically significant, as assessed by Student's t test. Data provided 
by Dr Shane Wilkinson. 
 
To shed light on BG-M2’s trypanocidal mechanism of action a whole genome loss of 
function assay was performed. During the selection process BG-M2 exhibited no 
discernible effect on parasite growth until day 6. At this point and until day 10, 
parasite numbers remained relatively static. From day 10 onwards a BG-M2 resistant 
parasite population was selected.  
 
Figure 7.11:Screening for BG-M2 resistant determinants using a genome wide 
T. brucei RNAi library. The BSF T. brucei RNAi library (Alsford et al. 2012; 
Glover et al. 2015) was co-treated with tetracycline (1 µg ml-1) to induce RNAi, and 
BG-M2 (3 µM) with the cumulative cell growth of the culture followed. The arrows 
correspond to culture dilution and addition of fresh BG-M2 (3 µM) and tetracycline 
(1 µg ml-1). Genomic DNA (as indicated by stars) was extracted from parasites at 
days 13. The above data was collected by Dr S. Alsford, LSHTM.  
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Genomic DNA was extracted from the BG-M2 selected parasite population and used 
as template in a PCR-based low resolution screen (Figure 7.12). Sequence analysis 
of the resultant fragments demonstrated that the major (brightest) ~1.2 kbp band 
spanned the 3' region of Tb927.10.1740 and 5' region of Tb927.10.1750 (designated 
here as TbORF1 and TbORF2, respectively) while a 0.8 kbp fragment represented 
the 5' region of Tb927.11.11380(designated here TbORF3). Several other fragments 
were also sequenced but as before these correlated to a series of non-specific DNA 
sequences (e.g. vsg genes, telomere associated regions) and were not analysed 
further. 
 
Figure 7.12:Identification of BG-M2 resistance determinants. (A) Amplification 
of the RNAi targets from the BG-M2 screen using gDNA extracted on day 14 of the 
selection using PCR conditions described (Alsford et al. 2012; Glover et al. 2015) 
(lane 1). M indicates a size marker in base pairs. Arrows indicate the DNA fragments 
obtained from the screen. (B) and (C) The position of the DNA fragments recovered 
from the BG-M2 RNAi relative to the genome locations are shown by the grey 
boxes.   
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Bioinformatic analysis of the three BG-M2 resistance determinants were carried out 
as described previously, however no putative domains were identified. Using the 
RNAit algorithm, DNA fragments containing sequences internal to TbORF1, 
TbORF2 and TbORF3 were amplified from T. brucei genomic DNA and the 
resultant fragments cloned into the p2T7Ti RNAi vector. Each construct was then 
processed before being transfected into T. bruceiSMB. Following selection of 
recombinant parasites, the growth of each line was followed (in triplet) (data not 
shown) and in all cases cells induced to undergo RNAi were viable and grew at the 
same rate as non-induced controls, having a doubling time of around 8 hours. The 
susceptibility of each cell line towards BG-M2 while induced to undergo RNAi was 
then evaluated (Figure 7.13). From the resultant dose response curves and IC50 
values, parasites undergoing RNAi, irrespective of which transcript was being 
targeted, exhibited a similar sensitivity to BG-M2 as wild type. This suggests that 
loss of function of TbORF1 to 3 does not lead to resistance to the O6–benzylguanine 
derivative. As no potential activator was identified from the above RNAi library 
screen, BG-M2 appears not to function as a prodrug in T. brucei. 
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Figure 7.13: Susceptibility of T. brucei RNAi lines to BG-M2. Dose response 
curve of tetracycline induced (dashed line) and non-induced (solid line) BSF T. 
brucei to BG-M2. All data are means for experiments performed in quadruplicate ± 
standard deviation. 
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Chapter 7 summary 
This chapter has focused on trying to unravel the mechanism of action of two 
nitrobenzyl based compounds, CB1954 and BG-M2. We have demonstrated that: 
1. Screening of an RNAi library using CB1954 as a selective agent identified 
TbNTR as the major resistance determinant to this compound resistant 
parasites, confirming previous findings (Bot et al 2010). 
2. T. brucei Tbntr heterozygote parasites are resistant to CB1954, with these 
recombinant cells having an IC50 value ~3-fold greater than wild type 
3. Other possible determinants identified from the CB1954 selected RNAi 
library parasite population were shown not to be involved in mediating 
resistance to CB1954. 
4. The O6-alkylguanine-DNA alkyltransferase inhibitor BG-M2 displays 
trypanocidal activity. 
5. Screening of an RNAi library using BG-M2 as selective agent indicates that 
this compound does not function as a prodrug in T. bruceidespite containing 
a nitrobenzyl grouping.  
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Chapter 8. Discussion 
Estimates indicate that as many as 50 million people living in sub-Saharan Africa are 
at risk of contracting HAT. The arsenal of drugs currently used to combat this 
infection are problematic as they cause adverse side effects, have limited efficacy 
and require medical supervision with lengthy treatment times. To further complicate 
drug therapy, resistance is on the raise (Barrett et al. 2003; Delespaux & de Koning 
2007; Wilkinson & Kelly 2009). Against this backdrop there is an urgent call for 
new antitrypanosomatid therapies to enter the market. 
 
The natural world has provided us with a range of medicinal agents that can be used 
to treat infectious diseases (e.g. quinine, penicillin, artemisinin), cancer (e.g. taxol, 
bleomycin) and as analgesics (e.g. salicin, morphine) (Kayser et al. 2003). One 
group of natural compounds that have been exploited for their pharmacological 
properties are the quinones. Frequently used in folk medicine, structures such as 
plumbagin, emodin, lapachol, senna, menatetrenone, nigrosporin have been 
chemically derivatized to generate synthetic agents that function on a variety of 
different biological pathways. 
 
Here, we investigated the antiparasitic properties of a library of quinone based 
chemicals against the three trypanosomatid species Trypanosoma brucei, 
Trypanosoma cruzi and Leishmania major with these structures spanning a range of 
carbocyclic backbones. Together, 24, 15 and 22 quinones yielded IC50’s of < 1 µM 
against T. brucei, T. cruzi and L. major respectively, with 6, 6 and 3 of these 
generating values below 100 nM. When comparing the potency of each compound 
class, representative members of each demonstrated significant activity against one 
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or more of the pathogens tested. For example, the natural product mitomycin c, an 
indolequinone, exhibited activity against all three parasites having a high level of 
potency towards T. brucei (IC50 value of 20 nM) but was less effective against T. 
cruzi (IC50 of 2.1 µM) and L. major (IC50 of 4.2 µM) while the 1,4 benzoquinone 
RH1 displayed an equivalent activities against all parasites (IC50’s ranging from 20 
nM against T. brucei to 68 nM against L. major (Table 3.1)). Based on the entire 
growth inhibition data sets, no one single group of quinone exhibited a greater 
antiparasitic activity than any of the others. 
 
More than half of the quinones tested belong to a related sub-group with all members 
containing a 1,4 benzoquinone backbone and two aziridinyl groups at the 2 and 5 
positions. The sheer number of compounds available gave us scope to conduct SAR 
studies with these focusing on the medically relevant BSF T. brucei: such studies 
were not performed using the T. cruzi and L. major growth inhibitory data as these 
screens were carried out on insect form parasites. 
 
For most of the 1,4 benzoquinone structures, the 3 and 6 positions contained 
equivalent substitutions (e.g., H for DZQ, 22&23, CH3 for MeDZQ, aziridinyl for 22 
etc.), although in some cases divergent groupings were present (e.g., CH2OH and 
CH3 in RH1, aziridinyl and H in TZQ, or morpholinyl and F in 14). Whether a 
compound does or does not possess equivalent substitutions at these sites played no 
role in determining the potency of the compound: MeDZQ and RH1 both generate 
IC50’s of around 20 nM. When comparing the effect of compounds containing simple 
side chains at the 3 and 6 positions, the presence of small hydrocarbon chains such as 
methyl and/or hydroxymethyl (see MeDZQ and RH1 in Table 3.1) resulted in the 
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greatest trypanocidal activity relative those that containing hydrogen (DZQ), halogen 
(3, 4) or amine (9) substituents. This may be because these small hydrocarbon chains 
may promote interaction of enzymes such as the trypanosomal type I NTR with the 
substrate or could help these structures (or their products) accessing their site(s) of 
action (Hall et al 2012). 
 
For most (thirteen) compounds containing an amine or amide grouping attached via 
the nitrogen atom to the 3 and 6 positions no activity against T. brucei at 10 µM was 
observed, with some of these reported to be poor substrates for the trypanosomal 
type I NTR (Hall et al. 2012). By analogy with the situation in mammalian toxicity 
studies, the presence of such bulky side chains may decrease the ability of the 
prodrug to produce DNA damage by hindering access to the oxygen on the carbonyl 
groupings on the 1,4 benzoquinone backbone thus minimising their conversion to the 
corresponding hydroxyl or by reducing electron movement around the carbocyclic 
backbone following activation that then facilitates unfolding of the aziridine (Fourie 
et al2004). 
 
By analysis of the T. brucei IC50 data there appears to be a direct correlation between 
the number of aziridine groupings attached to the 1,4 benzoquinone backbone and 
the trypanocidal activity such that compounds that possess more of these motifs 
generates increased potency. For the tetra- (22), tri- (TZQ) and bi- (DZQ) aziridinyl 
compounds IC50’s of ~ 150, 180 and 270 nM was observed. This increased activity 
may be due to the ability of the compound to form interstrand and intrastrand DNA 
crosslinks, such that the presence of three or more aziridinyl substituents may 
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promote multiple mutagenic lesions within DNA whereas those that contain a pair of 
these groups can only form a single crosslink. 
 
Figure 8.1: The effect of the aziridine motif upon the benzoquinone backbone 
and trypanocidal properties. IC50 values shown are the compound activity against 
BSF T. brucei displayed in Table 3.1.  
 
Based on whether the aziridine groupings at the 2 and 5 positions on the 1,4 
benzoquinone backbone contain substituent groupings, these compounds can be split 
into those that do not have any attached motifs (1-22; designated here as ABQs) 
from those that have methyl substituent(s) (23-34; designated here as MeABQs). In 
general the MeABQs, irrespective of the number (1 or 2) of methyl attachments, 
displayed a lower activity against T. brucei than their non-substituted counterparts. 
For example the three 2,5-dibromo ABQs 3, 25 and 26 contain 0, 1 and 2 methyl 
groups upon each of the aziridine groups respectively, with the trypanocidal effect of 
the agents decreasing as the number of methyl groups increases (Figure 8.2). 
Similarly, DZQ (1) which does not contain a methyl substitution is more potent 
towards T. brucei than its methyl containing counterparts (23, 24) with this effect 
extending to other quinone such as the naphthoquinones: compare the IC50 values of 
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41, 42 and 49 (Figure 8.2). This pattern is in keeping with observations made in high 
throughput oncological assays where the MeABQs were deemed inactive whereas 
the unsubstituted ABQ counterparts had significant anti-cancer properties (see 
Pubchem BioAssay results). One possible explanation accounting for such a trend 
may be that following prodrug activation, the methyl groups upon the aziridine ring 
hinders the unfolding of the aziridine ring to form an alkyl group that then promotes 
DNA adduct formation.  
 
 
Figure 8.2: The effect of methyl addition on the aziridine ring. IC50 values shown 
are the compound activity against BSF T. brucei.This effect is also observed in 
chloride containing ABQ and MeABQs.  
 
As ABQs tended to show activity against all three trypanosomatid lines tested, the 
toxicity of selected members was investigated against the immortal THP-1 
mammalian cell line (Table 3.2). For all structures, growth inhibitory effects were 
observed with all except one generating a LD50 value below 10 µM with some 
yielding values < 100 nM. Given that many of the available ABQs have been 
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selected and trialled for use against hypoxic cancers it is probably not surprising that 
these compounds did exert such a potent effect on a mammalian line derived from a 
patient with acute monocytic leukaemia (Schilsky et al. 1982; Tan et al. 1984; 
Falletta et al. 1990; Danson et al. 2011). To determine whether this toxicity was 
limited to immortal cells some of the ABQ were screened against peritoneal 
macrophages extracted from BALB/c mice (in collaboration with Dr K Seifert 
(LSHTM)). This demonstrated that all compounds tested blocked cell growth at 
concentrations < 1 µM thus showing that in vitro even against primary cells ABQs 
show significant toxicity. As such this type of compound is unlikely to be beneficial 
in targeting systemic trypanosomal/leishmanial infections although may still be of 
use in treating cutaneous lesions. Against this disappointing result we begun to view 
quinones as a whole and ABQs in particular not as potential anti-trypanosomatid 
drugs but rather as chemical tools for dissecting biochemical pathways in the 
parasite. 
 
Many nitroaromatic compounds can function as prodrugs, which require activation 
before exerting their effect. One enzyme that has been linked to the activation of 
nitro based compounds is the type I nitroreductase (NTR) (Wilkinson et al. 2008; 
Sokolova et al. 2010). This oxidoreductase is present in prokaryotes and absent from 
eukaryotes with some protozoan parasites being an exception to this rule (de Oliveira 
et al. 2007; Wilkinson et al. 2008; Pal et al. 2009; Hall et al. 2010; Voak et al. 
2013). The trypanosomatid type I NTRs are FMN containing, oxygen insensitive 
enzymes that using NADH to mediate a 2 electron reduction of the conserved nitro 
group to generate cytotoxic products (Wilkinson et al. 2008; Hall et al. 2010; Hall & 
Wilkinson 2011; Hall et al. 2011; Hall et al. 2012). The mammalian equivalent to 
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this activity is NQO1, a protein known to be upregulated in many hypoxic cancers 
(Ross et al. 2000; Siegel et al. 2012; Parkinson et al. 2013). Several of the quinones 
evaluated in this thesis as anti-trypanosomatid agents have been demonstrated to be 
undergo NQO1 mediated activation with this mechanism of activation being key to 
their anti-cancer activity (Nemeikait-Čniene et al. 2003; Tudor et al. 2005; Siegel et 
al. 2012). As many of these quinones display antimicrobial activity against BSF T. 
brucei we decided to investigate their mechanism of action by selecting a whole 
genome loss of function library developed by Sam Alsford and David Horn (Alsford 
et al. 2012) for resistance to RH1, the archetypal ABQ. From this screen a resistant 
parasite population was selected (Figure 4.1). A low resolution PCR-based analysis 
of the genomes of this polyclonal population revealed that the major transcript 
undergoing down regulation was the trypanosomal type I NTR (Figure 4.1) with 
reduction of the encoded activity sufficient to generate the resistance phenotype. As 
a link between the level of this enzyme and prodrug activation has been previously 
reported (Wilkinson et al. 2008; Alsford et al. 2012; Hall et al. 2012) then this 
observation provides evidence that RH1 functions as a prodrug in T. brucei with this 
particular oxidoreductase playing a key role in the metabolism of this particular 
ABQ. To conclusively demonstrate this link between NTR and the trypanocidal 
activity of RH1 the susceptibility of parasites engineered to express altered levels of 
Tbntr to this compound was investigated (Figures 4.4 and 4.5). This demonstrated 
that trypanosomes expressing reduced levels of TbNTR displayed a 2.5-fold level of 
resistance to this ABQ relative to controls while cells with elevated levels of the 
enzyme were ~ 4-fold more susceptible. This indicates that the trypanosomal type I 
NTR does indeed activate RH1 in vivo. Furthermore kinetic studies using purified 
recombinant TbNTR and quinone based compounds demonstrated that the enzyme 
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showed a greater affinity (Kcat/Km) towards the quinones than the nitroaromatic 
compounds (Hall et al. 2012). The overexpression and kinetic studies lead us to 
conclude that TbNTR can function as a quinone oxidoreductase.   
 
Additional evidence relating to the anti-trypanosomal mechanism of action of ABQs 
stemmed from selection of RH1 resistant clonal lines generated from wild type T. 
brucei. The parasites obtained from this experiment displayed a statistically 
significant increase in their IC50 values relative to wild type with this phenotype 
being stable in the absence of selective pressure. Previous studies using T. cruzi has 
shown that there is a direct link between benznidazole or nifurtimox resistance and 
TcNTR activity with two distinct mechanism leading to this phenotype: reduction of 
this oxidoreductase activity can arise via 1. loss of one of the alleles containing Tcntr 
or 2. the acquisition of missense mutations in the Tcntr coding sequence resulting in 
production of non-functional TcNTR protein (Wilkinson et al. 2008; Mejia et al. 
2012; Bot and Wilkinson unpublished). Analysis of the copy number and sequence 
of Tbntr revealed that neither of these had been altered in the T. brucei RH1 
resistance lines. However, when these studies were extended to look at expression, a 
three-fold reduction in Tbntr mRNA was observed (Figure 5.7). The mechanism that 
led to a decrease of this transcript was not investigated here but could be due to 
sequence differences in the 5’ and/or 3’ untranslated regions of Tbntr affecting 
mRNA processing or stability. This does warrant further attention as it may inform 
as to how T. brucei can acquire resistance to other drugs. 
 
Once the above link between RH1 and NTR had been established we next evaluated 
whether other ABQs could also undergo a similar mechanism of activation within 
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the parasite (Figure 4.6). For five of the six compounds tested a similar 
hypersensitivity profile to that observed using RH1 was displayed by trypanosomes 
expressing elevated levels of TbNTR, with all five of these structures also being thus 
deemed good substrates for this enzyme in vitro (Hall et al 2013). The only quinone 
that did not follow this pattern was the tetra-aziridinyl compound 22 (Figure 8.1), 
which also happened to be one structure previously shown not to be metabolized by 
TbNTR in vitro (Hall et al 2013). The reasons why 22 does not interact with TbNTR 
may be due to a steric hindrance effect of multiple (four) aziridinyl groupings 
attached to the 1,4 benzoquinone core or an electronic inductive and resonance 
properties exerted by all six substituents on the carbocyclic backbone (Figure 8.3). In 
either case, the two carbonyl oxygen atoms are blocked or electronically neutralized 
thereby preventing their reduction by the trypanosomal type I NTR. Based on our 
observations, compound 22 appears to mediate its activity via an another mechanism 
to all the other ABQs analysed here possibly using another alternative activation 
system, assuming that this particular agent does function as a prodrug.  
 
Figure 8.3: Space arrangement of RH1 and 22. The presence of four nitrogen 
containing side groups forces compound 22 into the orientation observed here. The 
resultant shape may prevent the reduction of 22 by TbNTR. Images obtained using 
PubChem3D (Bolton et al. 2011) 
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Cytochrome P450 reductases (CPRs) represent a class of membrane bound, FNM- 
and FAD-containing enzyme that utilize NADPH to mediate reduction of 
cytochrome P450 (Iyanagi 2005; Masters 2005; Portal et al. 2008). Their activity can 
be subverted such that they can catalyse the one electron reduction of other 
substrates such as nitroaromatic and quinone-based compound that in the presence of 
oxygen results in formation of reactive oxygen species which can then promote 
oxidative stress. As such CPRs are representative of the so-called type II NTRs. In 
trypanosomes several CPRs have been identified (Portal et al. 2008; Hall et al. 2011) 
with the role of at least one of these  being implicated in the sterol biosynthesis 
pathway (De Vas et al. 2011). As noted, 22 is the only structure tested that does not 
interact TbNTR in vitro and in vivo(Hall et al. 2012). As we hypothesized that this 
compound most likely functions as a prodrug we evaluated whether it could undergo 
activation via a one electron reduction mechanism by evaluating the susceptibility of 
two T. brucei lines engineered to express ectopic copies of CPR (isoforms 2 or 3) 
(Figures 4.7 and 4.8). This demonstrated that trypanosomes expressing elevated 
levels of either of these enzymes were up to 25-fold more susceptible to 22 than 
controls indicating that the trypanosomal CPRs are indeed involved in the activation 
of this particular ABQ in vivo. This activity was specific to 22 as these recombinant 
parasite lines exhibited the same sensitivities to the other ABQs (and to 
nitroaromatic produgs – see  Hall & Wilkinson 2011; Bot et al. 2013) as wild type. 
 
The ABQs evaluated here for their anti-trypanosomatid properties were initially 
designed to function as anti-cancer agents that following activation promote double 
stranded DNA breaks via the formation of interstrand DNA cross links (ICLs) 
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(Figure 1.10 and 1.11) (Fourie et al. 2004; Pierce et al. 2011). Following activation 
by an oxidoreductase(s), the carbonyl oxygen atoms are reduced to the 
corresponding hydroxyl to form a hydroquinone intermediate having the knock on 
effect of causing an increase in the pKa of the aziridine nitrogen. This facilitates 
protonation of this atom to form an aziridinium cation that is attracted to 
nucleophilic DNA strand. Interaction of the aziridinium cation with the nucleic acid 
promotes unfolding to form aziridinyl ring exposing an alkyl group that then 
covalently bonds to DNA, preferentially targeting guanine residues. This then 
triggers the same process to occur at the second aziridine group present on the ABQ 
eventually leading to a linkage across onto a residue on the complementary strand 
(Figure 1.11). Once this cross linkage has been formed, the “activated” hydroxyl 
groups undergo oxidation to reform the carbonyl oxygen groups of the 1,4 
benzoquinone core (Rajski & Williams 1998). If not repaired, this covalent link 
blocks any process that requires separation of the DNA strands that can lead to 
double stranded DNA breaks. The lethality of this resultant lesion is such that a 
single ICL can induce cell death in unicellular organisms whilst as little as 20 can be 
fatal to a mammalian cell (Magaña-Schwencke et al. 1982; Lawley & Phillips 1996). 
To combat such insults, all cells have evolved a series of complementary and 
overlapping pathways that function to repair this damage thus preserving a genome’s 
integrity with members of the so-called PSO2p/SNM1 family of nucleases playing a 
key role in one arm of these processes (Li et al. 2005; Barber et al. 2005; Dudáš et 
al. 2007). Recently, we have identified and characterised a T. brucei homologue of 
this protein, designated as TbSNM1 (Sullivan et al. 2015). An in silico analysis 
reveal that this protein possessed many of the key functional domains exhibited by 
the yeast and human orthologues including MBL, β-CASP and ubiquitin zinc finger 
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domains (Sullivan et al. 2015). Gene deletion studies revealed that the encoded 
activity was not essential for the growth of the clinically relevant stage of the African 
trypanosome although cells lacking TbSNM1 were hypersensitive towards 
multifunctional DNA alkylating agents such as the nitrogen mustards and aziridine 
based therapies. Here, we have shown that ABQs exhibit a similar phenotype to the 
previously screened ICL inducing agents such that trypanosomes null for Tbsnm1 
are ~3-fold more sensitive towards the di- and tri-functional aziridine compounds 
(DZQ, RH1 and TZQ) and ~ 6-fold more sensitive towards the tetra aziridine 
compound 22 than wild type, a phenotype that can be reversed by expression of 
ectopic copies of the repair enzyme (Table 5.2) It is well documented that bi-, tri- 
and tetra- alkylating agents are clastogenic therefore integration of these agents 
within the DNA duplex results in structural chromosomal changes with this 
promoting double strand breaks (Noll et al. 2006). The difference in sensitivity of 
the Tbsnm1 null mutant trypanosomes to the different types of ABQs tested could 
reflect the degree of lesions that each agent can induce within the parasite’s genome. 
In this context DZQ, RH1 and TZQ contain sufficient aziridine substituents (two) to 
generate a single ICL, with RH1 and TZQ also having the potential to form 
intrastrand cross links via an additional reactive grouping: for RH1 this is a hydroxyl 
and TZQ a third aziridine. For 22, two pairs of the aziridinyl could potentially 
generate two ICLs within close proximity to each other, inducing severe structural 
changes to the DNA helix.   
 
The susceptibility of Tbsnm1 null mutant T. brucei to ICL inducing ABQ produgs 
was exacerbated by manipulation of the bioreductive activation mechanism. To 
achieve this, the Tbsnm1 alleles in T. brucei expressing ectopic copies 
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ofmitochondrial prodrug activators Tbntr, Tbcpr2 and Tbcpr3 were disrupted (Hall 
et al. 2011; Sullivan et al. 2015). In line with previous data (Sullivan et al 2015), 
parasites lacking TbSNM1 activity but expressing elevated TbNTR were ~ 15- and ~ 
5-fold more susceptible towards the TbNTR activated compounds ABQs than wild 
type and Tbsnm1 null mutant parasites, respectively (Figure 5.3; Table 5.3). When 
this analysis was extended to 22 using parasites lacking TbSNM1 activity but 
expressing elevated TbCPR2 or 3, a similar trend was observed (Figure 5.4; Table 
5.4). Together this indicates that upon activation by TbNTR (RH1 and TZQ) or 
TbCPR (22) the resultant ABQ hydroquinone products are able to leave the 
organelles where the above enzymes are/postulated to be located (TbNTR is found in 
the mitochondrion while TbCPRs are believed to in the endoplasmic reticulum) and 
access the parasites nucleus where they can interact with the nuclear genome to 
promote ICL formation.  By elevating the level of the activator (TbNTR or TbCPRs) 
the rate and hence amount of hydroquinone formed is increased leading to a degree 
of DNA damage that can then be exacerbated in the absence of the nuclear ICL 
repair protein SNM1.  
 
The whole genome loss of function (RNAi) assay developed by Alsford (LSHTM) 
and Horn (University of Dundee) has greatly aided in our understanding of how all 
the clinically used anti-HAT drugs mediate their activities being especially useful in 
identifying uptake mechanisms and prodrug activators (Baker et al. 2011; Alsford et 
al. 2012). Here, we have used this approach to inform us as to the mechanism of 
action of not only RH1 but also of CB1954, an aziridine benzamide. As with RH1, a 
low resolution screen of the CB1954 resistant populations identified TbNTR as the 
key player in resistance, in agreement of the previous findings (Bot et al 2010). 
      
 
 
(159) 
 
Intriguingly, RH1 or CB1954 selection failed to identify sequences encoding for any 
obvious transporter, the type of transcript normally enriched in this sort of study 
(Baker et al. 2011; Alsford et al. 2012), suggesting that these two compounds can 
readily cross biological membranes without the need for a transporter. Indeed the 
indices of polar surface area (PSA), a measure of the hydrophobicity of a given 
agent, and partition coefficient (LogP), a measure of the affinity of a molecule for a 
lipophilic environment, of both RH1 and CB1954 meet the parameters defined by 
Lipinski's rule of five and more recent computational drug models suggest that these 
moieties can readily pass through the biological membrane without the aid of a 
transporter (Clark & Pickett 2000) (Table 8.1).  
 
Drug 
Hydrogen bond 
Molecular 
weight LogP3 
Polar surface 
area 
(PSA) (A2) acceptors donors 
RH1 1 5 234 0.1 60.4 
CB1954 6 1 252 0 138 
Nifurtimox 7 0 287 1.3 117 
Lipinski's rule ≤ 10 ≤ 5 < 500 -0.4 - +5.6 ≤ 140 
Table 8.1: Physiochemical properties of RH1, CB1954 and nifurtimox in 
accordance to Lipinski's rule of five for drug likeness.   
 
When the CB1954 selected population was subject to an indepth deep sequence 
analysis, a number of additional 'hits' were identified. When these sequences were 
analysed further by using RNAi to target specific transcripts all of the resultant T. 
brucei cell lines exhibited similar sensitivities to CB1954 as to the controls. This 
indicates that either the RNAi vector used (a head to head promoter arrangement) 
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was not down regulating gene expression sufficiently to generate a resistance 
phenotype (unlikely) or that all of the “hits” were false positives and have nothing to 
do with the biology underlying CB1954’s mode of action (more likely). Ideally, a 
northern blot analysis of the RNAi cell lines would confirm whether down regulation 
of the transcript had occurred but we were unable to establish this due to the lack of 
facilities in the department at present. 
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Chapter 9: Future work 
This project has explored the potential use of quinone based compounds as anti-
trypanosomatid therapies with our primary focus being on the ABQs. Our work has 
shown that these agents displayed potent anti-parasitic activity although their 
mammalian toxicity may hinder their use as treatment for systematic parasitic 
infections. Therefore, we came to the conclusion that these structures should be 
viewed as chemical tools to explore trypanosome biology.  
 
In Chapter 4, we considered the mode of action of selected ABQ compounds. In 
most cases these chemicals were metabolised by a trypanosomal type I NTR both in 
vivo and in vitro. Further studies using these structures could revolve around the 
identification and characterisation of the reduction products generated following 
NTR-mediated activation. This could involve performing enzyme assays using the 
ABQ as substrate then the fractionation and identification of the resultant material 
using LC/MS similar to that previously conducted by Hall et al. (2011) and Hall & 
Wilkinson (2012). It may be possible to purify the reduction products by 
modification of the above procedure such that these activation structures could be 
used in anti-proliferation screens against trypanosomatid and mammalian cells. 
Additionally, in silico docking of the trypanosomal type I NTR with the selected 
ABQs could be performed following the determination of the structure of this 
enzyme (work being performed in conjunction with Dr Nonato, University of Sao 
Paulo) or by fitting the parasite protein onto an existing bacterial homologue 
framework. This would aid in drug design targeting this particular oxidoreductase, 
potentially highlighting differences between the human NQO1 and parasitic NTR 
that can be exploited to develop specific quinone-based compounds that can 
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discriminate between the host and pathogen activities. A similar type of analysis to 
this could be performed using compound 22, the only ABQ identified here as 
undergoing an alternative mechanism of activation. In these studies we would use 
the trypanosomal CPRs in place of NTR to conduct the above experiments.  
 
Regarding mechanism of action following activation, all the ABQs tested in this 
thesis appear to function as DNA alkylating agents promoting nucleic acid damage. 
Our primarily focus in this area replied on phenotypic screens using trypanosomes 
null for the DNA repair protein SNM1(Sullivan et al. 2015)with these recombinant 
cells being more susceptibility to a specific set of damaging agents that promote ICL 
formation. To conclusively demonstrate this link in vitro the NTR (or CPR) activated 
ABQs could be used to treat double stranded DNA with the resultant products 
analysed by various means including Isothermal titration calorimetry or by LC/MS. 
Additionally, in vivo studies using wild type and TbSNM1 null mutant parasites 
treated with an ICL inducing agent could be undertaken using a qPCR based 
technique similar to that described by Machado and colleagues (2014).  
 
Further studies aimed at evaluating the role of SNM1 could be undertaken to 
ascertain whether, in response to DNA damage, the localisation of this protein 
changes, if this protein undergoes post translational modification, characterisation of 
SNM1 interacting partners and identification of potential inhibitors of this activity. 
In the latter case this could potentially lead to structures that exacerbate the DNA 
damaging activity of compounds such as the ABQs and could help improve these 
compounds selectivity against the trypanosome relative to the mammalian cell. 
Furthermore, additional proteins involved in the ICL repair pathway could be 
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identified following informatics screens (e.g. trypanosomal homologues of the 
mammalian fanconi anaemiaDNA interstand cross-link repair pathway, homologous 
repair etc) with functional studies conducted aimed at unravelling whether these 
have an eptistatic or non-eptistatic effect in relation to SNM1. 
 
In Chapter 6, we reported the selection of an RH1 resistance T. brucei line and were 
able to determine that ntr played a role in mediating the phenotypes displayed by 
these cells. The mechanism responsible for these properties via the down regulation 
of the encoded transcript was not established here but could warrant further attention 
as this process could explain how resistance to other NTR activated (and non-
activated) drugs may arise. Intriguingly not all of the phenotypic properties shown 
by the RH1 resistantT. brucei line could be explained by down regulation of this 
oxidoreductase. Therefore a more in depth analysis of these cells would be required 
based around using high throughput genomic or transcriptomic sequence analysis. 
This could provide a global insight into how these cells respond to the damage 
caused by ICL forming agents. 
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Thesis findings 
1. A range of compounds possessing a quinone core display significant anti-
parasitic activity against the medically and veterinary relevant form of T. 
brucei and against the replicative T. cruzi and L. major stages found in the 
insect vector. 
2. Several compounds yielded very low IC50 values (< 100nM) indicating that 
these were of promise in treatment development targeting trypanosomiasis 
and leishmaniasis.  
3. Unfortunately further evaluation of one particular grouping, the ABQs, which 
display potent anti-trypanosomatid activity revealed that they also exhibited 
significant toxicity against primary and secondary mammalian cell lines 
(macrophages and macrophage-like cells). As such these agents could not be 
considered as therapies for the systemic forms of trypanocidal infections. 
4. Using ABQs as chemical tools to understand biological function we 
demonstrated that these compounds function as prodrugs with different 
mechanisms operating to activate different types of closely related 
compounds: TbNTR functions as activator of ABQs such as RH1, DZQ and 
TZQ while TbCPR2 and TbCPR3 can metabolize compound 22. 
5. Following activation (by which ever mechanism) the ABQs then mediate 
their trypanocidal activity by promoting DNA damage via the formation of 
ICLs in the trypanosome nuclear genome with the DNA repair protein SNM1 
playing a key role in fixing this type of damage. 
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Appendix 1:Structures of the compounds used in this project 
Aziridinyl 1,4-benzoquinones 
   
Compound NSC# IUPAC Structure 
DZQ (1) 30706 2,5-bis(1-aziridinyl)-1,4-benzoquinone R1=R2=H 
MeDZQ (2) 646714 2,5-dimethyl-3,6-diaziridinyl-1,4-benzoquinone R1=R2=CH3 
3 197039 2,5-bis(aziridin-1-yl)-3,6-dibromocyclohexa-2,5-diene-1,4-dione R1=R2=Br 
4 208829 3,6-difluoro-2,5-bis(aziridinyl)-1,4-benzoquinone R1=R2=F 
RH1 (5) 697726 2,5-bis(aziridin-1-yl)-3-(hydroxymethyl)-6-methylcyclohexa-2,5-diene-1,4-dione R1=CH2OH; R2=CH3 
6 95139 2,5-bis(aziridin-1-yl)-3,6-dimethoxycyclohexa-2,5-diene-1,4-dione R1=R2=OCH3 
7 18270 2,5-bis(aziridin-1-yl)-3,6-diethoxycyclohexa-2,5-diene-1,4-dione  R1=R2=OCH2CH3 
8 17261 2,5-bis(aziridin-1-yl)-3,6-dipropoxycyclohexa-2,5-diene-1,4-dione
 
R1=R2=O(CH2)2CH3 
9 246111 2,5-diamino-3,6-bis(aziridin-1-yl)cyclohexa-2,5-diene-1,4-dione R1=R2=NH2 
10 220267 2,5-bis(aziridin-1-yl)-3,6-bis(methylamino)cyclohexa-2,5-diene-1,4-dione R1=R2=NHCH3 
11 224066 2,5-bis(aziridin-1-yl)-3,6-bis(ethylamino)cyclohexa-2,5-diene-1,4-dione R1=R2=NHCH2CH3 
12 328408 2,5-bis(aziridin-1-yl)-3,6-bis(heptylamino)cyclohexa-2,5-diene-1,4-dione R1=R2=NH(CH2)6CH3 
13 249989 2,5-bis(aziridin-1-yl)-3,6-bis(dimethylamino)cyclohexa-2,5-diene-1,4-dione R1=R2=NH(CH3)CH3 
14 251728 2,5-bis(aziridin-1-yl)-3-fluoro-6-morpholin-4-ylcyclohexa-2,5-diene-1,4-dione R1=morpholinyl; R2=F 
15 18269 N-[4-acetamido-2,5-bis(aziridin-1-yl)-3,6-dioxocyclohexa-1,4-dien-1-yl]acetamide R1=R2=NHCOCH3 
16 18271 N-[2,5-bis(aziridin-1-yl)-3,6-dioxo-4-(propanoylamino)cyclohexa-1,4-dien-1-yl]propanamide R1=R2=NHCOCH2CH3 
17 18274 N-[2,5-bis(aziridin-1-yl)-4-(butanoylamino)-3,6-dioxocyclohexa-1,4-dien-1-yl]butanamide R1=R2=NHCO(CH2)2CH3 
18 51916 -[2,5-bis(aziridin-1-yl)-4-(heptanoylamino)-3,6-dioxocyclohexa-1,4-dien-1-yl]heptanamide R1=R2=NHCO(CH2)5CH3 
19 51915 N-[2,5-bis(aziridin-1-yl)-4-(cyclohexanecarbonylamino)-3,6-dioxocyclohexa-1,4-dien-1-
yl]cyclohexanecarboxamide 
R1=R2=NHCOPhenyl 
AZQ (20) 182986 ethyl N-[2,5-bis(aziridin-1-yl)-4-(ethoxycarbonylamino)-3,6-dioxocyclohexa-1, 
4-dien-1-yl]carbamate 
R1=R2=NHC(O)OCH2CH3 
TZQ (21) 29215 2,3,5-tris(aziridin-1-yl)cyclohexa-2,5-diene-1,4-dione R1=aziridinyl; R2=H 
22 31717 2,3,5,6-tetrakis(aziridin-1-yl)cyclohexa-2,5-diene-1,4-dione R1=R2=aziridinyl 
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Methyl and di-methyl substituted aziridinyl 1,4-benzoquinones 
   
Compound NSC# IUPAC Structure 
23 83705 2,5-bis[(2r)-2-methylaziridin-1-yl]cyclohexa-2,5-diene-1,4-dione R1=R2=X=H;Y=CH3 (r orientation) 
24 83706 2,5-bis[(2s)-2-methylaziridin-1-yl]cyclohexa-2,5-diene-1,4-dione R1=R2=X=H;Y=CH3 (s orientation) 
25 197038 2,5-dibromo-3,6-bis(2-methylaziridin-1-yl)cyclohexa-2,5-diene-1,4-dione R1=R2=Br; X=H; Y=CH3 
26 199106 2,5-dibromo-3,6-bis(2,2-dimethylaziridin-1-yl)cyclohexa-2,5-diene-1,4-dione R1=R2=Br; X=Y=CH3 
27 200115 2,5-dichloro-3,6-bis(2-methylaziridin-1-yl)cyclohexa-2,5-diene-1,4-dione R1=R2=Cl; X=H;Y=CH3 
28  202394 2,5-dichloro-3,6-bis(2,2-dimethylaziridin-1-yl)cyclohexa-2,5-diene-1,4-dione R1=R2=Cl; X=Y=CH3 
29 208830 2,5-dichloro-3,6-bis(2,2-dimethylaziridin-1-yl)cyclohexa-2,5-diene-1,4-dione R1=R2=Fl; X=H;Y=CH3 
30 208831 2,5-bis(2,2-dimethylaziridin-1-yl)-3,6-difluorocyclohexa-2,5-diene-1,4-dione R1=R2=Fl; X=Y=CH3 
31 18273 N-[4-acetamido-2,5-bis(2-methylaziridin-1-yl)-3,6-dioxocyclohexa-1,4-dien-1-yl]acetamide R1=R2=NHCOCH3; 
X=H; Y=CH3 
32 199377 N-[4-acetamido-2,5-bis(2,2-dimethylaziridin-1-yl)-3,6-dioxocyclohexa-1,4-dien-1-
yl]acetamide 
R1=R2=NHCOCH3; 
X=Y=CH3 
33 18272 N-[2,5-bis(2-methylaziridin-1-yl)-3, 6-dioxo-4-(propanoylamino)cyclohexa-1,4-dien-1-
yl]propanamide 
R1=R2=NHCO(CH)CH3; 
X=H;Y=CH3 
34 199378 Ethyl N-[2,5-bis(2,2-dimethylaziridin-1-yl)-4-(ethoxycarbonylamino)-3,6-dioxocyclohexa-
1,4-dien-1-yl]carbamate 
R1=R2=NHCOO(CH)CH3; 
X=Y=CH3 
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1,4-naphthoquinones 
   
Compound MTL/NSC# IUPAC Structure 
Menadione (35) - 2-methylnaphthalene-1,4-dione R1=CH3,R2=R3=R4=H 
Plumbagin (36) NSC236613 5-hydroxy-2-methylnaphthalene-1,4-dione R1=CH3, R2=H, R3=R4=OH 
37 MTL6-022 2,5,8 trimethylnaphthalene-1,4-dione R1=R3=R4=CH3, R2=H,  
38 MTL6-023 5,8-dihydroxy-1,4-dihydronaphthalene-1,4-dione R1 =R2 =H, R3=R4=OH 
39 MTL6-026 
 
2-[(2-chloroethyl)amino]-8-hydroxy-1,4-dihydronaphthalene-1,4-dione R1=R4=H, R3=OH. 
R2=(2-chloroethyl)(methyl)amine,  
40 MTL6-027 5,8-dioxo-5,8-dihydronapthalen-1-yl-acetate R1=R2=R4=H, R3=C2H4O2 
41 MTL6-030 2-(aziridin-1-yl)-3-chloro-1,4-dihydronaphthalene-1,4-dione R1=Cl, R2=aziridine, R3=R4=H  
42 MTL6-031 2-chloro-3-(2-methylaziridin-1-yl)-1,4-dihydronaphthalene-1,4-dione R1=Cl, R2=2-methylaziridine, 
R3=R4=H  
43 MTL6-032 3-(aziridin-1-yl)-2-chloro-5-hydroxy-1,4-dihydronaphthlene-1,4-dione R1=R4=H, R2=aziridine, R3=OH 
44 MTL6-033 2-chloro-5-hydroxy-3-(2-methylaziridin-1-yl)-1,4-dihydronaphthalene-1,4-dione R1=R4=H, R2=methylaziridine, 
R3=OH 
45 - 5-hydroxy-1,4-dihydronaphthalene-1,4-dione R1=R2=R4=H, R3=OH 
Lapachol (46) MTL6-038 2-hydroxy-3-(3-methylbut-2-en-1-yl)-1,4-dihydronaphthalene-1,4-dione R1=OH, R2=C6H12 , R3=R4=H 
47 NSC39051 2-(aziridin-1-yl)-3-methoxynaphthalene-1,4-dione R1=OCH3,R2=aziridine, R3=R4=H 
48 NSC139346 2-(aziridin-1-yl)-3-methylnaphthalene-1,4-dione R1=CH3, R2=aziridine, R3=R4=H 
49 NSC35852 2-chloro-3-(2,3-dimethylaziridin-1-yl)naphthalene-1,4-dione R1=Cl, R2=aziridine, R3=R4=H 
50 NSC260640
  
2-[bis(2-chloroethyl)amino]naphthalene-1,4-dione R1=R3=R4=H, R2=N(CH2CH2Cl)2 
51 NSC35854 N-[3-[bis(2-chloroethyl)amino]-1,4-dioxonaphthalen-2-yl]acetamide R1=NOHCH3, R3=R4=H 
R2=N(CH2CH2Cl)2 
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1,4-benzoquinone mustards 
   
Compound Alternative 
name 
IUPAC Structure 
52 BM 2-[di(chloroethyl)amino]-1,4-benzoquinone R1=R2=R3=H 
53 5MeBM 5-methyl-2-[di(chloroethyl)amino]-1,4-benzoquinone R1=R3=H, R2=CH3  
54 5MeOBM 5-methoxy-2-[di(chloroethyl)amino]-1,4-benzoquinone R1=R3=H, R3=OCH3 
55 6MeBM 6-methyl-2-[di(chloroethyl)amino]-1,4-benzoquinone R1=CH3, R2= R3=H 
56 6PhBM 6-phenyl-2-[di(chloroethyl)amino]-1,4-benzoquinone R1=Phenyl, R2= R3=H  
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Other aziridinyl-containing quinone. 
 
Compound NSC# IUPAC 
Mitomycin C (57) 26980 [6-Amino-8a-methoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-
octahydroazireno[2',3':3,4]pyrrolo[1,2-a]indol-8-yl]methyl carbamate 
 
58 651080 [6-(aziridin-1-yl)-7-methyl-5,8-dioxo-2,3-dihydro-1H-pyrrolo[1,2-a]benzimidazol-3-yl] 2-
chloroacetate 
 
59 651079 [6-(aziridin-1-yl)-7-methyl-5,8-dioxo-2,3-dihydro-1H-pyrrolo[1,2-a]benzimidazol-3-yl] 
propanoate 
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Appendix 2: Chemical and physical properties of the compounds 
The values were obtained from the PubChem database (http://pubchem.ncbi.nlm.nih.gov/) or calculated using Molinspiration chemoinformatics 
software (http://www.molinspiration.com/) 
1. Aziridinyl 1,4-benzoquinones 
Compound NSC# MW 
(Daltons) 
H-bond 
donors 
H-acceptors Rotatable 
bonds 
clogP PSA (Å) 
DZQ (1) 30706 190.20 0 4 2 0.2 40.2 
MeDZQ (2) 646714 218.25 0 4 2 0.8 40.2 
3 197039 347.99 0 4 2 2.0 40.2 
4 208829 226.18 0 6 2 0.3 40.2 
RH1 (5) 697726 234.25 1 5 3 0.1 60.4 
6 95139 250.25 0 6 4 0.2 58.6 
7 18270 278.30 0 6 6 0.9 58.6 
8 17261 306.36 0 6 8 2.0 58.6 
9 246111 220.23 2 6 2 -0.7 92.2 
10 220267 248.28 2 6 4 0.1 64.2 
11 224066 276.33 0 6 6 0.6 64.2 
12 328408 416.60 2 6 16 5.6 64.2 
13 249989 276.33 0 6 4 1.0 46.6 
14 251728 293.29 0 7 3 0.0 52.6 
15 18269 304.30 2 6 4 -1.6 98.4 
16 18271 332.35 2 6 6 -0.6 98.4 
17 18274 360.41 2 6 8 0.1 98.4 
18 51916 444.57 2 6 14 3.3 98.4 
19 51915 440.54 2 6 6 2.6 98.4 
AZQ (20) 182986 364.35 2 8 8 0.0 117.0 
TZQ (21) 29215 231.25 0 5 3 -0.1 43.2 
22 31717 272.30 0 6 4 0.8 46.2 
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2. Methyl and di-methyl substituted aziridinyl 1,4-benzoquinones 
 
Compound NSC# MW 
(Daltons) 
H-bond 
donors 
H-acceptors Rotatable 
bonds 
clogP PSA (Å) 
23 83705 218.25 0 4 2 1.1 40.2 
24 83706 218.25 0 4 2 1.1 40.2 
25 197038 376.04 0 4 2 2.8 40.2 
26 199106 404.10 0 4 2 3.3 40.2 
27 200115 287.14 0 4 2 2.7 40.2 
28  202394 315.20 0 4 2 3.2 40.2 
29 208830 254.23 0 6 2 1.6 40.2 
30 208831 282.29 0 6 2 2.1 40.2 
31 18273 332.35 2 6 4 -0.2 98.4 
32 199377 360.41 2 6 4 -0.3 98.4 
33 18272 360.41 2 6 6 0.8 98.4 
34 199378 420.46 2 8 8 1.2 117.0 
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3. 1,4-naphthoquinones 
Compound MTL/NSC# MW 
(Daltons) 
H-bond 
donors 
H-acceptors Rotatable 
bonds 
clogP PSA (Å) 
Menadione (35) - 172.18 0 2 0 2.2 34.1 
Plumbagin (36) NSC236613 188.18 1 3 0 2.3 54.4 
37 MTL6-022 200.23 0 2 0 2.8 34.1 
38 MTL6-023 190.15 2 4 0 1.1 74.6 
39 MTL6-026 251.66 2 4 3 1.8 66.4 
40 MTL6-027 216.19 0 4 2 1.2 60.4 
41 MTL6-030 233.65 0 3 1 2.2 37.1 
42 MTL6-031 247.68 0 3 1 2.8 37.2 
43 MTL6-032 215.20 1 4 1 1.3 27.4 
44 MTL6-033 229.23 1 4 1 1.7 27.4 
45 - 174.15 1 3 0 1.4 54.4 
Lapachol (46) MTL6-038 242.27 1 3 2 2.8 54.4 
47 NSC39051 229.23 0 4 2 1.9 46.4 
48 NSC139346 213.23 0 3 1 1.5 37.2 
49 NSC35852 261.70 0 3 1 3.3 37.2 
50 NSC260640 298.16 0 3 5 3.1 37.4 
51 NSC35854 355.22 1 4 6 2.3 66.5 
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4. 1,4-benzoquinone mustards 
Compound Alternative 
name 
MW 
(Daltons) 
H-bond 
donors 
H-acceptors Rotatable 
bonds 
clogP PSA (Å) 
52 BM 248.11 0 3 5 1.8 37.4 
53 5MeBM 262.14 0 3 5 2.2 37.4 
54 5MeOBM 278.14 0 4 6 1.1 46.6 
55 6MeBM 262.14 0 3 5 2.2 37.4 
56 6PhBM 324.21 0 3 6 3.5 37.4 
 
 
 
5. Other quinone containing compounds 
Compound NSC# MW 
(Daltons) 
H-bond 
donors 
H-acceptors Rotatable 
bonds 
clogP PSA (Å) 
Mitomycin C (57) 26980 334.32 3 8 4 -0.4 147.0 
58 651080 335.74 0 6 4 1.1 81.3 
59 651079 315.32 0 6 4 1.0 81.3 
 
Lipinski's rule states that, in general, an orally active drug has no more than one violation of the following criteria: 
• No more than 5 hydrogen bond donors (the total number of nitrogen–hydrogen and oxygen–hydrogen bonds) 
• Not more than 10 hydrogen bond acceptors (all nitrogen or oxygen atoms) 
• A molecular mass less than 500 daltons (Da) 
• An octanol-water partition coefficient log P not greater than 5 
Polar surface area no greater than 140 Ǻ2 
10 or fewer rotatable bonds
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Appendix 3: Primers 
Primers used to amplify type I nitroreductases and fragments from RNAi library 
screen. The sequence in lower case italics refers to restriction sites incorporated into the 
primer to facilitate DNA cloning. The non-italicised, lower case sequence corresponds to a 
clamp that aids binding of the DNA polymerase to the primer. The identifiers given after a 
gene name correspond to accession numbers on the Kinetoplastid genome resource 
TritrypDB (http://tritrypdb.org/tritrypdb/). 
Gene & primer name 
 
Sequence 5’ to 3’ 
RNAi library screen  
L1B2F TAGCCCCTCGAGGGCCAGT 
L1B2R GGAATTCGATATCAAGCTTGGC 
TbNTR(Tb927.7.7230) 
 
TbNTR-3 gggaagcttATGAACGTGAGCCGCGCTGCCGT 
TbNTR-4 gggtctagaGAAGCGATTCCATCGGACGAG 
LmNTR (LmjF.05.0660) 
 
LmNTR-1 aaaggatccCTCGACGCCGTCGAGGCCGTCG 
LmNTR-2 gggaagcttCTAGAACTTGTTCCACCGCAC 
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Primers used to generate RNAi constructs. The sequence in lower case italics refers to 
restriction sites incorporated into the primer to facilitate DNA cloning. The non-italicised, 
lower case sequence corresponds to a clamp that aids binding of the DNA polymerase to the 
primer. The identifiers given after a gene name correspond to accession numbers on the 
Kinetoplastid genome resource TritrypDB (http://tritrypdb.org/tritrypdb/). 
Gene & primer name Sequence 5’ to 3’ 
TbNTR(Tb927.7.7230) 
TbNTR-RNAi-1 tttggatccCCCGTCGACCACACTCTTATC 
TbNTR-RNAi-2 gggctcgagAGCCCACAACCTCCCTAACTT 
TbORFa (Tb927.11.6370) 
CB1954-RNAi-1 tttggatccAGCGCTGGACCTTTCTGATAA 
CB1954-RNAi-2 gggctcgagCGAGTTGGTTCCGACGTAATA 
TbORFb (Tb927.7.7310) 
CB1954-RNAi-3 tttggatccTCTCTTGCTTTCCTCGTGCTG 
CB1954-RNAi-4 gggctcgagACAAACAGGGGCAATTAACGA 
TbORFc (Tb927.3.3670) 
CB1954-RNAi-5 tttggatccGATGACCTCCAAGAATCGGAA 
CB1954-RNAi-6 gggctcgagGCAGCATAAGCAGGGATAGCG 
TbORFd (Tb927.10.3130) 
CB1954-RNAi-7 tttggatccGAGTGCCTCAAGAGACAGGGG 
CB1954-RNAi-8 gggctcgagTCAGCGAGCACACCATTAAGC 
TbORFe (Tb927.8.8070 & Tb927.8.8110) 
CB1954-RNAi-9 tttggatccCTGTCAAGCCTCCCAGCCGTT 
CB1954-RNAi-10 gggctcgagTGTTAATCGTAGTAACGCTCA 
TbORFf (Tb927.8.4050) 
CB1954-RNAi-11 tttggatccATCGCCTGAGTCTTGATGCTC 
CB1954-RNAi-12 gggctcgagGCGATACCGTGCGGTTCGTTA 
TbORFg (Tb927.10.3910) 
CB1954-RNAi-13 tttggatccCCTGCACCGTGCCTTCGCTGA 
CB1954-RNAi-14 gggctcgagGGATCACTACCACCACGCCTT 
TbMCM9 (Tb927.9.9600) 
CB1954-RNAi-15 tttggatccCACCCTCATGGACGCGCTCAG 
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CB1954-RNAi-16 gggctcgagGCGGTAGGAGTCCATCACGTT 
TbRad2 (XPG) (Tb927.9.11760) 
TbRAD2 RNAi-1 tttggatccAACCTGGTGAAAGTGTGGAGG 
TbRAD2-RNAi-2 gggctcgagCTGAATTGATTCAGCTTCCCC 
BG-M2 TbORF1 (Tb927.10.1740) 
TbBGM2-RNAi-1 aaaggatccTTGCACGGTGATGAAGGAAT 
TbBGM2-RNAi-2 aaactcgagAAGGGCCGCCACTCACCGCCT 
BG-M2 TbORF2 (Tb927.10.1750) 
TbBGM2-RNAi-3 aaaggatccCCGCGAGGAGCGAAGGTAC 
TbBGM2 RNAi-4 aaactcgagAACTCCTGCCGTGCGCTGCTC 
BG-M2 TbORF3 (Tb927.11.11380) 
TbBGM2 RNAi-5 aaaggatccGCCTGGCTCAAATGGAAGGAT 
TbBGM2 RNAi-6 aaactcgagTGGGTTGAAACAACCAA 
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Primers used in qPCR. Each primer set was predicted to yield a band of between 100-
150 base pairs. The sequence in lower case italics refers to restriction sites incorporated into 
the primer to facilitate DNA cloning. The non-italicised, lower case sequence corresponds to 
a clamp that aids binding of the DNA polymerase to the primer. The identifiers given after a 
gene name correspond to accession numbers on the Kinetoplastid genome resource 
TritrypDB (http://tritrypdb.org/tritrypdb/). 
Gene & primer name 
 
Sequence 5’ to 3’ 
TbNTR (Tb927.7.7230) 
TbNTR-1 tttctcgagGGTACCTTGATGCATTTATACGTGTT 
TbNTR-6 TCATGTACGACAATGGCAAC 
TbSNM1(Tb427.04.1480)  
TbSNM1-seq1 CACCAGATCACCATTGCGGAG 
TbSNM1-q2 GGTATTACTGAGAAGTGGTCG 
TbTERT (Tb11.01.1950)(Brenndörfer & Boshart 2010)(Brenndörfer & Boshart 
2010)(Brenndörfer & Boshart 2010)(Brenndörfer & Boshart 2010)(Brenndörfer & Boshart 
2010)(Brenndörfer & Boshart 2010) 
TbTERT-R AGGAACTGTCACGGAGTTTGC 
TbTERT-f GAGCGTGTGACTTCCGAAGG 
TbCPR2(Tb927.9.15380) 
TbCYPRII-4 gggggatccACGAAGCGATATTAGTGATCT 
TbCYPRII-6 GTTGAGGAGTATGTTGAGCAA 
TbCPR3 (Tb11.02.5420) 
TbCYPRIV-4 gggggatccGACTCGACGTTCGCGTTCTCT 
TbCYPRIV-6 CGTGGCGCAGATAATAATGAC 
TbMRE11 (Tb927.2.4390)  
TbMRE11-q1 GGGTTTGACATCATTCAGCCG 
TbMRE11-q2 CCGGACGACAGGACGAATACT 
TbRad51 (Tb427.03.5230)  
TbRad51-q1 AGTGTGTCGGACATGCTGGCA 
TbRad51-q2 CGGGGTTCCTGCGAGCAGGCG 
TbRad2 (XPG)(Tb927.9.11760) 
TbRAD2-q1 GCTGAGCCCTACGCCGTTGCT 
TbRAD2-RNAi-2 gggctcgagCTGAATTGATTCAGCTTCCCC 
TbMSH3 (Tb927.9.5240) 
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TbMSH3-qPCR-1 AAGGCTATCGAGCTGCTGTGT 
TbMSH3-qPCR-2 CACACGGTAACCACACGCTAC 
TbHP1 (Tb927.9.11810) 
Tb11810-qpcr-1 ATGCTAGTCAGCACCAGTCCA 
Tb11810-qpcr-2 CAATGTCCATCCCAAGCATTA 
TbHP2 (Tb927.9.11670) 
Tb11670-qpcr-1 GAGGGTCTTGTGCATGGCAGT 
Tb11670-qpcr-2 ATCACAGGCACGGACAACATC 
TbXPF (Tb927.5.3670)  
TbXPF-qPCR-f CAACCTACCGTCACCCAATGC 
TbXPF-qPCR-r ACCACTGCCACCGAGTTATCA 
(179) 
 
Appendix 4: Summaries of trypanosome mutant sensitivities towards ABQ agents.  
 
Table 5.2 (Expanded): Susceptibility of T. brucei lines expressing altered levels of Tbsnm1 to ABQ compounds. Data represents the IC50 
values in µM of T. brucei wild type, Tbsnm1-/- null mutants (Tbsnm1-/-), Tbsnm1-/- expressing an ectopic copy of Tbsnm1 (Tbsnm1-/- Tbsnm1RV) 
and T. brucei wild type expressing elevated levels of Tbsnm1 (Tbsnm1RV) to selected ABQs. All values are means ± standard deviation of four 
independent experiments. The fold difference in IC50 values between the two treatments are given. The differences in susceptibility of wild type 
and Tbsnm1-/- lines to DZQ, RH1, TZQ or 22 was statistically significant (P < 0.01), as assessed by Student's t test. 
Compound 
IC50 values (µM) ± standard deviation Ratios 
wild type Tbsnm1-/- Tbsnm1-/- 
Tbsnm1RV 
Tbsnm1RV Wild type: 
Tbsnm1-/- 
Tbsnm1-/- : 
Tbsnm1-/- 
Tbsnm1RV 
wild type: 
Tbsnm1RV 
DZQ 0.157 ± 0.023 0.043 ± 0.002 0.204 ± 0.022 0.206 ± 0.017 3.7 4.7 1.3 
RH1 0.019 ± 0.001 0.005 ± 0.001 0.012 ± 0.001 0.011 ± 0.001 3.0 2.4 0.6 
TZQ 0.253 ± 0.033 0.046 ± 0.001 0.376 ± 0.006 0.300 ± 0.023 2.7 8.2 1.2 
22 0.091 ± 0.008 0.012 ± 0.001 0.069 ± 0.007 0.056 ± 0.007 6.6 5.8 0.6 
DFMO 24.150 ± 3.940 24.240 ± 6.710 26.960 ± 1.400 25.410 ± 6.440 1.0 1.1 1.1 
(180) 
 
Table 5.3 (Expanded): The growth inhibitory effects of selected ABQ compounds on T. brucei snm1-/- null mutants over expressing TbNTR. Data 
represents the IC50 values in µM of T. brucei wild type, T. brucei expressing elevated levels of TbNTR (Tbntr), TbSNM1 null mutants (Tbsnm1-/-) and 
TbSNM1 null mutants expressing an ectopic copy of Tbntr (Tbsnm1-/- Tbntr) to RH1, TZQ and DFMO. All values are means ± standard deviation of four 
independent experiments. a valve for DFMO taken from Sullivan et al (2015). 
 
 
Table 5.4 (Expanded): The growth inhibitory effects of selected ABQ compounds on T. brucei snm1-/- null mutants over expressing TbCPR2. Data 
represents the IC50 values in µM of T. brucei wild type, T. brucei expressing elevated levels of TbCPR2 (Tbcpr2), TbSNM1 null mutants (Tbsnm1-/-) and 
TbSNM1 null mutants expressing an ectopic copy of Tbcpr2 (Tbsnm1-/- Tbcpr2) to 22 and DFMO. All values are means ± standard deviation of four 
independent experiments.  
Compound 
 IC50 values (µM) ± standard deviation Ratios 
wild type Tbcpr2 Tbsnm1-/- Tbsnm1-/- 
Tbcpr2 
Wild type: 
Tbcpr2 
Tbsnm1-/- : 
Tbsnm1-/- Tbcpr2 
Wild type: 
Tbsnm1-/- Tbcpr2 
22 0.138 ± 0.025 0.020 ± 0.003 0.021 ± 0.001 0.011 ± 0.004 7.0 1.9 12.5 
DFMO 27.500 ± 0.108 33.250 ± 5.123 27.100 ± 0.850 29.250 ± 3.862 0.8 1.1 0.9 
 
 
  
Compound 
IC50 values (µM) ± standard deviation Ratios 
Wild Type Tbntr Tbsnm1-/- Tbsnm1-/- Tbntr 
Wild type: 
Tbntr 
Tbsnm1-/- : 
Tbsnm1-/- Tbntr 
Wild type: 
Tbsnm1-/- Tbntr 
RH1 0.015 ± 0.001 0.003 ± 0.001 0.005 ± 0.001 0.001 ± 0.001 5.0 5.0 15.0 
TZQ 0.202 ± 0.006 0.060 ± 0.009 0.076 ± 0.004 0.013 ± 0.001 3.4 5.8 15.5 
DFMOa 27.500 ± 0.108 30.720 ± 1.330 27.100 ± 0.850 26.710 ± 2.060 0.9 0.9 1.0 
      
 
 
(181) 
 
 
Table 5.5: The growth inhibitory effects of selected ABQ compounds on T. brucei snm1-/- null mutants over expressing TbCPR3. Data 
represents the IC50 values in µM of T. brucei wild type, T. brucei expressing elevated levels of TbCPR3 (Tbcpr3), TbSNM1 null mutants 
(Tbsnm1-/-) and TbSNM1 null mutants expressing an ectopic copy of Tbcpr3 (Tbsnm1-/- Tbcpr3) to 22 and DFMO. All values are means ± 
standard deviation of four independent experiments. Ratios can be found in Appendix 4.  
Compound 
IC50 values (µM) ± standard deviation    
wild type Tbcpr3 Tbsnm1-/- Tbsnm1-/- 
Tbcpr3 
Wild type: 
Tbcpr3 
Tbsnm1-/- : 
Tbsnm1-/- Tbcpr3 
Wild type: 
Tbsnm1-/- Tbcpr3 
22 0.138 ± 0.025 0.019 ± 0.003 0.021 ± 0.001 0.010 ± 0.001 7.3 2.1 13.8 
DFMO 27.500 ± 0.108 36.500 ± 3.697 27.100 ± 0.850 39.125 ± 2.170 0.75 0.7 0.7 
(182) 
 
Flow diagrams to summarise the results shown in Chapter 5 (part 2). These results are 
shown in tables 5.2, 5.3, 5.4 and 5.5  
Tbntr activation in snm1-/- background 
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Tbcpr2 activation in snm1-/- background 
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Tbcpr3 activation in snm1-/- background 
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